SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions November recently filed with US Patent Office 11/10

20100297003 - Anti-human tenascin monoclonal antibody: An anti-human tenascin monoclonal antibody is described, whose light and heavy chain variable region sequences are SEQ ID 1 and SEQ ID 2, respectively, its proteolytic fragments capable of binding to an antigenic epitope within the region A(1-4)-D of human tenascin, its recombinant derivatives, its conjugates and its similar functional... Agent: Lucas & Mercanti, LLP

20100297004 - High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection: The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The present invention also provides methods for the detection, visualization, and treatment of various... Agent: Townsend And Townsend And Crew, LLP

20100297005 - Nucleic acids and corresponding protein entitled 125p5c8 useful in treatment and detection of cancer: A novel gene 191P4D12(b) and its encoded protein, and variants thereof, are described wherein 191P4D12(b) exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 191P4D12(b) provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 191P4D12(b) gene or... Agent: Agensys C/o Morrison & Foerster LLP

20100297006 - Nucleic acids and corresponding proteins entitled 191p4d12(b) useful in treatment and detection of cancer: A novel gene 191P4D12(b) and its encoded protein, and variants thereof, are described wherein 191P4D12(b) exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 191P4D12(b) provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 191P4D12(b) gene or... Agent: Agensys C/o Morrison & Foerster LLP

20100297007 - Ligand directed toroidal nanoparticles for therapy and diagnostic imaging: The present invention provides nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to deliver therapeutic agents and/or imaging agents.... Agent: Polsinelli Shughart PC

20100297015 - Cancer biomarker and uses thereof: A method of determining the cancer status of a subject, comprising the steps of (a) providing a sample of material obtained from a subject; (b) determining the level GTPCH in the sample; and (c) comparing the level determined in (b) with one or more reference values.... Agent: Jeffrey J. King, Esq. Patent Networks Law Group PLLC

20100297008 - Ganglioside associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors: The present invention is related with the obtaining of modified antibodies by means of the DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3) produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026 and from its anti-idiotype murine monoclonal antibody 1E10 (MAbai... Agent: Lackenbach Siegel, LLP

20100297012 - Humanized antibody: The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies that specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies of the present invention are particularly useful for the treatment of ocular diseases associated with pathological abnormalities/changes in the... Agent: Jones Day

20100297013 - Humanized antibody: The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies that specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies of the present invention are particularly useful for the treatment of ocular diseases associated with pathological abnormalities/changes in the... Agent: Jones Day

20100297011 - Isolated peptides and uses thereof: The present invention provides isolated preproinsulin-derived peptides of 8 or 9 amino acids, comprising the amino acid sequence WGPDPAA (SEQ ID NO: 1), isolated Class I peptide-HLA complexes presenting said peptides and isolated molecules having binding affinity for said peptides and/or said peptide-HLA complexes. Such compositions are useful in the... Agent: Stites & Harbison, PLLC

20100297017 - Method for synthesizing and using pegylated peptide-photoactive chromophore conjugates and micellular formulations thereof: The invention relates to a PEGylated peptide-chromophore conjugate, which forms irregular micelles, for use in photodiagnostic and phototherapeutic applications. Methods for synthesizing and using the conjugates of the invention are also provided.... Agent: Licata & Tyrrell P.C.

20100297014 - Method of detecting the risk of cancer using genetic markers: e

20100297016 - Quarternary nitrogen heterocyclic compounds for detecting aqueous monosaccharides in physiological fluids: Quaternary nitrogen heterocyclic boronic acid-containing compounds are described, which are sensitive to glucose and fructose, as well as a variety of other physiologically important analytes, such as aqueous chloride and iodide, and a method of using the compounds. Also disclosed is a contact lens doped with the quaternary nitrogen heterocyclic... Agent: Moore & Van Allen PLLC

20100297009 - Self-assembled polyhedral multimeric chemical structures: Self-assembled, closed and hollow chemical multimer structures having a dodecahedral morphology, composed of chemical monomers having a structurally symmetric core which possess a 5-fold rotational symmetry, are provided. Also provided are methods of creating such chemical monomers, methods of creating such chemical multimer structures and compositions comprising these chemical multimer... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100297010 - Tumor suppressor gene screening using rna interference libraries and method of treatment: The present invention is directed to methods of identifying tumor suppressor genes in vivo, tumor suppressors thus found, methods of treatment taking advantage of the identified tumor suppressors, methods of and kits for diagnosis of cancer using the identified tumor suppressor, and pharmaceutical composition comprising an identified tumor suppressor or... Agent: Wilmerhale/cold Spring Harbor Laboratory

20100297019 - Particles for imaging: The invention encompasses particles comprising metal atoms, methods of making the particles, and methods for using the particles. In particular, the particles may be used to image biological tissues or to deliver a bioactive agent.... Agent: Polsinelli Shughart PC

20100297020 - Phosphorylated and phosphonated pyrone analogs for therapeutic treatment: Methods are described for the treatment and prevention of metabolic disorders or other diseases by administering a pyrone analog or a derivative thereof. Methods are also described for the treatment and prevention of metabolic disorders and other diseases by administering a pyrone analog, or a derivative thereof, in combination with... Agent: Seed Intellectual Property Law Group PLLC

20100297018 - Prognosis and therapy of liver failure: A method for assessing prognosis in an individual suffering from liver failure, which method comprises detecting endotoxin in the individual, for example by determining the neutrophil function in the individual. The method can be used to determine whether there is an increased risk of infection in the individual, an increased... Agent: Foley And Lardner LLP Suite 500

20100297021 - Variants of c-type natriuretic peptide: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia),... Agent: Marshall, Gerstein & Borun LLP (biomarin)

20100297023 - Lipid: The present invention provides a lipid of the formula (I) R3R4N—[Y]q—(CpH2p)—X-Linker-NR1R2 (I) wherein R3 and R4 are independently selected from H and hydrocarbyl groups; q is an integer selected from 1 to 10; Y represents a group (CnH2n)NR5, wherein (i) when q is 1, n is 2, or (ii) when... Agent: Foley And Lardner LLP Suite 500

20100297022 - Magnetosome gene expression in eukaryotic cells: The invention is the production of magnetosome-like structures in cells. The invention provides in vitro and in vivo diagnostic and therapeutic methods using eukaryotic cells expressing magnetosome-like structures that act as contrast agents.... Agent: Sim & Mcburney

20100297025 - Novel compositions magnetic particles covered with gem-bisphosphonate derivatives: The invention relates also to a process for the preparation of the compositions and their use, in particular as contrast products for Magnetic Resonance Imaging (MRI).... Agent: Jacobson Holman PLLC

20100297026 - Imaging of activated vascular endothelium using immunomagnetic mri contrast agents: Immunomagnetic nanoparticles are used as a contrast agent for enhancing medical diagnostic imaging such as magnetic resonance imaging (MRI). The present invention is directed to methods of making targeted MRI contrast agents from immunomagnetic particles, and to methods of using such MRI contrast agents. Typically, such targeted MRI contrast agents... Agent: Philip S. Johnson Johnson & Johnson

20100297024 - Promoter inducible by reactive oxygen species and vector comprising the same: The invention provides promoters inducible by reactive oxygen species (ROS), capable of driving the expression of a gene of interest, particularly in a tumor cell. More particularly, it refers to promoters inducible by reactive oxygen species, that may be used to drive the expression of a gene of interest, such... Agent: Muncy, Geissler, Olds & Lowe, PLLC

20100297027 - Overt authentication features for compositions and objects and methods of fabrication and verification thereof: Overt anti-counterfeiting features on objects and compositions, especially pharmaceutical compositions. In a preferred embodiment, a counterfeiting-proof overt feature that presents a visually distinctive optical variable or invariable effect is manufactured on a pharmaceutical composition using a purely physical process. Further preferred are counterfeiting-proof, overt features that comprise at least one... Agent: Foley And Lardner LLP Suite 500

20100297028 - Medicament combinations for the treatment of respiratory diseases: e

20100297030 - Composition, device, and method for treating sexual dysfunction via inhalation: A composition, device, and method for treating sexual dysfunction via inhalation is provided which comprises inhaling a dose of apomorphine or pharmaceutically acceptable salt(s) or ester(s) thereof.... Agent: Davidson, Davidson & Kappel, LLC

20100297031 - Orodispersible tablets: This invention relates to a an orally disintegrating tablet obtainable by direct compression of a dry powdered mixture, said mixture comprising up to 15% by weight of calcium silicate, at least 50% of a diluent, a disintegrant agent and an active ingredient. It also relates to a process for preparing... Agent: Moore & Van Allen PLLC

20100297032 - Transdermal delivery system: A transdermal delivery system comprising a composition comprising a physiologically active agent and a penetration enhancer wherein the penetration enhancer comprises a combination of (i) an ester of salicylic acid, preferably selected from the C6 to C30 aliphatic ester of salicylic acid and (ii) polyethylene glycol (PEG) of average molecular... Agent: Foley And Lardner LLP Suite 500

20100297029 - Virucidal composition: t

20100297033 - Megaribavirin alone or combination of other antiviral, antioxidant and a perflubron emulsion for treatment of viral disease: The present invention is a novel method using a MegaRibavirin aerosol or a MegaRibavirin combination of therapeutics for the treatment of viral disease particularly the pandemic influenza strains “swine” 2009 H1N1 and H5N1. This invention utilizes Ribavirin in an aerosol Mega Dose (61-161 mg/ml) alone or combined with or without... Agent: Thomte Law Office, L.L.C.

20100297034 - Osmolyte-containing preparation for use in case of dry mucous membranes: The present invention relates to osmolyte-containing preparations for the local treatment of dry mucous membranes. It describes the use of osmolytes for the production of a medicament, medical product or cosmetic product for the prevention, therapy and/or care of dry mucous membranes. The present invention relates to topical compositions based... Agent: Berliner & Associates

20100297035 - Thiazole amides, imidazole amides and related analogues: Thiazole amides, imidazole amides and related analogues of the Formula: are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous... Agent: Cantor Colburn LLP

20100297036 - Pressurized cosmetic composition comprising at least one anionic polyurethane elastomer and at least one propellant: Provided is a cosmetic composition packaged in an aerosol device comprising in a cosmetically acceptable medium, at least one film-forming anionic polyurethane elastomer and at least one propellant. Also provided is a method for shaping the hair comprising applying this cosmetic composition to the hair.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100297038 - Benzimidazole derivatives and their use as cooling agents: o

20100297037 - Material composition for oral hygiene product: The present invention relates to a material composition, particularly for an oral hygiene product suitable for combating caries and also for combating parodontitis and gingivitis. Said material composition or oral hygiene product is characterized in that it comprises an extract of Curcuma xanthorrhiza or xanthorrhizol and folic acid.... Agent: Renner Otto Boisselle & Sklar, LLP

20100297040 - Cellular age advantage; nutrient reservoir cosmetic composition: In recent years the demand for cosmetic compositions and cosmetic methods for improving the appearance and condition of skin has grown enormously; consumers are seeking topical skin care products that help treat or delay the signs of natural (chronoaging) and environmental aging. The present invention relates to topical compositions for... Agent: Apriori Beauty

20100297042 - Cosmetic compositions and methods comprising rhodiola rosea: A cosmetic composition comprising a UV-protective amount of at least one rosavin, preferably present in an extract of Rhodiola rosea in a cosmetically acceptable vehicle, and methods of use thereof, including preventing or reducing the signs of photoaging.... Agent: The Estee Lauder Cos, Inc

20100297045 - Effect pigments based on artificially produced substrates with a narrow size distribution: c

20100297044 - Emulsifier mixture containing fatty alcohols, ethoxylated fatty alcohols and oil or wax components: A cosmetic composition is provided consisting of (1) an emulsifier consisting of (a) about 0.002% to about 12% of one or more fatty alcohols, based on the cosmetic composition, (b) about 0.6% to about 19.4% of one or more ethoxylated fatty alcohols, (c) about 0.002% to about 4.0% of a... Agent: Fox Rothschild LLP

20100297039 - Oil-in-water emulsion composition and method for producing the same: The present invention provides an oil-in-water emulsion composition having excellent emulsion stability, low sticky feeling, and low skin irritation. The oil-in-water emulsion composition according to the present invention comprises (a) 1 to 20 mass % of a powder component, (b) 0.001 to 0.5 mass % of a cationic surfactant having... Agent: Rankin, Hill & Clark LLP

20100297043 - Skin coating composition and uses thereof: A composition for coating skin comprising shellac, ethanol, castor oil, ethyl cellulose and fumed silica or nano zinc oxide, wherein the composition forms a long lasting waterproof flexible film on skin. The composition may include different ingredients for different applications. In one embodiment, the composition includes pigment and/or dye and... Agent: Cantor Colburn LLP

20100297041 - Stable dispersions of solid particles in a hydrophobic solvent and methods of preparing the same: A method of dispersing a solid particles in a hydrophobic solvent is disclosed. The method utilizes an acrylate copolymer containing long siloxane chains to provide stable dispersions of solid particles in hydrophobic solvents having a solubility parameter of about 8 or less, such as a silicone fluid.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100297046 - Compositions and methods related to fructosamine-3-kinase inhibitors: The invention relates to compounds and methods for inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin, by way of fructosamine-3-kinase inhibition, thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100297047 - Esters of glycerol and their uses in cosmetic and pharmaceutical applications: The invention provides mixtures of tri-, di-, and mono-glycerides obtained by esterification of fatty acids from vegetal oils such as olive oil with glycerine, their production process and their use in cosmetic and pharmaceutical preparations, in particular as vehicle or solubiliser for active ingredients.... Agent: Young & Thompson

20100297049 - Lightening and/or dyeing of human keratin fibres by means of a composition comprising a particular amino silicon compound and composition and device: The present disclosure provides a method of lightening and/or colouring human keratin fibres using at least one first composition comprising at least one specific aminosilicon compound and at least one oxidizing composition. It also provides a composition containing less than 10% by weight of water comprising at least one specific... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100297048 - Use of derivatives of 4-hydroxyphenoxy acetic acid: The present invention relates to substances which can be used as cosmetic ingredients, especially for skin whitening and as cosmetic agents against signs of ageing skin. The present invention also relates to the use of such substances for the manufacture of a medicament for the treatment of disorders related to... Agent: Fox Rothschild LLP

20100297050 - Compositions containing silicone polymer, wax and volatile solvent: The invention relates to compositions containing at least one polyorganosiloxane-containing polymer, at least one volatile non-silicone oil, at least one alkylene polymer wax, at least one silicone film-forming agent and, optionally, at least one long-chain alcohol wax, at least one coloring agent, and/or at least one volatile silicone oil, as... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100297051 - Cosmetic composition comprising at least one elastomeric anionic polyurethane and at least one non-ionic thickener: The present disclosure relates to a cosmetic composition comprising, in a cosmetically acceptable medium, at least one elastomeric anionic film-forming polyurethane and at least one non-ionic thickening polymer, as well as a hairdressing method for the shaping of the hair comprising the application of this composition.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100297052 - Cosmetic composition comprising at least one elastomeric polyurethane: Provided is a cosmetic composition comprising, in a cosmetically acceptable medium, at least one film-forming elastomeric, anionic polyurethanes, as well as a method for the styling of the hair comprising applying this composition to the hair.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100297053 - Deoderant and deoderizing product: The invention provides a deodorant excellent in the deodorization performance against aldehyde gases such as acetaldehyde and formaldehyde and a deodorant having excellent deodorization performance even against various bad smells other than aldehyde gases. The invention has been accomplished on the basis of the finding that a mixture of an... Agent: Buchanan, Ingersoll & Rooney PC

20100297055 - Cosmetic composition comprising multifunctionalised poly (alpha olefin-copolymer-maleic anhydride): The present invention relates to cosmetic compositions comprising multiple functionalized maleic anhydride/α-olefin copolymers which have been functionalized with a first reactive —OH or —NH2 group containing organic compound and subsequently with a second reactive —OH or —NH2 group containing organic compound, different from the first one. Typical examples are multiple... Agent: Seed Intellectual Property Law Group PLLC

20100297054 - 1,2,3-triazole derivatives for use as stearoyl-coa desaturase inhibitors: e

20100297056 - Composition based on perhydrosqualene and collagen-polyvinylpyrrolidone for filling minor cutaneous depressions: The present invention concerns a composition based on collagen-polyvinylpyrrolidone and perhydrosqualene for filling by intracutaneous delivery route minor depressions of the skin in order to enhance the appearance thereof without causing a negative immune reaction or rejection of the extraneous body, a method for preparing the composition and the use... Agent: Brooks Kushman P.C.

20100297057 - Pesticide compositions exhibiting enhanced activity and methods for preparing same: Pest controlling compositions exhibiting enhanced pesticidal activity levels and methods for preparing the same are disclosed. In one embodiment, a method includes providing a liquid composition that includes at least one pesticide and at least one co-ingredient that enhances pesticidal activity of the composition compared to a composition dissimilar only... Agent: Krieg De Vault LLP

20100297058 - Prebiotic composition: The present invention provides for use of a composition comprising black tea flavonoids as a prebiotic and/or for the treatment or prevention of conditions associated with poor gut health or low immunity. The flavonoids comprise thearubigin in an amount of at least 82% by weight of the tea flavonoids. Also... Agent: Unilever Patent Group

20100297059 - Methods and compositions for control of gypsy moths, lymanria dispar: e

20100297060 - Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents: Disclosed are methods and compositions for treating tumors. Disclosed methods and compositions enhance the uptake of immunocytokines into tumors, and are based on a combination of an immunocytokine with an immunocytokine uptake enhancing agent. Disclosed methods and compositions are particularly useful for reducing tumor size and metastasis in a mammal.... Agent: Goodwin Procter LLP Patent Administrator

20100297062 - Stable formulations of recombinant human albumin-human granulocyte colony stimulating factor: Described herein are compositions and methods for treating, preventing and ameliorating diseases and conditions characterized by a lower than normal white blood cell count, such as leukopenia and neutropenia. The compositions and methods include recombinant human albumin-human granulocyte colony stimulating factor. Pharmaceutical formulations including the recombinant fusion protein, and methods... Agent: Foley And Lardner LLP Suite 500

20100297061 - Stat3 antagonists and their uses as vaccines against cancer: The present invention relates to methods for treating and/or preventing cancer. In particular the present invention relates to ex vivo immunotherapeutic methods. The methods comprise decreasing Stat3 (signal transducer and activator of transcirption3) expression and/or function in tumor cells and the administration of such cells to a subject in need... Agent: Fish & Richardson, PC

20100297066 - Biodegradable peptide releasing polymers: Novel biodegradable compositions are disclosed. The biodegradable compositions include at least one hydroxyl-terminated component and at least one bioactive peptide in a linear chain. The compositions may be utilized as medical devices including drug delivery devices, tissue adhesives and/or sealants.... Agent: Tyco Healthcare Group Lp D/b/a Covidien

20100297072 - Combinations of immunostimulatory agents, oncolytic virus, and additional anticancer therapy: A method comprising administering, to a mammal, an oncolytic virus and an immunostimulatory agent. A method of treating a first tumor, a second tumor, or both in a mammal having a first tumor, comprising administering an oncolytic virus into the first tumor; and administering an immunostimulatory agent systemically to the... Agent: Williams, Morgan & Amerson

20100297070 - Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss: The invention provides compositions and methods for ameliorating, treating, reversing or preventing pathology or inflammation in the central nervous system (CNS), or the brain, caused or mediated by NFkB, IL-6, IL-6-R, NADPH oxidase (Nox), and/or superoxide and/or hydrogen peroxide production by a NADPH oxidase, including for example ameliorating, treating, reversing... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20100297063 - Cytokine zalpha11 ligand antibodies: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller... Agent: Zymogenetics, Inc. Intellectual Property Department

20100297064 - Cytokine zalpha11 ligand antibodies: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller... Agent: Zymogenetics, Inc. Intellectual Property Department

20100297073 - Heterocyclic antiviral compounds: t

20100297065 - Homogeneous preparations of il-31: Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity.... Agent: Zymogenetics, Inc. Intellectual Property Department

20100297071 - Immune response inducer: An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a... Agent: Birch Stewart Kolasch & Birch

20100297068 - Methods for treating viral infection using il-28 and il-29: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics, Inc. Intellectual Property Department

20100297067 - Methylation markers for prostate cancer and methods of use: The present invention provides methods for identifying prostate cancer by detecting nucleic acid methylation of one or more genes in one or more samples. The invention further relates to DNA methylation as a predictor of prostate cancer recurrence and patient prognosis.... Agent: Edwards Angell Palmer & Dodge LLP

20100297069 - Pegylated interleukin-10: Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus... Agent: Merck C/o Dnax

20100297074 - Wound healing compositions, systems, and methods: The present disclosure relates, according to some embodiments, to the ability of SAP to suppress the differentiation of monocytes into fibrocytes. It also relates to the ability of IL-4 and IL-3 to enhance the differentiation of monocytes into fibrocytes. Methods and compositions for binding SAP, decreasing SAP levels and suppressing... Agent: Baker Botts L.L.P. Patent Department

20100297075 - Combinational compositions and methods for treatment of cancer: The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound in combination with a therapeutically effective amount of a second anti-proliferative agent.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100297077 - Novel aryl potassium channel blockers and uses thereof: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis,... Agent: Knobbe Martens Olson & Bear LLP

20100297076 - Targeted interferon demonstrates potent apoptotic and anti-tumor activities: This invention provides novel chimeric moieties that show significant efficacy against cancers. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha... Agent: Weaver Austin Villeneuve & Sampson LLP

20100297079 - Compounds, compositions and methods for treating viral infection: The present invention describes compounds of formulae I and II and methods for treating viral infection, such as Flaviviridae virus infection, including Hepatitis C infection (HCV).... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100297080 - Genetic markers associated with interferon-alpha response: The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-α). These IFN-α response markers arc useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-α pharmaceutical compositions and drug products, in methods of... Agent: Merck Patent Department (k-6-1, 1990)

20100297078 - Method for producing a hydroxyalkyl starch derivative with two linkers: A method of producing a hydroxyalkyl starch (HAS) derivative, comprising a) reacting optionally oxidized hydroxyalkyl starch with a compound (D) comprising at least two functional groups —O—NH2 or a salt thereof, and b) reacting the hydroxyalkyl starch derivative obtained in step a) with a compound (L) comprising at least two... Agent: Occhiuti Rohlicek & Tsao, LLP

20100297081 - Pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein: The present invention provides a pharmaceutical formulation containing a recombinant human serum albumin-interferon α fusion protein (rHSA-IFNα), said formulation is prepared by dissolving the fusion protein and a pharmaceutically acceptable stable excipient in a pharmaceutically acceptable buffer which pH ranges from 5.0 to 8.0. The recombinant human serum albumin-interferon α... Agent: Jacobson Holman PLLC

20100297082 - Weight-bearing polyurethane composites and methods thereof: Present inventions present composites of particles and polymers, as well as methods of making such composite and uses thereof. A low or non-porous composite comprises a plurality of bone particles; and polyurethane components with which the bone particles are combined. Provided composites can be prepared in a one-shot process. Alternatively... Agent: Choate, Hall & Stewart LLP

20100297084 - method for transducing cells with primary cilia: This invention provides methods for transducing a ciliated cell with a recombinant serotype 2 adeno-associated virus (AAV) vector. Additionally, the invention provides methods of treating diseases associated with a mutated gene by transducing a ciliated cell with a recombinant serotype 2 AAV vector containing a corrective transgene.... Agent: Pearl Cohen Zedek Latzer, LLP

20100297083 - Polynucleotides and polypeptide of human kv1.3, compositions comprising same and methods of using same: An isolated polypeptide comprising, contiguously, a first amino acid sequence being at least 90% homologous to amino acid coordinates 1-398 of SEQ ID NO: 2, a tryptophan residue and a second amino acid sequence being at least 90% homologous to amino acid coordinates 400-523 of SEQ ID NO: 2. Also... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100297091 - Compositions and methods for treatment of melanomas: In certain embodiments, an expression construct is provided that contains a tissue-specific promoter such as tyrosinase linked to one or more cytotoxin genes. The cytotoxin genes may be saporin genes. In certain embodiments, a vector is provided that contains an expression construct as discussed above. The vector may be an... Agent: Perkins Coie LLP

20100297090 - Hematopoietic cell culture nutrient supplement: The present invention provides a serum-free supplement which supports the growth of hematopoietic cells in culture. Also provided are a medium comprising a basal medium supplemented with the serum-free supplement of the present invention. The present invention also provides methods for culturing and for differentiating hematopoietic cells.... Agent: Life Technologies Corporation C/o Intellevate

20100297089 - Method for promoting the self-renewal of adult stem cells using mesenchymal stromal cells: The present invention relates to a composition for promoting the self-renewal of adult stem cells, comprising β-catenin or notch ligand-overexpressed mesenchymal stromal cells. Further, the present invention relates to a method for promoting the self-renewal of adult stem cells by co-culturing adult stem cells with the mesenchymal stromal cells. Furthermore,... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20100297092 - Inactivated bacterial cell formulation: The invention relates to the use of lactic acid-producing bacteria to boost the immune system.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100297086 - Bacteriophage preparations and methods of use thereof: Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality of Clostridium species strains, in particular C. perfringens, C. septicum and C. difficile. In one embodiment, a purified bacteriophage preparation includes four or more C. perfringens-specific bacteriophage, wherein each bacteriophage has lytic activity against at least five Clostridium species... Agent: G. Kenneth Smith

20100297085 - Synthetic herpes simplex viruses type-1 for treatment of cancers: A recombinant herpes simplex virus type-1 (HSV-1) has been constructed that carries a deletion of one of the two viral γ1 34.5 genes and other immediate early genes, which render the virus able to selectively replicate in cancer cells but not efficiently replicate in normal cells, and in which specific... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20100297088 - Methods for culturing minimally-passaged fibroblasts and uses thereof: The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is seeded directly into a large tissue culture flask, and passaged no more than three times.... Agent: Fish & Richardson P.C.

20100297087 - Pluripotent stem cells characterized by expression of germline specific genes: The present invention relates to pluripotent or multipotent somatic stem cells characterized by the expression of the germline specific gene, DAZL. The somatic stem cells expressing the DAZL marker are further characterized by expression of additional markers and absence of expression of certain blood markers. In particular, the present invention... Agent: Winston & Strawn LLP Patent Department

20100297093 - Modified t cell receptors and related materials and methods: The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with one or more amino acid substitutions in the CDR2 and/or CDR3 regions of the alpha and/or beta chains of the TCR, wherein the modified TCR, as compared to... Agent: Leydig, Voit & Mayer, Ltd.

20100297094 - Therapy or prevention of diseases with cells or cell supernatant: Methods and compositions for the treatment or prevention of diseases or disorders including media conditioned by mesenchymal stem cells and BCL2A1 are provided. Methods for the production of therapeutic or preventative compositions contacted with BCL2A1 are also provided.... Agent: University Of Washington/fenwick

20100297096 - Amphiphilic peptide matrices for treatment of osteoporosis: The present invention provides methods for prevention, prevention of progression, and treatment of osteoporosis and pre-osteoporotic conditions comprising direct administering to osteoporetic bone of a composition comprising amphiphilic peptides and peptide matrices thereof, useful in promoting biomineralization, local osteoporetic medications and inducing bone repair.... Agent: Winston & Strawn LLP Patent Department

20100297095 - Porifera-based therapeutic compositions for treating and preventing skin diseases: Therapeutic compositions and methods for using same for treating skin conditions and diseases are disclosed. Treatable skin conditions and diseases include without limitation acne vulgaris, rosacea, seborrheic dermatitis, eczema (atopic dermatitis), psoriasis, photo-aging and actinic keratosisacne vulgaris, psoriasis, photo-aging and eczema. Therapeutic compositions disclosed are derived from Porifera species, specifically... Agent: K&l Gates LLP

20100297097 - Compounds: and salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for inhibiting SCD activity, such as diseases related to elevated lipid levels, cardiovascular disease, diabetes, obesity, metabolic syndrome, skin disorders such as acne, diseases or conditions related to cancer and... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100297098 - Purification of factor xiii polypeptides from biological materials: The invention relates to a method for purifying a factor XIII polypeptide from a biological material, the method comprising subjecting the material to sequential chromatography on an anion-exchange matrix and a hydrophobic interaction matrix.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100297099 - Airway administration of activated protein c in inflammatory conditions affecting the respiratory tract: The present invention provides methods for the local treatment of acute and chronic extravascular pulmonary fibrin deposition and/or reducing unwanted effects associated with systemic administration of anticoagulants to a subject via airway administration to the subject by intratracheal, intrabronchial or intraalveolar routes of human activated protein C or biologically active... Agent: Licata & Tyrrell P.C.

20100297100 - Composition for treating retinopathy or glaucoma comprising thrombin derived peptides: Disclosed is a composition for treating retinopathy comprising thrombin derived peptide as an effective component.... Agent: Clark & Elbing LLP

20100297105 - Administering antisense oligonucleotides complementary to human apolipoprotein b: Methods for long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated ApoB are provided.... Agent: Jones Day For Genzyme Corporation

20100297103 - Antibody having enhanced adcc activity and method for production thereof: Disclosed is an antibody having an enhanced ADCC activity. Also disclosed is a method for producing the antibody. It was attempted to advance the technique of the amino acid mutation in an Fc region established by researchers of Genentech Inc. or the like, and a study was made on whether... Agent: Edwards Angell Palmer & Dodge LLP

20100297104 - Dendritic macromolecule and a process thereof: The present invention is in relation to a dendritic molecule having symmetrically sited branches having four or more generations of dendrimers wherein the branch points are tertiary amines linked together with oxygen atom of ether and the heteroatoms are separated by a substituted or non-substituted linear three methylene linker. In... Agent: The Nath Law Group

20100297107 - Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases: A method of treating vascular diseases by administering an antagonist molecule that inhibits the interaction between a protein of the HMG box family and a receptor for the protein of the HMG box family.... Agent: Young & Thompson

20100297101 - Integrin alpha. ii .b.beta.3 specific antibodies and peptides: The present invention provides integrin αIIbβ3 specific antibodies and peptides. The antibodies and peptides demonstrate little or no immunoreactivity with other integrins. Methods for inhibiting platelet aggregation using the antibodies and peptides are also provided.... Agent: Bell & Associates

20100297108 - Method of providing patient specific immune response in amyloidoses and protein aggregation disorders: A novel treatment of Alzheimer's disease and other disorders involving protein misfolding or aggregation is provided by enhancing or sustaining an antibody response against predominantly directed against pathological protein aggregates or neo-epitopes present on pathogenic forms of said protein or protein complex. Furthermore, therapeutic methods are also described, wherein ex... Agent: Cooper & Dunham, LLP

20100297109 - Methods for inhibiting fascin: The invention relates to compositions and methods useful for inhibiting fascin. These compositions and methods can be used to inhibit fascin-related diseases. For example, according to the invention inhibition of fascin inhibits metastasis of tumor cells in mammals.... Agent: Foley & Lardner LLP

20100297106 - Pharmaceutical formulations: A stable pharmaceutical formulation is provided that comprises a biologically active protein and an excipient selected from carnitine, creatine or creatinine.... Agent: Marshall, Gerstein & Borun LLP

20100297102 - Serotonin 5-ht3a receptors in treatment of neurological and psychiatric disorders: Methods are provided for modulating post-natal migration of neurons. Activation of the 5-HT3A receptor increases migration, while pharmacological blockade of the 5-HT3A receptor disrupts neuroblast migration into the cortex and hippocampus. These neuroblasts mature into GABAergic interneurons, and thus are relevant to conditions associated with disturbances in 5-HT levels and... Agent: Bozicevic, Field & Francis LLP

20100297110 - Antibody specific for human il-4 for the treatment of cancer: The present invention relates to the use of an antibody or an antigen-binding fragment thereof with specific binding activity for human interleukin-4 for the prevention and/or treatment of cancer.... Agent: Duane Morris LLP - (prev. San Francisco)IPDepartment

20100297111 - nanobodies against tumor necrosis factor-alpha: The present invention relates to improved Nanobodies™ against Tumor Necrosis Factor-alpha (TNF-alpha), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host... Agent: Wolf Greenfield & Sacks, P.C.

20100297114 - Antigen presenting cell targeted vaccines: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides... Agent: Chalker Flores, LLP

20100297117 - Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration: The present invention relates to stable aqueous protein formulations. In particular, disclosed herein are therapeutic protein formulations suitable for parenteral administration having one or more antioxidants.... Agent: Marshall, Gerstein & Borun LLP

20100297112 - Combinations comprising dmxaa for the treatment of cancer: The present invention relates to combinations of compounds such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and vascular endothelial growth factor binders, in particular the monoclonal antibody Avastin™ (bevacizumab). More particularly, the invention is concerned with the use of such combinations in the treatment... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100297113 - Quinone derivatives, pharmaceutical compositions, and uses thereof: This application describes quinone derivatives which target the redox site of Ape1/Ref1. Also included in the invention are pharmaceutical formulations containing the derivatives and therapeutic uses of the derivatives.... Agent: Barnes & Thornburg LLP

20100297118 - Therapeutic cancer treatments: Provided are methods for treating non-small cell lung cancer by administering a therapeutically effective amount of a hedgehog inhibitor.... Agent: Fish & Richardson P.C.

20100297115 - Use of trkb antibodies for the treatment of respiratory disorders: The invention discloses TrkB antibodies for the development of new therapeutics to treat, prevent or ameliorate respiratory disorders. The invention also relates to methods to treat, prevent or ameliorate said conditions and pharmaceutical compositions therefor, as well as to a method to identify compounds with therapeutic usefulness to treat conditions... Agent: Genomics Institute Of The Novartis Research Foundation

20100297116 - Uses of a glycoprotein vi (gpvi) inhibitor: The present invention describes a method for reducing reperfusion injury and/or infarction by using an inhibitor of platelet GPVI. This method may be used to treat patients during or after a heart attack or elective cardiac surgery.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100297120 - Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues: Based on our identification of a polypeptide (Angiopep-7) that is efficiently transported to cells such as liver, lung, kidney, spleen, and muscle, the invention provides polypeptides, conjugates including the polypeptides, and methods for treating diseases associated with these cell types. Unlike other aprotinin related polypeptides identified herein (including Angiopep-3, Angiopep-4a... Agent: Clark & Elbing LLP

20100297119 - Bone targeted alkaline phosphatase, kits and methods of use thereof: A bone targeted alkaline phosphatase comprising a polypeptide having the structure: Z-sALP-Y-spacer-X-Wn-V, wherein sALP is the extracellular domain of the alkaline phosphatase; wherein V is absent or is an amino acid sequence of at least one amino acid; X is absent or is an amino acid sequence of at least... Agent: Clark & Elbing LLP

20100297123 - Combination therapy to inhibit t cell effector function: Methods and compositions are provided for inhibiting the responsiveness of CD4+ T cells that have been sensitized to antigen, i.e. CD4+ memory, or effector T cells. It is shown herein that such effector T cells will fail to proliferate in response to antigen when inhibited by two compounds, which act... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20100297122 - Formulations for taci-immunoglobulin fusion proteins: The invention relates to formulations of TACI-Immunoglobulin fusion proteins.... Agent: Alston & Bird LLP

20100297124 - Induced internalization of surface receptors: Disclosed is a hetero-bifunctional ligand for use in inducing internalization of a target receptor. The hetero-bifunctional ligand includes a target receptor-binding agent that specifically binds the target receptor linked to an internalizing receptor-binding agent that specifically binds to an internalizing receptor, where the two binding agents are non-identical. Also disclosed... Agent: Klarquist Sparkman, LLP (ott-nih)

20100297121 - Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists: This invention relates to methods for promoting neuronal survival and regeneration using LINGO-1 antagonists and TrkB agonists. Additionally, the invention relates to methods for treating pressure induced optic neuropathies using LINGO-1 antagonists. The invention also relates generally to methods for increasing TrkB activity and inhibiting JNK pathway signaling using a... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20100297125 - Methods of treating pain using antagonists of il-31, il-31ra and/or osmrb: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.... Agent: Zymogenetics, Inc. Intellectual Property Department

20100297126 - Monoclonal antibodies specific to hemagglutinin from influenza virus h5-subtype and uses thereof: Monoclonal antibodies and related binding proteins that are specific for conformational epitopes of avian influenza virus K5 subtype hemagglutinin glycoprotein are provided. The antibodies can be used for the detection and treatment of H5 subtype AIV in specimens.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100297127 - Use of il-27 antagonists to treat lupus: This invention relates to methods of treating the autoimmune disorder lupus with IL-27 antagonists, as well as articles of manufacture comprising IL-27 antagonists. The invention also relates to methods and kits for identifying patients that are likely to respond to an IL-27 antagonist treatment.... Agent: Morrison & Foerster LLP

20100297128 - Gamma secretase modulators: This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula [Chemical formula should be inserted here as it appears on abstract in electronic form.] Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's disease using the compounds of formula... Agent: Merck Patent Department (k-6-1, 1990)

20100297129 - Method for extending pregnancy in patients exhibiting at least one symptom of preeclampsia and eclampsia: A composition is provided to prevent, limit the effects of, delay the onset of, or treat one or more of the causes, symptoms or complications of gestational hypertension, preeclampsia, eclampsia and/or intrauterine growth restriction. The composition comprises a therapeutically effective amount of an antibody that reacts immunologically with or binds... Agent: Hunton & Williams LLP Intellectual Property Department

20100297130 - Protective anti-glucan antibodies with preference for beta-1,3-glucans: Anti-β-1,3-glucan antibodies have been found to be protective against systemic fungal infection with Candida albicans. The present invention provides monoclonal antibodies that bind to β-1,3-glucan, hybridoma cell lines producing the antibodies, compositions comprising the antibodies and methods of using such antibodies for treatment of microbial infections, particularly against Candida albicans... Agent: Robins & Pasternak

20100297131 - Binding domain of plasmodium reticulocyte binding proteins: The present invention provides isolated polynucleotides, polypeptides, antibodies and/or vaccines for the prevention and/or treatment of malaria caused by Plasmodium falciparum and/or Plasmodium vivax. In particular, the polypeptide fragments are derived from the binding domain of the reticulocyte binding proteins of Plasmodium falciparum and/or Plasmodium vivax. The present invention also... Agent: Remenick PLLC

20100297135 - Epitope for neutralizing antibodies: Provided herein are immunogenic peptides of GM-CSF comprising an amino acid sequence set forth in any one of SEQ ID NOs:2 to 6, or a portion thereof, and compounds and molecules that specifically interact with or bind to a region of GM-CSF located between, or corresponding to a region located... Agent: Howson & Howson LLP

20100297136 - Gastric and prostate cancer associated antigens: The invention relates to an antigen associated with cancers such as prostate and gastric cancers, known as T21. Nucleic acid sequences and polypeptide sequences encoding the antigen are provided, as are uses of such sequences.... Agent: Barnes & Thornburg LLP

20100297134 - Humanised antibodies with anti-tumour activity: The present invention provides humanised antibodies and binding domains thereof with anti-tumour activity. In particular the humanised antibodies have specific binding to and direct killing of human colon tumour cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement... Agent: Ross J. Oehler Cephalon, Inc.

20100297133 - Immunogenic polypeptides and monoclonal antibodies: Provided herein are compositions and methods for eliciting an immune response against Streptococcus pneumoniae. More particularly, the compositions and methods relate to immunogenic polypeptides, including fragments of PhtD and variants thereof, and nucleic acids, vectors and transfected cells that encode or express the polypeptides. Methods of making and using the... Agent: Patrick J. Halloran, Ph.d., J.d

20100297132 - Monoclonal antibody: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The... Agent: Jones Day

20100297137 - Hematopoietic lineage cell specific protein (hs1) as a marker for lymphoid malignancy: Use of a phosphorylated form of hematopoietic-lineage-cell-specific-protein-1 (HS1) as a prognostic or diagnostic marker for a Lymphoid Malignancy, a disease in which B cell receptor stimulation is dysregulated or disease characterised by B lymphocyte proliferation.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100297138 - Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions... Agent: Baker Botts L.L.P.

20100297139 - Methods and compositions for the treatment of proteinuric diseases: The present invention is directed to methods of treating proteinuric diseases by the administration of avβ3 integrin inhibitors.... Agent: Novak Druce + Quigg LLP (wpb)

20100297141 - Anti-adhesin based passive immunoprophlactic: The invention relates to an immunogenic composition and method of the immunogenic composition for the production and administration of a passive immunoprophylactic against enterotoxigenic Escherichia coli. The immunoprophylactic is made collecting anti-adhesin in the colostrum or milk of vaccinated domesticated animals such as cows. The immunoprophylactic is administered either as... Agent: Naval Medical Research Center Attn: (code 00l)

20100297140 - Uses of antibodies: The present invention provides a method of preparing an antibody-containing milk or egg product for use in preventing and/or treating of a non-infectious medical condition. The invention also provides non-systemic modes of administering pharmaceutical compositions including the antibody-containing milk or egg products, including to the GI tract.... Agent: The Firm Of Hueschen And Sage

20100297143 - Methods for treating psoriasis: The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.... Agent: Mccarter & English, LLP / Abbott Laboratories Ltd.

20100297142 - Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy: Methods of treating, preventing or managing cancers are disclosed. The methods encompass the administration of SNS-595 in combination with a second active agent. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cisplatin, carboplatin, gemcitabine or a combination thereof.... Agent: Jones Day

20100297144 - Multitype hpv peptide compositions and methods for treatment or prevention of human papillomavirus infection: Embodiments of the invention are directed to methods and compositions of multitype HPV polypeptides.... Agent: Venable LLP

20100297145 - Apoptosis promoter, cell proliferation inhibitor, prophylactic/therapeutic agent for cancer, screening method for the promoter, inhibitor or agent: Disclosed is an apoptosis promoter, cell proliferation inhibitor, prophylactic/therapeutic agent for cancer or the like which comprises a compound capable of inhibit the expression or function of PCA-1 as an active ingredient. Also disclosed is a method for screening of a compound for use in the promotion of apoptosis, the... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100297148 - Cd38 modulated chemotaxis: The present invention relates to methods for modulating the migratory activity of cells expressing CD38 for the treatment of disorders including, but not limited to, inflammation, ischemia, asthma, autoimmune disease, diabetes, arthritis, allergies, infection with pathogenic organisms, such as parasites, and transplant rejection. Such cells include, for example, neutrophils, lymphocytes,... Agent: Kenyon & Kenyon LLP

20100297149 - Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities: Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.... Agent: Seed Intellectual Property Law Group PLLC

20100297147 - Compositions and methods for modulating tlr14 activity: Methods and compositions for modulating neural cell function using antagonists of TLR14 are disclosed. In particular, methods for treating, preventing and/or diagnosing TLR14-associated neurodegenerative conditions and/or disorders are disclosed. Screening methods for evaluating TLR14 modulators, e.g., agonists and antagonists, are also disclosed.... Agent: Lando & Anastasi, LLP

20100297150 - Disease treatment via antimicrobial peptide inhibitors: A method of treating a disease in a subject in need thereof is disclosed. The method comprises providing to the subject a therapeutically effective amount of a compound being capable of decreasing an activity and/or level of an antimicrobial peptide (AMP) and/or AMP-like molecule, thereby treating the disease in the... Agent: Martin Moynihan C/o Anthony Castorina

20100297146 - Immune system programming through b7-dc: Materials and methods related to modulating immune responses (e.g., altering the polarity of immune responses) are provided.... Agent: Fish & Richardson P.C.

20100297151 - Antibodies against human il-21 receptor and uses therefor: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The antibodies can act as antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used... Agent: Fitzpatrick Cella Harper & Scinto

20100297153 - Binding molecules for treatment and detection of cancer: Provided are new tumor-associated antigens, binding molecules that specifically bind to the antigens, nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules, and methods of identifying or producing the binding molecules. The tumor-associated antigens are expressed on cancer cells and binding molecules capable of specifically binding to... Agent: Traskbritt, P.C.

20100297152 - Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer: Described herein are genes whose expression are up-regulated or down-regulated in prostate cancer. Also described are such genes whose expression is further up-regulated or down-regulated in drug-resistant prostate cancer cells. Related methods and compositions that can be used for diagnosis and treatment of prostate cancer are disclosed. Also described herein... Agent: Davis Wright Tremaine LLP/los Angeles

20100297156 - Analogues of phosphatidylinositol mannosides: The invention relates to compounds which are immunomodulatory compounds and, in particular, can induce IL-12 secretion. The invention also relates to compositions containing the compounds, precursors, and prodrugs of these compounds, use of these compounds as adjuvants in combination with vaccines, and use of these compounds for treatment of diseases... Agent: Marshall, Gerstein & Borun LLP

20100297154 - Cd40 ligand-enhanced cells and methods of modulating an immune response to an antigen: The invention provides for a method of vaccinating a mammal to a selected antigen, wherein the method comprises administering to a mammal a vaccine composition comprising a CD40 ligand-enhanced cell, wherein the CD40 ligand-enhanced cell comprises a selected antigen and is admixed with an engineered ligand for CD40.... Agent: Edwards Angell Palmer & Dodge LLP

20100297155 - Phosphazene hydrogels with chemical corss-link, preparation method thereof and use thereof: A phosphazene-based polymer hydrogel with a chemical cross-linkings formed by radiating ultraviolet (UV) and/or mixing with cross-linking agent and/or enzyme, a method of preparing the same, and a hydrogel forming a chemical cross-linking by radiating ultraviolet and/or mixing with a cross-linking agent and/or an enzyme; where the hydrigel shows a... Agent: LexyoumeIPGroup, PLLC

20100297158 - Anticancer vaccine and diagnostic methods and reagents: The invention provides a method for vaccinating a patient against a malignancy comprising introducing a protein or peptide comprising of all or an immunogenic fragment of a cyclin protein into the patient. The invention further provides a method of identifying tumor antigens.... Agent: Leydig Voit & Mayer, Ltd

20100297160 - High molecular weight amyloid beta as a carrier for the oral delivery of vaccine antigens: Compositions and methods are provided for stabilizing polypeptide antigens such as amyloid-beta (Aβ) to produce vaccines for oral delivery. One embodiment provides an immunogenic polypeptide complex of Aβ42 and an fragment of receptor for advanced glycation endproducts (RAGE).... Agent: Pabst Patent Group LLP

20100297159 - Thomsen-friedenreich disaccharide modified immunogen (tfd), preparation procedure, compositions comprising it, uses, and treatment methods: Modified Thomsen-Friedenreich disaccharide (TFD) immunogen, preparation procedure, compositions containing it, uses, and treatment methods. More specifically, the present invention refers to a immunogen obtained by modifying TFD, and comprising the general formula D-TFD-Lys(n)-C, wherein D is a hydrophobic terminal residue, TFD is disaccharide Galβ3GalNAcα; Lys(n) is a lysine connector, and... Agent: The Nath Law Group

20100297157 - Vaccine therapy for choroidal neovascularization: The present inventors administered a peptide derived from VEGFR-2, which is known as one of the proteins involved in neovascularization, to model mice (A2/Kb transgenic mice) expressing human HLA-A*0201, and tested whether or not the peptide has vaccine effect. As a result, the present inventors successfully discovered that vaccination using... Agent: Townsend And Townsend And Crew, LLP

20100297161 - Immunoprotective influenza antigen and its use in vaccination: The present invention relates to an influenza antigen, comprising a fusion product of at least the extracellular part of a conserved influenza membrane protein or a functional fragment thereof and a presenting carrier, which may be a presenting (poly)peptide or a non-peptidic structure, such as glycans, peptide mimetics, synthetic polymers.... Agent: Edward P. Gamson

20100297162 - S. epidermidis antigens: Hyperimmune serum reactive antigens and fragments thereof are disclosed. In addition, methods for isolating such antigens and specific uses thereof, including the treatment of S. epidermidis infections, are disclosed.... Agent: Fulbright & Jaworski L.L.P.

20100297163 - Recombinant malaria vaccine: The present invention refers to a recombinant malaria vaccine and a method for its manufacture.... Agent: Bozicevic, Field & Francis LLP

20100297164 - Chlamydial antigens: The invention is in the field of immunology and vaccinology. In particular, it relates to antigens derived from Chlamydia trachomatis that are expressed on the cell surface and so are ideal for use in immunisation as well as combinations of these antigens.... Agent: Novartis Vaccines And Diagnostics Inc.

20100297165 - Immunostimulatory combinations of tlr ligands and methods of use: The present invention provides immunostimulatory combinations of TLR ligands and therapeutic and/or prophylactic methods that include administering an immunostimulatory combination to a subject. In general, the immunostimulatory combinations described herein can provide an increased immune response compared to other immunostimulatory combinations and/or compositions.... Agent: Ott-nih C/o Edwards Angell Palmer & Dodge LLP

20100297166 - Meningococcal oligosaccharide linked polysaccharides and diptheria protein conjucate vaccine for all ages: Methods for producing quadrivalent meningococcal meningitis polysaccharide and conjugate vaccines for serotypes A, C, Y and W-135 disclosed. Neisseria meningitidis fastidious medium was designed to maximize the yield of capsular polysaccharides and generate minimal cellular biomass and endotoxin in a short duration of fermentation. The crude polysaccharides are isolated, purified,... Agent: Jeeri R. Reddy

20100297168 - Lentiviral gene transfer vectors and their medicinal applications: The present invention relates to the design of gene transfer vectors and especially provides lentiviral gene transfer vectors suitable for either a unique administration or, for iterative administration in a host, and to their medicinal application (such as vaccination against Immunodeficiency Virus, especially suitable in human hosts). Gene transfer vectors... Agent: Birch Stewart Kolasch & Birch

20100297167 - Method for the production of recombinant virus, dna constructs, recombinant virus and vaccine compositions: The purpose of the present invention is the production of recombinant virus through the cloning and expression of sequences of coding nucleotides of the whole or part of heterolog proteins, through the following method: (a) modification of the heterolog nucleotides sequences in such way they when cloned and expressed in... Agent: Michael Falco

20100297169 - Novel neutralizing immunogen (nimiv) of rhinovirus and its use for vaccine applications: The invention relates to methods and compositions for preventing or treating human rhinovirus infection.... Agent: Clark & Elbing LLP

20100297170 - Vaccines: The invention refers an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R1—XZSZN—XZX—R2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.... Agent: Fulbright & Jaworski L.L.P.

20100297171 - Development of a preventive vaccine for filovirus infection in primates: The present invention relates generally to viral vaccines and, more specifically, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.... Agent: Townsend And Townsend And Crew, LLP

20100297172 - Replication-defective arenavirus vectors: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100297173 - Prophylactic and therapeutic immunization against protozoan infection and disease: Polypeptide and polynucleotide vaccines effective to treat or prevent infection of a mammal, such as a dog, a cat, or a human, by a protozoan. Methods of treatment and prevention are also provided, including therapeutic administration of the vaccine to an infected mammal to prevent progression of infection to a... Agent: Mueting, Raasch & Gebhardt, P.A.

20100297174 - Influenza virus vaccines and uses thereof: Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use.... Agent: Jones Day

20100297175 - Mutations in a toll-like receptor motif in the ns4b of classical swine fever virus strain brescia influences virulence in swine: NS4B is one of the non-structural proteins of classical swine fever virus. By using functional genetics, we have discovered, in the predicted amino acid sequence of NS4B of CSFV strain Brescia, a motif that resembles those found in the toll-like receptor (TLR) proteins, a group of host cell proteins involved... Agent: Usda, Ars, Ott

20100297176 - Polyinosinic acid - polycytidylic acid - based adjuvant: The present invention provides a polynucleotide adjuvant composition and methods of use in eliciting an immune response. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with an antigen (e.g., as in a vaccine). The adjuvant compositions of the invention have particular physical properties (e.g.,... Agent: Bozicevic, Field & Francis LLP

20100297177 - Mutated parvovirus structural proteins as vaccines: The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid... Agent: Clark & Elbing LLP

20100297179 - Immunology treatment for biofilms: The invention provides a composition for use in raising an immune response to P. gingivalis in a subject, the composition comprising an amount effective to raise an immune response of at least one polypeptide having an amino acid sequence substantially identical to at least 50 amino acids, or an antigenic... Agent: Dla Piper LLP (us)

20100297178 - Novel genes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy: Novel polynucleotide and amino acids of Brachyspira hyodysenteriae are described. These sequences are useful for diagnosis of B. hyodysenteriae disease in animals and as a therapeutic treatment or prophylactic treatment of B. hyodysenteriae disease in animals. These sequences may also be useful for diagnostic and therapeutic and/or prophylactic treatment of... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20100297181 - Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ: The invention provides methods for treating epilepsy, mental disorders and/or deficits in sensory organ by administering to patients therapeutically effective amounts of AMPA receptor antagonists in combination with one or more other active ingredients useful for treating epilepsy, mental disorders and/or deficits in sensory organ. The invention also provides pharmaceutical... Agent: Clark & Elbing LLP

20100297180 - Botulinum neurotoxin vaccine: The invention provides compositions comprising an antigenic botulinum neurotoxin serotype E (BoNT/E) peptide, wherein the peptide has improved solubility and thus improved ability to stimulate an immune response against BoNT/E holotoxin. The composition may be used as part of a multivalent vaccine regimen via coordinated use with non-serotype E BoNT... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100297182 - Injectable amino-acid composition: An injectable amino-acid composition acts naturally to fuel collagen synthesis, which retards aging and helps to clear cellular decay while accelerating the cell division that promotes healthy, younger looking skin. The amino-acid composition includes carnosine. The composition is injected into the dermis of patients. The composition can be used in... Agent: Assouline & Berlowe

20100297183 - Immunogenic streptococcus proteins: The invention provides means and methods for identifying a Streptococcus protein which is capable of eliciting an immune response against at least two Streptococcus strains and/or serotypes. The invention further discloses immunogenic compositions capable of eliciting an immune response against Streptococcus uberis comprising at least two recombinant and/or isolated proteins... Agent: Traskbritt, P.C.

20100297184 - Vaccines: The invention provides Streptococcus vaccine strains (e.g. S. equi which is causative of ‘strangles’) comprising the following modifications in their genomes: (i) attenuation of one or more essential biosynthetic genes, (ii) attenuation of one or more genes which encode a haemolytic toxin, or protein involved in the production thereof, plus... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20100297185 - Mycobacterial mutants affecting host apoptosis: Provided are recombinant mycobacteria having a mutation in an nlaA gene or in a nuoG gene. Also provided are isolated and purified nlaA proteins and nuoG proteins from a mycobacterium. Additionally provided are isolated and purified nucleic acids comprising a recombinant nlaA gene or a recombinant nuoG gene. Further provided... Agent: Amster, Rothstein & Ebenstein LLP

20100297186 - Multicomponent or monocomponent vaccine to be used against chagas disease, pharmaceutical compositions containing them, procedure for the obtention of immunogen of said vaccines, and nucleic acid used in said procedure: A vaccine against the Chagas disease, capable of stimulating the immune response against the trans-sialidase virulence factor of the Trypanosoma Cruzi parasite, which is a multicomponent vaccine comprising: (a) an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of thereof and (b) one or more... Agent: Patent Central LLC Stephan A. Pendorf

20100297187 - Peptide sequences and compositions: v

20100297188 - Allergens and allergoids from bee venom: The present invention concerns the preparation of purified allergens and allergoids, both derived from whole bee venom, for the desensitisation (immunotherapy) of subjects affected by a specific allergy. In particular, the present invention concerns a preparation for immunotherapy based on purified bee venom, characterised in that said bee venom is... Agent: Dickstein Shapiro LLP

20100297189 - Allogeneic tumor therapeutic agent, a vaccine using allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such a vaccine, and transfected human tumor cells for use as a vaccine: Vaccine on the basis of allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such vaccine, furthermore transfected human tumor cells for their use as a vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As... Agent: Ursula B. Day, Esq. Ursula B. Day

20100297195 - Controlled release lamotrigine formulations: The present invention relates to controlled release formulations comprising lamotrigine and process for preparation thereof.... Agent: Ranbaxy Inc.

20100297196 - Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids: A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R1 and R2 together form a group —(CH2)n—CR4R5—(CH2)m— wherein n and m are independently selected integers 0, 1 or... Agent: Nixon & Vanderhye, PC

20100297194 - Formulation for oral administration of apoptosis promoter: An orally deliverable pharmaceutical composition comprises as a sole or first active ingredient a compound of Formula I defined herein or a pharmaceutically acceptable salt thereof, for example ABT-263 free base or ABT-263 bis-HCl salt, dispersed, in a free base equivalent amount of at least about 2.5% by weight of... Agent: Harness Dickey & Pierce, PLC

20100297190 - Identification features: Methods for providing pharmaceutical compositions and objects with identification regions and identification features which are difficult to detect. Microlithography, nanolithography, and stamping methods are used. The identification features can be positive protrusions or negative indentations with respect to the surface. The identification regions can comprise bar codes and holograms. DPN... Agent: Foley And Lardner LLP Suite 500

20100297191 - Method for manufacturing a cleansing and/or care article: t

20100297193 - Methods of therapeutic treatment of eyes: Provided are electrokinetically-altered aqueous fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating an irritation, infection or... Agent: Davis Wright Tremaine, LLP/seattle

20100297192 - Use of microparticles for vaccines and the release of biologically active molecules: The invention relates to microparticles based on a PLGA biodegradable polymer and an alginate polymer which encapsulate immunologically active peptides or proteins. Said microparticles, and the pharmaceutical compositions developed from them and the uses thereof, are applicable to the field of human and animal health as a vaccine and system... Agent: Intellectual Property / Technology Law

20100297203 - Impact of calcium phosphate complex on dental caries: The present invention relates to chewing gum and confectionery compositions and methods for reducing dental caries in mammals. In particular, the compositions may include a gum base or carrier, sweetening agents and casein phosphopeptide-calcium phosphate (CPP-ACP). The compositions may be employed to slow the progression and enhance the regression of... Agent: Hoffmann & Baron, LLP

20100297198 - Liquid-type dentifrice composition contained silver particles and mousse-type dentifrice using the same: Disclosed are a liquid type dentifrice composition primarily containing silver particles which is drawn out in foam state when used to brush teeth to prevent the liquid dentifrice from flowing down during tooth-brushing, resulting in effective and convenient tooth-brushing function and exhibit bactericidal action and protect mouth and teeth from... Agent: Jae Y. Park

20100297199 - Nanoemulsion of resveratrol-phospholipid complex and method for preparing the same and applications thereof: The present invention relates to a nanoemulsion of resveratrol-phospholipid complex, method for preparing the same and applications thereof. The nanoemulsion comprises: 1 part by weight of resveratrol, 2˜30 parts by weight of phospholipid, and 30˜490 parts by weight of an aqueous solution of polyol with the polyol concentration being 30˜99... Agent: Nexsen Pruet, LLC

20100297197 - Non-fluoride containing dietary supplement toothpaste and methods of using the same: A non-fluoride containing toothpaste enriched with at least one dietary supplement. The non-fluoride containing toothpaste comprising a dentally acceptable oral vehicle containing a sufficient amount of thickening agent to impart a pasty consistency; and at least one dietary supplement wherein a serving size portion of the non-fluoride containing toothpaste contains... Agent: Dilworth & Barrese, LLP

20100297202 - Planar antenna and method of manufacturing the same: Disclosed is an aqueous dispersion containing polysaccharide particulate gels, which is characterized by containing particulate gels substantially composed of a polysaccharide. The aqueous dispersion containing polysaccharide particulate gels is also characterized in that shapes of the particulate gels are maintained even after the particulate gels are heated for 30 minutes... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20100297200 - Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents: The present invention is directed to compositions comprising at least one nitric oxide donor and at least one second therapeutically active agent with antimicrobial or wound healing capability. In one embodiment, the nitric oxide donor is a nanoparticle which is designed to control for the amount and duration of release... Agent: Alston & Bird LLP

20100297201 - Use of polyelectrolyte complexes in antiperspirant technology: Polyelectrolyte complexes between cationic polymers and anionic polymers are used in antiperspirant compositions containing an active antiperspirant ingredient.... Agent: International Specialty Products William J. Davis, Esq.

20100297204 - Particulate polymers comprising biocidal active substance: The present invention relates to a particulate polymer matrix containing a biocidal active substance, distributed homogeneously in the polymeric matrix, processes for their preparation, dispersions containing this particulate polymer matrix, and their use as a microbiocidal composition for protecting industrial materials.... Agent: Lanxess Corporation

20100297205 - Patch for the expulsion of insect poison from the skin after stings from membranous insects (hymenoptera): This invention relates to a patch for the expulsion of insect poison from the skin after stings from membranous insects (Hymenoptera). The patch is characterized in comprising a poison-aspirating matrix comprising an expulsion agent as well as a swell layer, which swells after the addition of a liquid through a... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20100297206 - Antimicrobial upconversion system: Antimicrobial articles, systems, and methods may be used for killing, inactivating, and/or inhibiting microorganisms. The antimicrobial articles and systems utilize up-conversion luminescence wherein a phosphor or luminescent material is capable of absorbing visible, infrared light, or longer wavelength radiation and emitting antimicrobial ultraviolet radiation via upconversion thus inhibiting the growth... Agent: Troutman Sanders LLP 5200 Bank Of America Plaza

20100297207 - Quaternary ammonium salts as microbe inhibitors: The present invention relates to quaternary ammonium salts and their use as mold inhibitors. The quaternary salts can be prepared by a chloride ion-promoted reaction between a tertiary amine and an alcohol or polyol in strong acid solution. The quaternary ammonium salts can be applied to a substrate in order... Agent: Jackson Walker LLP

20100297208 - Scaffold: The present invention relates to scaffolds which can be used as medical devices for guided tissue regeneration and repair, in particular the invention is directed to a scaffold comprising fibres having a mean fibre diameter of between from about 1.2 to 4.0 microns, wherein the fibres comprise a glycolide. The... Agent: Knobbe Martens Olson & Bear LLP

20100297209 - Solvent/polymer solutions as suspension vehicles: A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be selected from the group... Agent: Intarcia Therapeutics, Inc. Attn: Barbara G. Mcclung

20100297211 - Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents: n

20100297210 - Repair and treatment of bone defect using agent produced by chondrocytes capable of hypertrophication and scaffold: The present invention provides a composite material for promoting or inducing osteogenesis in a biological organism. The composite material includes: A) an induced osteoblast differentiation inducing agent obtained by culturing chondrocytes capable of hypertrophication in a differentiation agent producing medium containing dexamethasone, β-glycerophosphate, ascorbic acid and a serum component; and... Agent: Seed Intellectual Property Law Group PLLC

20100297212 - Scaffold for cell growth and differentiation: The present invention provides a devitalized mammalian parenchymatous tissue composition which includes an interstitial structure which can serve as a scaffold for tissue repair or regeneration. The devitalized mammalian parenchymatous tissue composition can further include the basement membrane of the tissue.... Agent: Burns & Levinson, LLP

20100297213 - Method for making patches by electrospray: The invention relates to patches and methods for manufacturing patches intended for skin application of a substance wherein the patch includes a conductive support, and a liquid formulation of the substance is deposited on the support of the patch by electrohydrodynamic spraying.... Agent: Jones Day

20100297215 - Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy: Compositions, pharmaceutical preparations and methods are disclosed for protecting non-neoplastic cells from damage caused by cancer chemotherapeutic agents or radiation therapy, during the course of cancer therapy or bone marrow transplant. These are based on the use of chemoprotective inducing agents that induce or increase production of cellular detoxification enzymes... Agent: Intellectual Property Dept./dewitt Ross & Stevens Wisconsin Alumni Research Foundation

20100297217 - Isoprenoid compounds, their isolation and use: There is provided an isoprenoid according to the general formula (I) wherein R1 and R2 are independently selected from H and alkyl; and R3, R4, R5 and R6 are independently selected from groups of the general formula (II) and (III) wherein R7 and R8 each represent a group of general... Agent: Kimberly A. Chasteen

20100297216 - Method for administration of pegylated liposomal doxorubicin: An embodiment of the present invention comprises a method of treating malignancies in a subject in need of treatment comprising administering to the subject a high loading dose of a pegylated liposomal doxorubicin (PLD) in an initial cycle, followed by a reduced dose in a second cycle, wherein the second... Agent: Philip S. Johnson Johnson & Johnson

20100297219 - Methods and compositions for modifying apolipoprotein b mrna editing: Products and methods for modifying apolipoprotein B mRNA editing in vivo, reducing serum LDL levels, and treating or preventing an atherogenic disease or disorder are disclosed. Such methods involve the use of a protein including APOBEC-1 or fragments thereof which can edit mRNA encoding apolipoprotein B. The protein including APOBEC-1... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100297214 - Percolative drying for the preparation of particles: The present invention relates to dry particles and methods of preparing the same, in particular to methods of producing dry particles comprising a thermally labile component such as a colloidal system or a thermally labile biopharmaceutical compound, to the use of such dry particles, and to pharmaceutical compositions comprising the... Agent: Morgan Lewis & Bockius LLP

20100297218 - Tissue adhesive compositions and methods thereof: The present invention relates to composition and method for an adhesive composition. In particular, the present invention relates to a composition of an adhesive composition containing a protein component and an aldehyde component where the aldehyde component further comprises of a thickening agent. The adhesive composition is used for adhering... Agent: Townsend And Townsend And Crew, LLP

20100297220 - Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders: Pharmaceutical formulations in the form of a powder for suspension comprising at least one proton pump inhibitor in micronized form; at least one antacid; and at lest one suspending agents are provided herein. Also provided herein are methods for making and using pharmaceutical formulations comprising at least one proton pump... Agent: Wilson, Sonsini, Goodrich & Rosati

20100297221 - pharmaceutical composition of tacrolimus: An oral tacrolimus composition comprises minicapsules having a core containing tacrolimus in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised tacrolimus throughout the entire gastrointestinal tract. The composition may be used, for example, for treatment or prevention of solid organ transplant rejection.... Agent: Klarquist Sparkman, LLP

20100297222 - Method for production of microcapsules using solid fat: A method for production of fine microcapsules which encapsulate a hydrophilic bioactive substance at a high content and can be used in wide range of applications such as foods and medical drugs, which method enabling efficient industrial production, is provided. A method for production of S/O type microcapsules including the... Agent: Sughrue Mion, PLLC

20100297223 - Pharmaceutical dosage form comprising a liquid or flowable core composition: A pharmaceutical dosage form, comprising a) a liquid or flowable core, b) a shell of a polysaccharide or proteinaceous material completely enclosing said core, the core comprising an active ingredient dissolved in a pharmaceutically acceptable compound of the formula (I) wherein n is an integer from 3 to 5, and... Agent: Edwards Angell Palmer & Dodge LLP

20100297224 - Nsaid dose unit formulations with h2-receptor antagonists and methods of use: The present invention generally relates to pharmaceutical unit dosage forms of NSAIDs and H2-receptor antagonists, in which the H2-receptor antagonist is formulated so as to be released in a sustained manner over a predetermined period of time so as to maintain gastric pH above a desired level for a duration... Agent: Townsend And Townsend And Crew, LLP

20100297225 - Sustained-release pharmaceutical formulation containing an antimuscarinic agent and a wetting agent as well as a process for the preparation thereof: The present invention relates to improved sustained release dosage forms such as tablets and capsules, and in particular to a pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of an antimuscarinic agent, such as Tolterodine or pharmaceutical acceptable salt, derivative, prodrug and metabolite thereof in combination with a... Agent: Akc Patents

20100297226 - Multiple unit pharmaceutical formulation: An orally disintegratable benzimidazole formulation, featuring a plurality of compressed pellets in a MUPS tablet. The individual units feature a substrate with the active ingredient and an enteric coating, optionally with a subcoating between the substrate and the enteric coating. The individual units are preferably at least partially coated with... Agent: Dr. D. Graeser Ltd.

20100297227 - Pharmaceutical composition comprising at least one active agent and a binder, which swells in an acidic media: The invention relates to a pharmaceutical composition, which comprises at least one active agent and which further comprises a binder and/or a retarding agent, wherein the binder swells in an acidic medium, and the retarding agent retards the release of the active agent in an acidic or alkaline medium.... Agent: Merchant & Gould PC

20100297228 - Universal coating for imprinting identification features: To improve anticounterfeiting protection, a method for imprinting pharmaceutical unit compositions comprising: providing a pharmaceutical unit composition, partially coating the exterior of the composition with a coating, stamping the coating with a stamp comprising a plurality of identification features, wherein identification features from the stamp are at least partially transposed... Agent: Foley And Lardner LLP Suite 500

20100297229 - Tapentadol compositions: The present invention provides a method of treating pain and pain related conditions by administering to a patient in need thereof, a therapeutically effective amount of a slow release Tapentadol Hydrochloride and therapeutically effective amount of a second analgesic, wherein the second analgesic is tramadol, gamma-aminobutyric acid (GABA) analogue or... Agent: Prout And Associates, LLC

20100297230 - Compositions and methods for prostate and menstrual/menopausal related health: The disclosure provides compositions and methods and maintaining prostate health and relieving menstrual and menopausal related symptoms. The compositions comprise at least two of an icariin component, a quercetin component, a Maca component, a cocoa polyphenols component, and/or a rosmarinic acid component.... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20100297234 - Method of using an extracellular matrix to enhance cell transplant survival and differentiation: Provided is a matrix for promoting survival and differentiation of cells transplanted thereon, comprising a base matrix and a cell-made matrix thereon. Methods and means for making and using same are also provided.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20100297232 - Ondansetron film compositions: The present invention relates to products and methods of making products having a taste masked active component. In particular, the present invention relates to taste-masked film dosage forms including at least one active component and a slow dissolving basic composition.... Agent: Hoffmann & Baron, LLP

20100297233 - Oscillating cell culture bioreactor: Methods and devices for cell or tissue culture are provided. One aspect provides a bioreactor having a gas permeable, closed-loop chamber for cell or tissue culture, and an oscillating means for moving the gas permeable, closed-loop chamber bidirectionally along an axis horizontal to an axis normal to the closed-loop chamber... Agent: Pabst Patent Group LLP

20100297231 - Preservation of bioactive materials by freeze dried foam: This invention provides methods, systems and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes. Bioactive materials can be preserved with high initial viability in a freeze-foam process employing... Agent: Quine Intellectual Property Law Group, P.C.

20100297236 - Hybrid inducible release vehicle: The hybrid inducible release vehicle of the invention comprises a gel, which gel comprises a cross-linked carbohydrate and/or protein polymer and an inorganic carrier, and at least one active ingredient bound to said inorganic carrier, wherein the release of the active ingredient is triggered by contact of the vehicle with... Agent: Reed Smith LLP

20100297238 - Multifunctional and biologically active matrices from multicomponent polymeric solutions: A functionalized electrospun matrix for the controlled-release of biologically active agents, such as growth factors, is presented. The functionalized matrix comprises a matrix polymer, a compatibilizing polymer and a biomolecule or other small functioning molecule. In certain aspects the electrospun polymer fibers comprise at least one biologically active molecule functionalized... Agent: Mccarter & English, LLP Wilmington Basil S. Krikelis

20100297237 - Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer: A pharmaceutical composition comprises nanoparticles comprising a poorly water soluble drug, a poorly aqueous soluble non-ionizable polymer, and an amine-functionalized methacrylate copolymer.... Agent: Chernoff, Vilhauer, Mcclung & Stenzel, LLP

20100297235 - Vascular puncture closure systems, devices, and methods using biocompatible synthetic hydrogel compositions: A hydrogel composition for application to vascular puncture site of an animal to arrest bleeding and promote hemostasis mixes a biocompatible, synthetic, electrophilic polymer component comprising a poly(ethylene glycol) (PEG) Succinimidyl Glutarate having a functionality of four and a molecular weight of about 10,000 g/mole, with a biocompatible, synthetic, nucleophilic... Agent: Ryan Kromholz & Manion, S.c.

20100297239 - Osseointegrative meniscus and cartilage implants based on beta-glucan nanocomposites: The present invention provides engineered composite materials for use in medical treatment of injured or degenerated menisci, cartilage, and bone. The composite materials include a cellulosic layer substantially or completely consisting of β-1→4-glucan units, and a hydrogel layer substantially or completely consisting of copolymers of β-1→2-glucan, β-1→3-glucan, and/or β-1→4-glucan, or... Agent: Latimer Intellectual Property Law, LLP

20100297240 - 1- [2- (2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.... Agent: Fish & Richardson P.C.

20100297241 - Amorphous fesoterodine fumarate: The present invention provides a novel amorphous form of fesoterodine fumarate, process for preparation, pharmaceutical compositions, and method of treating thereof.... Agent: Cantor Colburn LLP

20100297242 - Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same: Disclosed are a LDL-like cationic nanoparticle for delivering a nucleic acid gene with improved transfection efficiency and stability, which is surface modified and re-constructed by mimicking lipid components of a natural LDL, a method for preparation of the same, and a method for delivering nucleic acid genes using the same.... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20100297245 - Methods and compositions for oral administration of protein and peptide therapeutic agents: The present invention provides a pharmaceutical composition formulated for oral delivery, comprising a particulate non-covalently associated mixture of pharmacologically inert silica nanoparticles having a hydrophobic surface, a polysaccharide, and a biologically active protein or peptide suspended in an oil. The present invention further provides methods of manufacturing same and therapeutic... Agent: Fennemore Craig

20100297244 - Nanodispersion: The present invention provides a nanodispersion comprising nanoparticles having a mean size less than 300 nm dispersed in a vehicle comprising a water miscible solvent and water, said nanoparticles comprising one or more taxane derivative, a polymer and a surfactant comprising a mixture of fatty acids or its salts and... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100297243 - Prion free nanoparticle compositions and methods of making thereof: The present invention provides prion-free compositions comprising nanoparticles comprising albumin and substantially water insoluble drugs. Also provided are methods of making prion-free compositions and methods of removing prion proteins from the nanoparticle compositions. Methods of using the compositions, as well as kits useful for carrying out the methods are also... Agent: Morrison & Foerster LLP

20100297246 - Silica-based nanoparticles and methods of stimulating bone formation and suppressing bone resorptioin through modulation of nf-kb: Osteoporosis, is an exceedingly common malady that leads to bone fracture and results from an imbalance in the rate of osteoblastic bone formation with respect to osteoclastic bone degradation. Nanotechnology has raised exciting possibilities for the development of novel therapeutic agents. Embodiments of the disclosure provide silica-based fluorescent nanoparticles endowed... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20100297247 - Aqueous-core lipid nanocapsules for encapsulating hydrophilic and/or lipophilic molecules: The invention relates to a composition comprising in an aqueous phase, particles having a diameter in the range of 20 to 500 nm, said particles containing:—an oil phase;—in said oil phase,—an aqueous droplet, or—a nanocapsule (NC) comprising:—an aqueous core, and—a polymeric shell or a shell composed of an amphiphilic substance;... Agent: Thompson Coburn LLP

20100297248 - Encapsulated particles for amorphous stability enhancement: The present invention provides compositions and methods of making and encapsulating one or more active agents in a chemical vapor deposition layer to enhance the stability.... Agent: Chalker Flores, LLP

20100297249 - Enhancement of the efficacy of therapeutic proteins: The invention provides a formulation for the administration of at least one therapeutic mammalian protein to a mammal, and for enhancing the absorption, distribution and release of the at least one therapeutic mammalian protein in or on the mammal, the formulation consisting of at least one therapeutic mammalian protein in... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100297250 - Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds: 1,3-Dipole-functional compounds (e.g., azide functional compounds) can be reacted with certain alkynes in a cyclization reaction to form heterocyclic compounds. Useful alkynes (e.g., strained, cyclic alkynes) and methods of making such alkynes are also disclosed. The reaction of 1,3-dipole-functional compounds with alkynes can be used for a wide variety of... Agent: Mueting, Raasch & Gebhardt, P.A.

20100297251 - Encapsulated particles for enteric release: The present invention provides a system for delivery of an enteric coated active agent generally resistant to disintegration in an neutral environment having one or more active agents encapsulated by a polymer coating formed by chemical vapor deposition of one or more monomers on the one or more active agents... Agent: Chalker Flores, LLP

20100297252 - Nanoparticulate meloxicam formulations: The present invention is directed to nanoparticulate compositions comprising meloxicam particles having an effective average particle size of less than about 2000 nm.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner

20100297253 - Treatment of diabetes with milk protein hydrolysate: A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of diabetes or syndrome X. The invention also relates to a method of treatment or prevention of diabetes or syndrome X... Agent: Nestle Healthcare Nutrition

20100297254 - Nutraceutical composition and methods of use: A method of treatment for cartilage degradation in an organism, which includes administering to an organism a composition including a therapeutic amount of an extract from the plant Biota orientalis. Several key components of the extract of Biota orientalis have been identified that have also been shown to have an... Agent: Arc Patents

20100297255 - Malleable implants containing demineralized bone matrix: Described are malleable medical compositions such as pastes or putties that include solids combined with a liquid carrier. The solids include particulate collagen and particulate demineralized bone matrix. The liquid carrier includes an aqueous medium comprising a polysaccharide. Also described are methods for making and using such medical compositions.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20100297256 - Methods and compositions for inhibiting integrins using tellurium-containing compounds: Compositions and methods for inhibiting integrin and treating integrin-related conditions, utilizing tellurium-containing compounds, are disclosed. The tellurium-containing compounds comprise at least one tellurium dioxo moiety and may have any one of Formulae I to IV as defined in the specification. Further disclosed are compositions and methods for treating a neoplastic... Agent: Dr. Mark M. Friedman C/o Bill Polkinghorn - Discovery Dispatch

20100297257 - Anticoagulant antagonist and hemophillia procoagulant: A method for treating a coagulation deficient patient comprises administering an amount of polyP to the patient sufficient to reduce the PT Test value or Dilute PT Test value of the plasma of the patient.... Agent: Evan Law Group LLC

20100297258 - Treatment of burns: The invention relates to the treatment of burn injuries. Described are methods for modulating a burn injury in a subject, the method comprising providing the subject with a gene-regulatory peptide or functional analogue thereof, e.g., LQG, AQG, LQGV (SEQ ID NO:1), AQGV (SEQ ID NO:2), LQGA (SEQ ID NO:3), VLPALP... Agent: Traskbritt, P.C.

20100297259 - Pesticide compositions exhibiting enhanced activity: Pest controlling compositions exhibiting enhanced pesticidal activity levels are disclosed. In one embodiment, a composition includes at least one pesticide and at least one metal oxide. In this embodiment, the composition exhibits enhanced pesticidal activity levels compared to a composition dissimilar only in not having the at least one metal... Agent: Krieg Devault LLP Suite 2800

20100297260 - Pesticide compositions exhibiting enhanced activity: Pest controlling compositions exhibiting enhanced pesticidal activity levels are disclosed. In one embodiment, a composition includes at least one pesticide, at least one transition metal salt and at least one proteinaceous material. In this embodiment, the composition exhibits enhanced pesticidal activity levels compared to a composition dissimilar only in not... Agent: Krieg Devault LLP

20100297261 - Food product and fortification system therefor: A food product comprising a source of at least one metal ion selected from Fe and Cu ions and an ascorbic acid derivative substituted in the 2-position, wherein the molar ratio of the metal ion or metal ions in the source of metal ions to the ascorbic acid derivative is... Agent: Unilever Patent Group

20100297262 - Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses: Described herein are pharmaceutical compositions and medicaments, and methods of using such pharmaceutical compositions and medicaments in the treatment of inflammation and cancer.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100297263 - Colon cleansing compositions and methods: A composition comprising, per litre of aqueous solution, from 30 to 350 g polyethylene glycol, from 3 to 20 g of an ascorbic acid component selected form the group consisting of ascorbic acid, a salt of ascorbic acid, or a mixture thereof, an alkali metal or alkaline earth metal sulphate,... Agent: Leon R. Yankwich

20100297264 - Bowel purgative and uses thereof: The present invention is directed to a dry composition for admixture with water for oral administration to a mammal and methods of using the composition for cleansing the bowel of a mammal in need thereof.... Agent: David S. Resnick

20100297265 - Optimal compositions and methods for treating oral disease and pain: The present invention generally relates to compositions and methods for oral care. In particular it relates to optimal compositions and methods for treating oral disease and pain where the compositions include cesium and/or rubidium. In a composition aspect, the present invention provides a composition for treating oral disease or oral... Agent: Mckinney Law Group Apc

20100297268 - Agent for increasing blood adiponectin quantity: An agent for increasing blood adiponectin quantity is provided, the agent including: a pulverized product or extract of a plant of the genus Salacia.... Agent: Sughrue-265550

20100297267 - Compositions for diabetes treatment and prophylaxis: Gurmarin containing compositions are useful for modulation of glucose metabolism and the treatment of diabetes. Glucose metabolism in a human patient is regulated by isolated gurmarin-containing dosage forms that optionally contain a non-metabolizable polysaccharide such as the exudate of Sterculia urens.... Agent: Olson & Cepuritis, Ltd.

20100297266 - Preparations and methods for textile and or fiber surface finishing, surface finished articles prepared thereby, and uses therefor: Disclosed are food compositions, comprising aqueous extracts of Melissa officinalis (Lemon balm) and/or its active principle rosmarinic acid. Methods of preparing a food composition, and of making a medicament, both methods comprising rosmarinic acid and/or aqueous extracts of Melissa officinalis, are also disclosed.... Agent: Fox Rothschild LLP

20100297270 - Composition for treatment of ischemic heart disease, facilitation of blood circulation and angiogenesis, improving skin beauty, improving male sexual function containing ginseng berry extract: A composition containing ginseng berry extract as active ingredient is for facilitation of blood circulation, for prevention of vascular aging, for treatment of vascular inflammation, for facilitation of angiogenesis, for treatment of ischemic heart disease, for improvement and treatment of local blood circulation insufficiency, for improvement of skin beauty and... Agent: Merchant & Gould PC

20100297269 - Compositions for intranasal administration: Pharmaceutical compositions are for administration to the nasal tract. In particular, dry powder compositions are cellulose, and in particular hydroxypropylmethylcellulose (HPMC), and one or more therapeutic agents. It has been shown that administration of HPMC to the nasal cavity is capable of enhancing natural mucus. These powders, and the gel... Agent: Head, Johnson & Kachigian

20100297271 - Compositions and methods for reducing hepatotoxicity associated with drug administration: The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as... Agent: Coleman Sudol Sapone, P.C.

20100297272 - Cosmetic composition containing lingonberry extract and its uses: The invention relates to a cosmetic composition containing lingonberry extract and its use on skin cosmetology thereof. The present invention has provided a lingonberry extract wherein containing polyphenols components including anthocyanidin, procyanidin, resveratrol, catechin and so on. The present invention also relates to the application of lingonberry extract on skin... Agent: Lariviere, Grubman & Payne, LLP

20100297273 - Emulsified wax compositions and uses thereof: The present invention discloses emulsified wax compositions having a wide range of uses, including as cosmetic, pharmaceutical and agricultural compositions, particularly for improving skin moisture, appearance, and wound healing, for the treatment of inflammation and allergic responses of the skin, and for preservation of agricultural fresh produce. The composition of... Agent: Fennemore Craig

20100297274 - Cocoa extracts for use in providing skin benefits: A cocoa extract obtainable by the extraction of non-defatted cocoa beans which have not been fermented or have been allowed to ferment for no more than three days, having a polyphenol content of more than 25% by weight, may be used to provide skin benefits by oral administration.... Agent: Hoxie & Associates LLC

20100290982 - Solid in oil/water emulsion-diffusion-evaporation formulation for preparing curcumin-loaded plga nanoparticles: The present invention includes compositions and methods of making an activated polymeric nanoparticle for targeted drug delivery that includes a biocompatible polymer and an amphiphilic stabilizing agent non-covalently associated with a spacer compound that includes at least one electrophile that selectively reacts with any nucleophilic on a targeting agent and... Agent: Chalker Flores, LLP

20100290983 - Compositions and methods for drug delivery: The present disclosure is directed to surface-modified particles and to methods of making and using the same. The surface-modified particles comprise a particle core and a coating associated with the particle core, wherein the particle core comprises an active agent, the coating comprises a surfactant having formula I, and the... Agent: Marshall, Gerstein & Borun (baxter)

20100290984 - Anti-mrp3 antibodies and methods of use: An antibody having an antigen binding region capable of binding an epitope located in an extracellular portion of MRP3 and methods of utilizing same are provided. In particular, the invention provides antibodies targeted at a MRP3 antigen present on cells expressing MRP3 and methods useful in detecting or targeting cells... Agent: Womble Carlyle Sandridge & Rice, PLLC

20100290985 - Macromolecular compositions that cross the blood-brain barrier and methods of use thereof: The invention provides diagnostic and therapeutic macromolecular compositions that cross the blood-brain barrier, in some embodiments in both directions, while allowing their activity to remain substantially intact once across the barrier. Also provided are methods for using such compositions in the diagnosis or treatment of CNS disorders such as Alzheimer's... Agent: Wilson, Sonsini, Goodrich & Rosati

20100290986 - Therapeutic use of diaminophenothiazines: The present invention relates generally to methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimised pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines,... Agent: Foley And Lardner LLP Suite 500

20100290987 - Methods and compositions for detecting and modulating o-glycosylation: The invention relates to methods and products for modulating glycosylation of proteins. The invention is useful for identifying therapeutic compounds to treat glycosylation-associated disorders such as neurodegeneration, diabetes, including complications of diabetes such as insulin resistance, nephropathy, microvascular damage, and endothelial dysfunction. The invention is also useful for identifying therapeutic... Agent: Harvard University & Medical School C/o Wolf, Greenfield & Sacks, P.C.

20100290989 - Compositions affecting hyaluronic acid mediated activity: Compositions comprising hyaluronic acid (HA) or agents that interfere with HA binding of HA receptors and methods of using the same are provided. For example, there is provided a composition comprising HA oligomers ranging in size from 10-mer to 80-mer and use of the same for promoting migration, growth or... Agent: Knobbe Martens Olson & Bear LLP

20100290988 - Fluorinated fructose derivatives for pet imaging: The present invention is directed to fructose-based radiopharmaceuticals, pharmaceutical compositions comprising same, precursors and methods for preparing same, and methods of using same for diagnostic imaging of cancer cells and non-imaging tracer studies.... Agent: Edward Yoo C/o Bennett Jones

20100290990 - Method for preparing a marked purine derivative, said derivative and uses thereof: The present invention relates to a method for preparing a 2-fluoropurine marked with the radioisotope 18F comprising a fluorination step for a 2-nitropurine derivative. The present invention comprises a 2-fluoropurine derivative marked with the radioisotope 18F which can be obtained by or during a method according to the invention and... Agent: Miles & Stockbridge PC

20100290991 - Novel [f-18]-labelled l-glutamic acid and l-glutamine derivatives (i), their use and processes for their preparation: What is described are the compounds and the synthesis of [F-18]-labelled L-glutamic acid, [F-18]-labelled L-glutamate, their derivatives of the formula (I) and their use.... Agent: Millen, White, Zelano & Branigan, P.C.

20100290993 - Antibodies to il-6 and use thereof: The present invention is directed to antibodies and fragments thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also... Agent: Hunton & Williams LLP Intellectual Property Department

20100290992 - Nanoparticle nucleic acid binding compound conjugates forming i-motifs: The present invention concerns the field of nanoparticle bioconjugates which form an i-motif or an i-motif related structure (compositions) without or with at least one further nucleic acid binding compound. The i-motif base pairs can be charged or non-charged. Their assembly can be controlled by the pH value or temperature.... Agent: Dinsmore & Shohl, LLP Fifth Third Center

20100290994 - O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders: The present invention relates to methods of alleviating and inhibiting a lymphoproliferative disorder in a mammal, the method comprising administering one or more rapamycin derivatives (including rapamycin) to the mammal. Further, the invention provides a method for identifying agents which are useful for alleviating and inhibiting a lymphoproliferative disorders, as... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100290995 - Radio-opaque compounds, compositions containing same and methods of their synthesis and use: Radio-opaque biodegradable compositions are formed by modifying terminal groups of synthetic and natural biodegradable polymers such as polylactones with iodinated moieties. The biodegradable property of the compositions renders them suitable for use in medical field such as drug delivery, imaging. Compounds disclosed in this invention exist as neat liquid. Certain... Agent: Dardi & Herbert, PLLC

20100290996 - Methods and compositions based on culturing microorganisms in low sedimental fluid shear conditions: This invention is directed to applying a low sedimental fluid shear environment to manipulate microorganisms, and to microorganisms and compositions obtained based on such manipulation. Specifically, the present invention provides methods of modifying a molecular genetic or phenotypic characteristic (e.g., virulence, stress resistance or biofilm formation) of a microorganism by... Agent: George A Leone, Sr Citadel Patent Law

20100290997 - Imaging agents and methods: The disclosure includes a composition including a poly(L-glutamic acid) and a NIRF dye. It also includes a method including providing to a plurality of cells an imaging agent including poly(L-glutamic acid), a NIRF dye and then imaging the cells to detect the imaging agent. It further includes a dual functional... Agent: Fulbright & Jaworski L.L.P.

20100290998 - Methods of preventing ischemic injury using peripheral nociceptive stimulation: Methods of inhibiting ischemia-related and ischemia-reperfusion-related injury are provided. Remote administration of a C-fiber activator or TRPV1 agonist or remote electrical stimulation and activation of TRPV1 reduces ischemia-related tissue damage in subjects at risk for ischemia-related tissue damage. In aspects of the invention, remote application of a TRPV1 agonist inhibits... Agent: Taft, Stettinius & Hollister LLP

20100291001 - Metalloproteinase-binding proteins: Disclosed are antibodies that interact with a matrix metalloproteases such as MMP-26. Exemplary antibodies inhibit MMP-26 activity. These antibodies can be used, e.g., to treat or prevent metastatic disorders, hyperproliferative disorders, disorders which are characterized by excessive extracellular matrix degradation, and inflammatory disorders.... Agent: Lando & Anastasi, LLP

20100291000 - Diagnostic value of systemic ace pathway activation in the detection by fluorescence of localized pathological lesions: Alternative cellular energy pigments (ACE-pigments) provide a source of cellular energy other than that provided through the oxidative metabolism of foods, or in the case of plants and certain bacteria, through the process of photosynthesis. In some patients, ACE pigments exist in a form that can be further energized or... Agent: William John Martin

20100290999 - Nanoparticles of light emissive polymers and preparation method thereof: Disclosed are nanoparticles of a light emissive polymer, comprising nanoparticles of a cyano-substituted poly(arylene vinylene) polymer; and a biocompatible surfactant adsorbed to the surface of the nanoparticles of the polymer, and preparation method thereof, wherein the method comprises: (1) uniformly mixing a dialdehyde monomer represented by a general formula OHC—Ar1—CHO,... Agent: Morrison & Foerster LLP

20100291002 - Combination comprising pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, and use thereof in the treatment of atopic dermatitis: Combination comprising pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, and use thereof in the treatment of atopic dermatitis The present invention relates to a composition comprising, in a physiologically acceptable carrier, pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, in racemic... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100291003 - Histone deacetylase inhibitors: Novel compounds of the general formula (I), having histone deacetylase (HDAC) inhibiting enzymatic activity, their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel compounds of the general formula (I). Also included is a... Agent: Oliff & Berridge, PLC

20100291004 - Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof: The present invention provides novel compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises the pH of saliva to a pH greater than about 7.8, thereby facilitating the substantially complete conversion of the hypnotic... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-13-a7

20100291005 - Use of trans-pellitorin as flavor substance: The invention concerns the use of 2E,4E-decadienoic acid-N-isobutylamide (trans-pellitorin) as flavorant, in particular as salivation inducing flavor substance, preferably in a foodstuff or nutrient, an oral hygienic preparation or a gourmet or snack preparation. Further, the invention concerns preparations, semi-finished preparations as well as fragrance, aroma and taste compositions, containing... Agent: Gregory A. Nelson Novak Druce & Quigg LLP

20100291006 - Natural preservatives and antimicrobial agents: The invention relates to preservatives and antimicrobial agents including extracts derived from sugar cane.... Agent: The Webb Law Firm, P.C.

20100291007 - Administration of extracts of nonfruiting nonphotosynthetic filamentous bacteria for increasing the endogenous synthesis of superoxide dismutase: The present invention relates to the cosmetic or pharmaceutical use of an extract of a nonfruiting nonphotosynthetic filamentous bacterium in a composition containing a cosmetically or pharmaceutically acceptable medium, as an agent increasing the endogenous synthesis of superoxide dismutase, in particular for preventing and/or limiting the formation of free radicals... Agent: Buchanan, Ingersoll & Rooney PC

20100291008 - Emulsion composition: An emulsion composition includes a UV scattering agent and at least one of an active oxygen remover or an anti-oxidizing agent. The UV scattering agent is added to one of an oil phase or an aqueous phase of the emulsion composition and the at least one of an active oxygen... Agent: Sughrue Mion, PLLC

20100291009 - Preparation comprising chroman-2-one derivatives: The invention relates to preparations comprising at least one compound of the formula (I), where the substituents R1 to R4 have a meaning indicated in claim 1, and salts and solvates thereof, and to the use thereof and selected compounds of the formula (I).... Agent: Millen, White, Zelano & Branigan, P.C.

20100291010 - Novel esters and compositions and uses thereof: A novel ester of an optionally substituted aromatic acid (for example benzoic acid) and a branched C13 primary alcohol is suitable for use in providing improved cosmetic and personal care compositions including sunscreen, antiperspirant and deodorant compositions.... Agent: Burns & Levinson, LLP

20100291011 - Water-in-oil emulsion type sunscreen cosmetic: n

20100291012 - Administration of amorolfine by iontophoresis for treating nail diseases: A regime or regimen for the treatment of a nail disease state includes topically applying onto the infected nail(s) of an individual a thus effective amount of a solution of amorolfine in ionized form and concomitantly applying thereto an iontophoretic current of such intensity as to deliver the amorolfine into... Agent: Buchanan, Ingersoll & Rooney PC

20100291013 - Comfortable, transfer-resistant colored compositions: A composition for application to the skin includes (a) at least one film forming resin chosen from a polypropylsilsesquioxane wax substituted with alkyl units having at least 30 carbon atoms; (b) at least one volatile solvent capable of solubilizing (a); (c) at least one gelling agent chosen from a modified... Agent: L'oreal Usa Patent Department

20100291014 - Pigment mixtures: Disclosed are pigment mixtures containing at least two components, where component A contains bismuth oxychloride (BiOCl) or boron nitride (BN) and component B contains synthetic flakes treated with at least one metal soap or mineral flakes treated with at least one metal soap and to the use thereof especially in... Agent: Millen, White, Zelano & Branigan, P.C.

20100291015 - Method for making up the lips: The invention relates to a method for making up the lips comprising the steps of selecting at least one composition, referred to as ‘first composition’, from a range of first compositions formulated in the liquid state, of selecting at least one composition, referred to as ‘second composition’, from a range... Agent: Oliff & Berridge, PLC

20100291016 - Perfuming ingredients imparting sap and/or earthy type notes: The present invention relates to the field of perfumery. More particularly, it concerns specific derivatives of 1-alkenyl cyclopentanol, or 1-alkenyl cyclohexanol, wherein the alkenyle group is branched. These compounds are useful perfuming ingredients capable of imparting sap and/or earthy notes.... Agent: Winston & Strawn LLP Patent Department

20100291017 - Hair treatment compositions: The invention provides a hair treatment composition comprising a combination of a sugar, an amino acid and a salt of an organic acid. The composition is particularly suitable for the treatment of hair which is dry, damaged and/or prone to manageability problems.... Agent: Unilever Patent Group

20100291018 - Conditioner for eyelash and eyebrow: A conditioner for eyelash and eyebrow includes: water; hydrolyzed soy protein; erythritol; trehalose; carbomer; arginine; polysorbate 80; niacinamide; panthenol; citric acid; phenoxyethanol; acorus calamus root extract; artemisia princes leaf extract; portulaca oleracea extract; polygonum multiflorum root extract; glycyrrhiza glabra root extract; ephedra sinica extract; sophora angustifolia root extract; arctium lappa... Agent: Park Law Firm

20100291019 - Methods of using ophthalmic compositions comprising povidone-iodine: A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well... Agent: Morgan, Lewis & Bockius LLP

20100291020 - Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors: The present invention is related to novel compounds of the general formula A, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods of making of the above compounds, and their use as Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors, which are useful in the treatment or prevention of... Agent: Merchant & Gould PC

20100291021 - Aliphatic prodrug linker: A polymeric prodrug is described which comprises at least one polymer attached via at least one permanent bond to a bicine linker. The bicine linker is attached via a temporary linkage to an amine containing biologically active moiety. The amine containing biologically active moiety—such as a drug—can be released by... Agent: Frommer Lawrence & Haug

20100291022 - Fly gel bait: The invention relates to baits for controlling flies (fly gels) comprising a) one or more neonicotinoids, b) one or more gelling agents, c) one or more attractants, and having a gel point between having a Brookfield yield value between 150 and 1000 and a Brookfield viscosity between 40,000 and 150,000... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100291027 - Hyaluronic acid (ha) injection vehicle: Disclosed herein are compositions that exhibit viscosities suitable for injectable formulations. The compositions comprise bioactive agent-loaded microparticles and hyaluronic acid or a salt thereof in a suitable liquid pharmaceutical carrier. Also disclosed are methods of making and using the compositions.... Agent: Ballard Spahr LLP

20100291025 - Indazole inhibitors of tyrosine kinase: The present invention relates to new indazole inhibitors of tyrosine kinase activity, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100291023 - Method for extending the half-life of exogenous or endogenous soluble molecules: The present invention relates to methods for extending the in vivo half-life of an exogenous soluble therapeutic molecule administered to a subject, by administering to said subject the exogenous soluble molecule and a monovalent antibody that binds to the exogenous soluble molecule, as well as method for treating a disease... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100291024 - Methods and compositions for the treatment of proliferative and pathogenic diseases: The invention features peptide fragments containing domain 4 of the Streptococcus intermedius intermedilysin (ILY) protein and the use of these fragments to sensitize cancer cells to antibody-based anticancer treatments. The invention also features use of these fragments to treat patients infected with microbial pathogens expressing CD59 or CD59-like molecules. CD59... Agent: Clark & Elbing LLP

20100291029 - Methods of using il-21: An allelic variation in the IL-21 receptor can result in reduced IFN-γ production in individuals and can require administration of different doses of IL-21 to achieve therapeutic effects seen individuals that do not have the allelic variant. Based on the genotype of a patient's IL-21 receptor allele, methods of predicting... Agent: Zymogenetics, Inc. Intellectual Property Department

20100291026 - Piperidine inhibitors of janus kinase 3: The present invention relates to new piperidine inhibitors of Janus kinase 3 activity, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100291028 - Use of il-18 inhibitors for treatment and/or prevention of peripheral vascular diseases: The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation.... Agent: David S. Resnick

20100291030 - Use of il-28 and il-29 to treat cancer and autoimmune disorders: Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as... Agent: Zymogenetics, Inc. Intellectual Property Department

20100291032 - Compositions and methods for the identification of inhibitors of retroviral infection: Methods of identifying inhibitors of retroviral propagation, tRNA used in the methods, and kits, including the tRNA, which can be used in the methods, are disclosed. Methods of treating or preventing retroviral infections by administering an effective amount of the inhibitors, and pharmaceutical compositions including the inhibitors, are also disclosed.... Agent: Intellectual Property / Technology Law

20100291031 - Bicyclic nucleosides and nucleotides as therapeutic agents: The invention relates to the use of bicyclic nucleosides and nucleotides based on formula (II) for the treatment of infectious diseases, and in particular, viral infections.... Agent: Seed Intellectual Property Law Group PLLC

20100291033 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100291034 - Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto: Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations comprising, separately or together: (a) a CYP3A4 inhibitor; and (b) a HCV protease inhibitor; for concurrent or consecutive administration in treating a human subject infected with HCV.... Agent: Merck Patent Department (k-6-1, 1990)

20100291035 - respiratory syncytial virus with a genomic deficiency complemented in trans: The invention relates to pneumoviral virions comprising a viral genome that has a mutation in a gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the... Agent: The Webb Law Firm, P.C.

20100291036 - Compositions and methods for modulating vascular endothelial growth factor c (vegf-c) expression: The present invention relates to compounds and methods for inhibiting the expression of vascular endothelial growth factor-C (VEGF-C) in a target cell. Particularly, the present invention relates to antisense polynucleotides complementary to a lens epithelium-derived growth factor (LEDGF/p75) mRNA and uses thereof for inhibiting tumor progression and tumor metastasis. The... Agent: Fennemore Craig

20100291037 - Immunogenicity using a combination of dna and vaccinia virus vector vaccines: This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immune response. The present invention further provides a particularly... Agent: Nih-ott C/o Sheridan Ross P.C.

20100291048 - Modification of cxcr4 using engineered zinc finger proteins: Disclosed herein are methods and compositions for modulating activity of CXCR4 genes, for example using zinc finger transcription factors (ZF-TFs) or zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZF-TFs or ZFNs, vectors comprising polynucleotides encoding ZF-TFs or ZFNs and... Agent: Robins & Pasternak

20100291038 - Novel medicinal formulation for inducing an immune response in patients with chronic and recurring infections: A composition for the treatment of respiratory tract infection (RTI) comprising, a homogenized mixture of at least two serially diluted and potentized substances, as herein described, selected from: 1. Mycobacterium tuberculosis (culture) (strain A), 2. Mycobacterium bovis (culture) (strain B), 3. Mycobacterium microti (culture) (strain C), 4. Mycobacterium African (culture)... Agent: Bio Intellectual Property Services (bio Ips) LLC

20100291049 - Anti-wrinkle agent: c

20100291050 - Nutritional compositions for reducing oxidative damage: A nutritional composition for reducing oxidative damage and lipid peroxidation in humans, while allowing for the oxidative reactions necessary to sustain vital biological functions. The nutritional compositions comprise adaptogens comprising astragalus root, ashwagandha root, cordyceps, holy basil leaf, maca root, reishi mushrooms, schizandra, and suma root; superfoods comprising acerola, camu-camu,... Agent: Connolly Bove Lodge & Hutz LLP

20100291051 - Agent for prevention of alcoholic hepatopathy: The present invention provides an agent for inhibition of alcoholic hepatopathy comprising cells of a strain belonging to Lactobacillus brevis, or treated product thereof as an active ingredient. The agent for inhibition of alcoholic hepatopathy of the present invention is safe for living body and can be used as a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100291052 - Novel microorganism having gastric-juice promoting activity, and its secretory product: Designed to afford a novel microorganism promoting gastric juice secretion and having platelet increasing activity, and to afford a pharmaceutical agent composed of a product secreted by the novel microorganism. The novel microorganism, international deposit number: NITE BP-295, belongs to the species Bacillus pumilus, and is characterized by taking either... Agent: Judge Patent Associates

20100291039 - Novel micro-organisms controlling plant pathogens: The invention relates to control of pathogen caused diseases on leaves, fruits and ears in plants, such as apple scab (Venturia inaequalis by treatment of plant with an isolate of Cladosporium cladosporioides. The treatment is effective in both prevention and treatment of the fungal infection.... Agent: Reed Smith LLP

20100291053 - Inflammatory disease treatment: We describe a composition comprising a source of long chain polyunsaturated fatty acid, for example, docosahexaenoic acid (DHA), and a carotenoid, for example, astaxanthin and other nutrients for prophylactic and/or therapeutic use in the healing of trauma- and stress-induced inflammatory conditions.... Agent: Klarquist Sparkman, LLP

20100291041 - Bacteriophage preparation and use: The invention relates to a bacteriophage preparation having at least one bacteriophage in alkaline buffer solution, said bacteriophage being specifically effective against at least one bacterial strain, in combination with at least one surface-active agent that is preferably a polyhexamethyl biguanide (polyhexanide) stabilized in an alkaline range between pH 7.5... Agent: Senniger Powers LLP

20100291040 - Virus-like particles for treatment of viral infections: The invention provides virus-like particles for treatment of viral infections based on the virus causing the infection. The virus-like particles comprise the virus recombinant proteins that form a capsid, recombinant virus membrane proteins attached to the capsid and vRNA packaged within said capsid. The vRNA is generated from a DNA... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100291045 - Dynamic vibrational method and device for vocal fold tissue growth: Dynamic vibrational methods and devices for inducing differentiation of stem cells into vocal fold fibroblast-like cells or for generating vocal fold-like tissue from cultured cells. Also provided are matrices providing sustained release of growth factors, and bioreactors generating and delivering a high frequency vibration with in-plane shear stress to cultured... Agent: Ratnerprestia

20100291046 - Equine progenitor cells: An isolated mammalian progenitor cell or its progeny, isolated from articular cartilage, is disclosed. Further is disclosed an equine progenitor cell isolated from the surface zone of equine articular cartilage tissue and uses thereof. Also disclosed are a method of tissue repair, a medicament, and a method of treating mammalian... Agent: King & Schickli, PLLC

20100291043 - Il-12 immunotherapy for cancer: Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20100291044 - Lunasin-induced regulation of disease-related gene expression: Methods are provided for screening a test compound for anti-neoplastic activity by providing a test compound to a cancer cell and measuring the acetylation of Lysine 16 of the N-terminal tail of histone H4. Methods are also provided for using a test compound for staging a cancer tissue and for... Agent: Bell & Associates

20100291042 - Multipotent stem cells and uses thereof: The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which... Agent: Edwards Angell Palmer & Dodge LLP

20100291047 - Use of mesenchymal stem cells for treating genetic disease and disorders: A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal.... Agent: Mcandrews Held & Malloy, Ltd

20100291054 - Novel regulatory t cells and uses thereof: The invention provides isolated regulatory T cells and methods of obtaining regulatory T cells. The invention also provides methods for inhibiting an antigen-specific immune response (e.g., graft rejection, an autoimmune disorder, graft versus host disease, a response to a tumor cell, a response to an infection, and a response to... Agent: Clark & Elbing LLP

20100291057 - Composition for reducing oxidative stress and/or side effects occurring during cancer chemotherapy or improving nutritional status during cancer chemotherapy: Provided is a composition for reducing oxidative stress and/or side effects occurring during cancer chemotherapy or improving a nutritional status during cancer chemotherapy. The composition is one for reducing oxidative stress and/or side effects occurring during cancer chemotherapy or improving nutritional status during cancer chemotherapy and comprises the following components... Agent: Hogan Lovells US LLP

20100291056 - Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same: The present invention is directed to pharmaceutical compositions comprising prasugrel and a cyclodextrin derivative, and methods of making and using the same.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100291055 - Surgical hydrogel: The invention provides a hydrogel suitable for use in wound healing, particularly for reducing post-surgical adhesions. The hydrogel comprises cross-linked derivatives of chitosan and dextran polymers. The hydrogel forms when solutions of the polymers are combined.... Agent: Borson Law Group, PC

20100291058 - Sealants for skin and other tissues: The present invention relates to sealants for skin and other tissues. The sealants include an electroprocessed material. The sealants may contain more than one electroprocessed materials and may contain additional substances. The invention further relates to methods of making and using such sealants.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100291059 - Pharmaceutical composition for enzyme replacement therapy: The present invention provides a pharmaceutical composition comprising a protein having α-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry... Agent: Mcdermott Will & Emery LLP

20100291060 - Subcutaneous administration of alpha-galactosidase a: The invention relates, in part, to improved methods of administering α-galactosidase A for the treatment of α-galactosidase A deficiencies including Fabry disease.... Agent: Wolf Greenfield & Sacks, P.C.

20100291062 - Antimicrobial composition: A complex antimicrobial sorption composition possessing the necrolytic effect for treating the purulent wounds, the trophic ulcers, the wounds, and the infiltrates with the significant necrotic and exudative components represents the silica sorbent with the immobilized drug. Aerosil is used as a siliceous sorbent, and seratiopeptidase as a drug.... Agent: Fulbright & Jaworski L.L.P.

20100291064 - Compounds and methods for the treatment of vascular disease: The present invention relates to a method for the treatment of vascular dysfunction, reducing ischemic pain and/or treatment of a vascular disease comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. The vascular dysfunction, ischemic... Agent: Fulbright & Jaworski L.L.P.

20100291061 - Process for making oligopeptides: There is described a method of synthesising a family of oligopeptides of predetermined amino acid sequence, which together make up from 7 amino acids to the complete amino acid sequence of a target protein, which comprises: synthesising a nucleic acid construct which codes for a fusion protein composed of overlapping... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100291063 - Protease inhibition: The invention relates to a method for inhibiting an adam protease, comprising inhibiting binding to an integrin-binding loop of a disintegrin domain in the adam protease. Also provided are cyclic peptides which inhibit binding to an integrin-binding loop of an adam protease, as well as associated pharmaceutical compositions, uses and... Agent: Marshall, Gerstein & Borun LLP

20100291065 - Compositions for protein delivery and methods of use thereof: Compositions and methods for the delivery of a protein of interest are provided.... Agent: Dann, Dorfman, Herrell & Skillman

20100291066 - Donor specific antibody libraries: The present application concerns donor-specific antibody libraries derived from a patient donor who has suffered from, or is suffering from one or more diseases discussed herein. The present application also concerns the method of making and using the donor-specific antibodies. The present application further concerns the neutralizing antibodies obtained from... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20100291067 - Methods and compositions relating to viral latency: Disclosed are compositions and methods that relate generally to viruses, and more particularly to the agents and their identification and use of anti-HIV agents which cause latently infected cells to reactivate.... Agent: Ballard Spahr LLP

20100291069 - Methods of treating a diabetic embryopathy: Maternal diabetes can lead to a developmental malformation of an embryo. A developmental malformation caused by maternal diabetes is commonly referred to as a diabetic embryopathy. There is currently no effective treatment for reducing or inhibiting a diabetic embryopathy. To this end, the present invention is drawn to novel methods... Agent: Castellano PLLC

20100291068 - Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer: The invention relates to newly discovered nucleic acid molecules and proteins associated with ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers are provided.... Agent: Mccarter & English, LLP Boston

20100291070 - Type iii secretion system component protein pa1698 of pseudomonas aeruginosa: An object is to provide an antibody and a vaccine composition which have an ability to practically prevent or treat a Pseudomonas aeruginosa infection, and which can cope with the diversity of clinical isolates derived from patients infected with Pseudomonas aeruginosa. According to the present invention, an antibody against a... Agent: Sughrue Mion, PLLC

20100291076 - Antibodies specific for dkk-1 and their uses: The present invention provides antibodies and fragments thereof that bind to Dkk-1 and, in particular, to humanized antibodies and fragments thereof that bind to Dkk-1 and, even more particularly to fully humanized antibodies and immunologically functional fragments that bind to Dkk-1. Also provided are antibodies and fragments thereof which compete... Agent: Pfizer Inc

20100291071 - Antibody specific binding to a-beta oligomer and the use: The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100291072 - Antibody variants with faster antigen association rates: Antibody variants with faster antigen association rates are disclosed. The antibody variants have one or more amino acid alteration(s) in or adjacent to at least one hypervariable region thereof which increase charge complementarity between the antibody variant and an antigen to which it binds.... Agent: Genentech, Inc.

20100291074 - Cyclophilin d-amyloid beta interaction potentiates mitochondrial dysfunction in a transgenic mouse model of alzheimer's disease: The present invention is directed to methods for treating or preventing Alzheimer's disease by administering therapeutically effective amounts of an agent that reduces Cyclophilin D expression in a patient, or that reduce Cyclophilin D activity or its ability to form a complex with Amyloid beta. Such agents include antisense nucleotides... Agent: Ditthavong Mori & Steiner, P.C.

20100291075 - Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies: The invention provides a GM-CSF neutralizing human monoclonal antibody, 1783J22, as well as methods of making and use thereof. The monoclonal antibody is further characterized by its ability to bind epitopes from GM-CSF proteins of multiple species.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100291077 - Methods and compositions for modulating erbb2 activity: Modulating the interaction between ErbB2 and Erbin is an effective method for treating one or more symptoms of ErbB2-mediated disorders. It has been discovered that Erbin stabilizes ErbB2 in vivo and inhibiting the formation of heterodimers between Erbin and ErbB2 reduces or inhibits the biological activity of ErbB2 relative to... Agent: Pabst Patent Group LLP

20100291073 - Methods of reducing eosinophil levels: The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of... Agent: Medimmune, LLC Patrick Scott Alban

20100291078 - Proteinaceous binding molecules comprising purification tags or inert variable domains: The present invention provides proteinaceous binding molecules, in particular antibodies, having at least two variable domains. One variable domain binds to a target molecule of interest. At least one other variable domain comprises a purification tag suitable for purification of said proteinaceous binding molecule. The purification tag enables the convenient... Agent: Morphosys Ag

20100291082 - Antigen presenting cell targeted anti-viral vaccines: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides... Agent: Chalker Flores, LLP

20100291080 - Compositions and methods for tissue repair: The present invention provides compositions and methods for targeting an extracellular matrix derived (EMD) peptide predominantly to an injured tissue, as opposed to an uninjured tissue in vivo. The targeted EMD peptide facilitates the repair and/or regeneration of the injured tissue by providing a surface for cells to attach and... Agent: Townsend And Townsend And Crew, LLP

20100291079 - Heterodimeric follicle stimulating hormone-fc (fsh-fc) fusion proteins for the treatment of infertility: The invention provides novel heterodimeric fusion proteins comprising a first polypeptide including an alpha subunit of FSH (αFSH) linked directly or indirectly to a binding partner of neonatal Fc receptor (FcRn) and a second polypeptide including a beta subunit of FSH (βFSH) linked directly or indirectly to an FcRn binding... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20100291081 - Rage fusion proteins: The present invention provides novel therapeutics and methods of treatment for diseases associated with activation of the advanced glycation endproducts receptor (RAGE).... Agent: Connolly Bove Lodge & Hutz, LLP

20100291085 - Antibodies to ox-2/cd200 and uses thereof in inhibiting immune responses: This disclosure provides methods and compositions for inhibiting immune responses. The disclosure also provides methods and compositions for inhibiting graft rejection and promoting or prolonging graft survival.... Agent: Ropes & Gray LLP

20100291088 - Il-18 binding proteins: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a... Agent: Mccarter & English, LLP / Abbott Laboratories Ltd.

20100291087 - Method of treating fibrproliferative disorders: Materials and Methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides,... Agent: Townsend And Townsend And Crew LLP

20100291083 - Novel analgesic treatment with prolonged effect: Use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA, in particular capable of blocking the biological activity of TrkA, for the preparation of a medicament for treating and/or preventing chronic pain.... Agent: Edwards Angell Palmer & Dodge LLP

20100291086 - Use of estrogen and androgen binding proteins in methods and compositions for treating gynaecological cancers: The present invention provides a polypeptide comprising an estrogen or androgen binding region, the binding region capable of binding to an estrogen or androgen at a sufficient affinity or avidity such that upon administration of the polypeptide to a mammalian subject the level of biologically available estrogen or androgen is... Agent: Winston & Strawn LLP Patent Department

20100291084 - Use of il-23 antagonists for treatment of infection: Methods and compositions comprising antagonists of IL-23 are provided for the treatment of infections, such as chronic bacterial, viral and fungal infections.... Agent: Merck C/o Dnax

20100291093 - Antibody-mediated disruption of quorum sensing in bacteria: The invention provides an immunogenic molecular entity, a supramolecular assembly, and an antibody that can be used to inhibit Gram-positive bacterial quorum sensing, prevent infection or development of a disease condition associated with a Gram-positive bacterial infection. The invention also provides methods of inhibiting Gram-positive bacterial quorum sensing, and methods... Agent: The Scripps Research Institute

20100291091 - Cancer associated gene ly6k: LY6K is identified herein as a potential biomarker useful for the diagnosis of cancer, such as lung and esophageal cancers, as well as for the prognosis of patients with these diseases. As discussed in detail herein, LY6K is specifically over-expressed in most lung and esophageal cancer tissues examined, and is... Agent: Townsend And Townsend And Crew, LLP

20100291092 - Compositions and methods for detection, prevention, and treatment of anthrax and other infectious diseases: Compositions and methods for the detection, prevention, or treatment of anthrax or other infectious diseases. In one aspect, the present invention provides methods for immunizing humans or animals against Bacillus anthracis or other capsulated pathogens. The methods include administering a capsular polypeptide of a pathogen of interest and a CD40... Agent: Unr/dri Technology Transfer Office

20100291095 - Identification of a conserved region of plasmodium falciparum msp3 targeted by biologically active antibodies: Antigenic and immunogenic determinants of Merozoite surface protein 3 (MSP3). Antigenicity and functional assays identified a 68-amino acid conserved domain of MSP3 as a target of biologically active antibodies. A peptide comprising amino acid residues 184-251 of SEQ ID NO: 2, may also be employed as may peptides consisting of... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100291089 - Ligand of regulating immune response, and use thereof in treating an immune response-related disease: The present invention relates to a ligand to regulate immune response, i.e., PACAP27 which is one of pituitary adenylate cyclase-activating polypeptides and Serum amyloid A (SAA), and their novel use in treating or preventing diseases associated with immune response. More specifically, the present invention relates to a complex of PACAP27-FPRL1... Agent: Sheridan Ross PC

20100291094 - Nucleic acid encoding 238p1b2 useful in detecting cancer: A novel gene (designated 238P1B2) and its encoded protein, and variants thereof, are described wherein 238P1B2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 238P1B2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 238P1B2 gene... Agent: Agensys C/o Morrison & Foerster LLP

20100291090 - Prion protein as a receptor for amyloid-beta oligomers: The invention provides methods of inhbiting suppression of long term potentiation, improving acute memory retention and spatial memory performance and treating Alzheimer's disease by administration of a PrPc antagonist or combinations thereof. Additionally, this invention provides pharmaceutical kits comprising, and methods for making and using, such combinittions, as well as... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100291096 - Therapeutic peptides for the treatment of metatstatic cancer: Interaction between MUC1 and β-catenin can be interrupted using polypeptides or antibodies that specifically bind to the binding site on MUC1. Interruption provides the beneficial effect of inhibiting, reducing, and/or retarding invasiveness and metastasis. Fusion polypeptides and antibodies are provided to achieve a therapeutic effect.... Agent: Banner & Witcoff, Ltd.

20100291097 - Monoclonal antibody: The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies that specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies of the present invention are particularly useful for the treatment of ocular diseases associated with pathological abnormalities/changes in the... Agent: Jones Day

20100291098 - Diabetic nephropathy therapies: The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided.... Agent: Fibrogen, Inc.

20100291099 - Novel 27411, 23413, 22438, 23553, 25278, 26212, narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc: The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 20A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC... Agent: Millennium Pharmaceuticals, Inc.

20100291100 - Compositions and methods for screening and using compounds antagonizing spore-surface interactions: The present invention provides genes encoding novel microbial proteins (i.e., for example, exosporium genes and proteins) that mediate the attachment of microbial spores to surfaces. Specific fragments of these microbial spore proteins may be utilized to inhibit the attachment of microbial spores to surfaces, thereby providing an infection control agent.... Agent: Medlen & Carroll, LLP

20100291101 - New anti-irc85 monoclonal antibody; and composition comprising the same for preventing and treating tuberculosis or enteritis disease; and the use thereof: The present invention provides the novel anti-IRC85 monoclonal antibody specifically binding with IRC85 and it showed potent effect in removing the infected/phagocytosed bacteria from THP-I, a monocytic cell that expresses human IRC85 and is infected with Listeria monocytogenes or WR-tubercle bacillus. Accordingly, it can be useful as a medicament and... Agent: Ladas & Parry LLP

20100291103 - Polypeptides, antibody variable domains and antagonists: The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100291102 - Therapeutic agent: Anti-HLA and other antibodies are present in goat serum after injection of HIV antigenic material, and form the basis for a most surprisingly effective treatment of HIV, multiple sclerosis and other conditions.... Agent: Carella, Byrne, Cecchi, Olstein, Brody & Agnello

20100291104 - Bordetella outer-membrane protein antigens and methods of making and using the same: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need... Agent: Myers Bigel Sibley & Sajovec

20100291105 - Agent for the treatment of malignant diseases: The invention proposes an agent for the treatment of tumor diseases, for example the multiple myeloma, said agent acting upon NK cells through the activation of an anti-tumor immune response after stimulation of the NKp30 receptor and the natural cytotoxicity receptors (NCR). Said agent contains in an acceptable carrier material... Agent: Berliner & Associates

20100291106 - Compositions and methods for antibodies targeting complement protein c3b: The present invention relates to antibodies and antigen binding fragments thereof that bind to both human and cynomolgus complement protein C3b, as well as compositions and methods of use thereof.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100291107 - High affinity human antibodies to human il-4 receptor: The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.... Agent: Regeneron Pharmaceuticals, Inc

20100291108 - Antibodies to irem-1: Anti-IREM-1 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind IREM-1 and treat diseases, such as hematologic malignancies, which are characterized by expression of IREM-1.... Agent: Fulbright & Jaworski L.L.P.

20100291110 - Compositions and methods for regulating nk cell activity: The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100291109 - Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity: Fusion proteins and DNA conjugates are disclosed which contain a TLR/CD40/agonist and optional antigen combination. The use of these protein and DNA conjugates as immune adjuvants and as vaccines for treatment of various chronic diseases such as HIV infection is also provided.... Agent: Hunton & Williams LLP Intellectual Property Department

20100291112 - Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives: The present invention relates to a nucleic acid molecule encoding a polypeptide, wherein the polypeptide comprises (a) a first immunoglobulin domain comprising a VL domain linked to a VH domain, wherein the immunoglobulin domain specifically binds to an antigen expressed on tumour cells; (b) a second immunoglobulin domain comprising a... Agent: Brinks Hofer Gilson & Lione

20100291113 - Treatment of proliferative disorders using antibodies to psma: Methods of treating cancer in a patient are provided. In some embodiments the method comprises administering an antibody that is capable of binding to the extracellular domain of PSMA. In some embodiments, the method comprises restricting folate intake by the patient. Methods of monitoring cancer therapy are provided as well... Agent: Proskauer Rose LLP

20100291111 - Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation: The present invention provides methods for direct killing of cancer cells using anti-α5β1 antibodies. Generally, the method comprises contacting a cancer cell that expresses α5β1 on its surface with an anti-α5β1 antibody, and thereby inducing the death of the cancer cell. The methods of the invention may be employed at... Agent: Sughrue Mion, PLLC

20100291114 - Crystal structures and methods using same: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention concerns modulators of FGFR3 function, and the identification and uses of said modulators.... Agent: Genentech, Inc.

20100291118 - Class of gamma delta t cells activators and use thereof: e

20100291117 - Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases: The invention provides methods for the ex-vivo expansion of CD4+CD25+ Tregs. The invention provides a method for producing ex vivo expanded Tregs that may be used to inhibit unwanted human immune responses against self-antigens or allergens. Additionally, the ex vivo expanded Tregs may provide treatment for inflammatory/automimmune diseases.... Agent: Philip S. Johnson Johnson & Johnson

20100291116 - Microparticle comprising cross-linked polymer: Microparticle comprising a cross-linked polymer comprising (a) a cross-linker comprising two or more radically polymerizable groups, preferably selected from the group consisting of alkenes, sulfhydryl (SH), thioic, unsaturated esters, unsaturated urethanes, unsaturated ethers, and unsaturated amides; (b) a monofunctional reactive diluent comprising maximum one unsaturated C—C bond represented by the... Agent: Nixon & Vanderhye, PC

20100291115 - Pharmaceutical composition for the sublingual administration of vaccines, method for the preparation of the same and uses thereof: The subject of the present invention is a pharmaceutical composition for the sublingual administration of vaccines, a method for its preparation and the use thereof for modulating the absorption rate and substantially improving its effectiveness and safety. Said sublingual composition is applicable both to immunizing vaccines, which are employed against... Agent: Pearne & Gordon LLP

20100291125 - Eta-1 gene and methods for use: The present application relates to osteopontin (Eta-1) polypeptides, nucleic acids that encode Eta-1, antibodies that specifically bind to Eta-1, and methods for enhancing an immune response in an animal.... Agent: Merck Patent Department (k-6-1, 1990)

20100291124 - Extracellular serine protease: The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of... Agent: Benjamin Aaron Adler Adler & Associates

20100291122 - Method for enhancing immune response with peptide: An object of the present invention is to provide a safe and effective method for enhancing an immune response and a medicament for preventing or treating Alzheimer disease comprising amyloid β peptide that induces an enhanced immune response. An amyloid β peptide or a portion thereof with addition or insertion... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100291120 - Peptides regulating the surface expression of the t cell receptor: The present invention is related to a peptide comprising an amino acid sequence according to SEQ. ID. No 1.... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20100291126 - Protein showing enhanced expression in cancer cells: A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The... Agent: Agensys C/o Morrison & Foerster LLP

20100291123 - T cell receptor cdr3 sequences and methods for detection: The present invention relates generally to the field of treating autoimmune diseases, such as multiple sclerosis (MS), rheumatoid arthritis (RA) and others. Methods of treating and monitoring an autoimmune disease by utilizing T-cell receptors peptides are disclosed. Nucleic acid and peptide sequences of T-cell receptors found in a population of... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20100291127 - Tumor associated antigen peptides and use of same as anti-tumor vaccines: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA),... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100291121 - Tumour-specific animal proteins: CASB7439 polypeptides and polynucleotides, immunogenic compositions comprising them and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB7439 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly colorectal, breast, and lung cancers, autoimmune diseases, and related... Agent: Glaxosmithkline Global Patents

20100291119 - Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis: The present invention discloses the first medical use of alpha B crystallin or derivatives thereof in the field of auto-immune diseases, particularly multiple sclerosis. It also discloses diagnostic methods and tools therefor based upon alpha B crystallin for the detection of multiple sclerosis. Human alpha B crystallin is a known... Agent: Londa, Bruce S. Norris Mclaughlin & Marcus, Pa

20100291129 - Norovirus and sapovirus antigens: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods... Agent: Novartis Vaccines And Diagnostics Inc.

20100291128 - Novel compositions and vaccines against influenza a and influenza b infections: Novel models of interactions of the Nonstructural Protein of influenza A and influenza B viruses (NS1A and NS1B, respectively) with dsRNA are presented. On the basis of the models, novel recombinant viruses and vaccines against influenza A and influenza B viruses are provided.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20100291130 - Cloned genome of infectious hepatitis c virus strain hc-tn and uses thereof: Embodiments described herein include nucleic acid sequences, which encode hepatitis C virus of strain HC-TN, genotype 1a, proteins and polypeptides and fragments thereof. Use of these compositions, and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV are also contemplated.... Agent: Townsend And Townsend And Crew, LLP

20100291131 - Clostridial toxin netb: The present invention relates to a polypeptide based toxin that originates from Clostridium perfringens. The invention further relates to immunogenic compositions comprising the toxin and methods to vaccinate animals, for example chickens, such that they are less susceptible to clostridial diseases. Methods to determine whether an animal has been exposed... Agent: Townsend And Townsend And Crew, LLP

20100291132 - Streptococcus uberis adhesion molecule: A polypeptide, designated as “Streptococcus uberis Adhesion Molecule” (SUAM), and fragments of SUAM, prevent internalization and adherence of Streptococcus uberis and other streptococcal pathogens to cells. The SUAM polypeptide and fragments may be used diagnostically and therapeutically. Nucleic acid sequences encoding the SUAM polypeptide and fragments are included in the... Agent: Howard Eisenberg, Esq.

20100291133 - Recombinant protein containing a c-terminal fragment of plasmodium msp-1: The invention relates to a recombinant protein fabricated in a baculovirus system, of which the essential constitutive polypeptide sequence is that of a C-terminal fragment of 19 kilodalton (p19) of the surface protein 1 (protein MSP-1) of the merozoite parasite of the Plasmodium type, particularly Plasmodium falciparum, which is infectious... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100291134 - Truncated hepatitis c virus ns5 domain and fusion proteins comprising same: The invention provides truncated HCV NS5 polypeptides and fusion proteins comprising the truncated NS5 polypeptides, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating an immune response to HCV, for example a cellular immune... Agent: Novartis Vaccines And Diagnostics Inc.

20100291135 - Species of fungi and their use in pest and disease control: The present invention describes substantially pure cultures of three new species of fungi, Meira geulakonigae (CBS 110052), Meira argovae (CBS 110053) and Acaromyces ingoldii (CBS 110050) (all nom. prow.), wherein said cultures are biologically pure. The conditioned medium for all three new fungi species is also described, as well as... Agent: Cooper & Dunham, LLP

20100291137 - Method for refolding neisserial nspa protein: The present invention provides an isolated refolded NspA protein, and a method of preparing it.... Agent: Glaxosmithkline Global Patents

20100291136 - Pharmaceutical liquid composition of botulinum toxin with improved stability: Disclosed herein is a liquid pharmaceutical composition of botulinum toxin which is improved in stability. It comprises botulinum toxin, polysorbate 20, and methionine and optionally isoleucine. Employing, instead of the animal-derived protein albumin or gelatin, a combination of polysorbate 20 and methionine and optionally isoleucine as botulinum toxin stabilizers, the... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100291138 - Vaccine: The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to vaccines comprising a pneumococcal polysaccharide antigen, typically a pneumococcal polysaccharide conjugate antigen, formulated with a protein antigen form Streptococcus pneumoniae, and optionally a Th1-inducing adjuvant.... Agent: Glaxosmithkline Global Patents

20100291139 - Recombinant mva virus and the use thereof: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production... Agent: Law Office Of Salvatore Arrigo

20100291140 - Antibiotic resistance free listeria strains and methods for constructing and using same: The present invention provides Listeria strains that express a heterologous antigen and a metabolic enzyme, and methods of generating same.... Agent: Pearl Cohen Zedek Latzer, LLP

20100291141 - Truncated l1 protein of human papillomavirus type 11: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20100291142 - Bacterial artificial chromosome containing feline herpes virus type 1 genome and uses thereof: The present invention relates to recombinant feline herpes virus type 1 (FHV-1) nucleic acids and proteins. In particular the present invention provides compositions comprising the full length FHV-1 genome or portions thereof, and infectious FHV-1 virions produced therefrom. The FHV-1 compositions are suitable for use in inducing an immune response... Agent: Medlen & Carroll, LLP

20100291145 - Ii-key/antigenic epitope hybrid peptide vaccines: Disclosed is a nucleic acid molecule comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope, or said encoded protein or peptide. In addition, the nucleic acid molecule comprises a second expressible nucleic acid sequence encoding an antigen presentation... Agent: Kevin M. Farrell, Pierce Atwood

20100291143 - Inhibition of hiv and shiv replication with antisense interleukin-4: A method of treating or preventing SHIV or HIV infection in a subject comprising administering a therapeutically effective amount of a antisense IL-4. The antisense IL-4 inhibits viral replication in the liver, lungs, spleen, and even the lymph nodes of the subject. Further, the antisense IL-4 can be used in... Agent: Polsinelli Shughart PC

20100291144 - Novel vaccines against multiple subtypes of dengue virus: An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal... Agent: Vgx Pharmaceuticals, LLC

20100291146 - Method of eliciting an immune response against pandemic influenza virus: A method for eliciting or inducing a protective immune response in a subject against a pandemic subtype of influenza virus comprises administering to the subject a composition comprising (i) at least one immunogen of an endemic influenza subtype, and (ii) an immunogen-free immunostimulating complex as adjuvant.... Agent: Foley And Lardner LLP Suite 500

20100291147 - Recombinant rsv antigens: This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection.... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100291149 - Attenuated listeria spp. and methods for using the same: Attenuated Listeria bacteria are provided. The subject bacteria are characterized by having a mutation in a gene chosen from the lplA gene and the hly gene. The subject bacteria find use in a variety of applications, where representative applications of interest include, but are not limited to: (a) use of... Agent: Uc Berkeley - Otl Bozicevic, Field & Francis LLP

20100291148 - Shigella mutants in the functions pertaining to the processes of maturing and recycling peptidoglycans and their uses as immunogens: Bacteria belonging to the Shigella genus, mutated to inactivate the function of at least one of the gene products responsible for the metabolism and/or recycling of the peptidoglycans of the cellular wall, for immunogenic use, especially mutated at SltY, MltA, MltB, ampG, amiA, MppA genes, and immunogenic compositions comprising them.... Agent: Lucas & Mercanti, LLP

20100291150 - Pseudomonas exotoxin a cd4+ t-cell epitopes: The present invention provides PE CD4+ T-cell epitopes, as well as novel variants that exhibit reduced immunogenic responses, as compared to the parental PE. The present invention further provides DNA molecules that encode novel PE variants, host cells comprising DNA encoding novel PE variants, as well as methods for making... Agent: Medimmune, Limited

20100291151 - 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor: The present invention relates to new 1-methylpyrazole modulators of substance P release, calcitonin gene-related peptide activity, adrenergic receptor activity, and/or 5-HT receptor activity, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100291152 - Chemically modified peptides with improved immunogenicity: The invention provides processes for improving the ability of a peptide to stimulate an immune response, comprising exposing the peptide to a chemical modifying agent. It further provides compositions comprising an antigenic peptide, wherein the peptide has been treated with a chemical modifying agent to improve its ability to stimulate... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100291153 - Vaccines against bordetella pertussis based on lps glycosyltransferase mutants: The invention relates to an improved vaccine against pertussis wherein mutants of Bordetella pertussis having a modified LPS molecule or the obtainable LPS molecules are used. These mutants or the obtainable LPS molecules may further be used as an adjuvant.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100291154 - Composition for inhibition of transplant rejection containing the cordyceps mycellia extract as an active ingredient: Disclosed is a composition for the inhibition of transplant rejection and the prevention and treatment of skin diseases, comprising a cordyceps mycellia extract as an active ingredient. The cordyceps mycellia extract significantly suppresses the production of antibodies to transplants without side effects, such as weight change. Based on natural material,... Agent: Lucas & Mercanti, LLP

20100291155 - Allergy vaccine composition for mucosal administration: The present invention relates to an allergy vaccine composition for mucosal administration comprising a cysteine protease allergen in a reduced active state or in an oxidised inactive state, The inventions further relates to an adjuvant system for use in a vaccine for mucosal administration comprising a cysteine protease.... Agent: Birch Stewart Kolasch & Birch

20100291156 - Composition for treating lung cancer, particularly of non-small lung cancers (nsclc): The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use... Agent: Connolly Bove Lodge & Hutz, LLP

20100291161 - Cellulose powder: Cellulose powder having an especially excellent balance among moldability, fluidity and disintegrating property is provided. Cellulose powder having an average polymerization degree of 150-450, an average L/D (the ratio of the major axis to the minor axis) value of particles of 75 μm or less of 2.0-4.5, an average particle... Agent: Greenblum & Bernstein, P.L.C

20100291157 - Composition for headache treatment: A nutritional composition for treating severe headaches and comprising a plurality of vitamins and a plurality of minerals that together represent at least a portion of required daily allowance thereof. The plurality of vitamins include at least vitamins A, C, D, E, K, B-1, B-2, B-6, and B-12, niacin, folic... Agent: Salter & Michaelson The Heritage Building

20100291159 - Film coatings containing fine particle size detackifiers and substrates coated therewith: The present invention is directed to film coating compositions for use on oral dosage forms such as compressed tablets and other orally-ingestible substrates which contain a fine particle size detackifier. The film coating compositions can be applied either directly to a substrate or after the substrate has been coated with... Agent: Lucas & Mercanti, LLP

20100291160 - Pharmaceutical system for trans-membrane delivery: Non-invasive drug delivery systems useful for the absorption of therapeutically active agents through the epithelial membrane are described. The non-invasive drug delivery system delivers a therapeutic active agent with an ionizable, or ionized, metal, transition metal or metal-containing vehicle. The non-invasive drug delivery system may also have a pH adjustable... Agent: Winston & Strawn LLP Patent Department

20100291158 - Sustained release oral composition of an antipsychotic agent: A sustained release oral composition of an antipsychotic agent comprising antipsychotic agent, λ-carrageenan and one or more pharmaceutically acceptable excipients; wherein the antipsychotic agent is 2-[2-(4-dibenzo{b,f}[1,4-thiazepin-11yl-1-piperazinyl)ethoxy ethanol] or its pharmaceutically acceptable salt.... Agent: Sughrue Mion, PLLC

20100291164 - Functionalized calcium phosphate hybrid systems for the remineralization of teeth and a method for producing the same: A dental remineralizing system, including a functionalized calcium-containing complex having an organic surfactant component mechanochemically attached to a distressed calcium phosphate component and blended with the comestible material.... Agent: Brannon & Sowers PC

20100291163 - Oral care composition comprising nanoparticulate titanium dioxide: The present invention relates to an oral care composition comprising nanoparticulate titanium dioxide, optionally together with a source of fluoride ions, for combating dental erosion and/or tooth wear. In addition such compositions may also have benefit in tooth whitening. When a source of fluoride ions is present such compositions are... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100291162 - Oral compositions providing enhanced tooth stain removal: This invention generally relates to oral compositions (e.g., a confection or chewing gum product such as a compressed chewing gum) effective for removal of stains from a tooth surface. In particular, this invention relates to oral compositions including a coated or an encapsulated protease enzyme to provide an oral composition... Agent: Wm. Wrigley Jr. Company Patent Department

20100291165 - Personal care composition in the form of an article having a hydrophobic surface-resident coating: The present invention relates to personal care compositions, especially those personal care compositions in the form of an article that is a porous, dissolvable solid structure. The article has a hydrophobic surface-resident coating that can provide enhanced deposition efficiency of hydrophobic actives contained therein.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100291167 - Porous carbon material composites and their production process, adsorbents, cosmetics, purification agents, and composite photocatalyst materials: Provided is a porous carbon material composite formed of a porous carbon material and a functional material and equipped with high functionality. A porous carbon material composite is formed of (A) a porous carbon material obtainable from a plant-derived material having a silicon (Si) content of 5 wt % or... Agent: Sonnenschein Nath & Rosenthal LLP

20100291166 - Use of nitrogen-doped titanium oxide nanoparticles as agents for protecting against ultraviolet radiation: A nanometric material includes nitrogen-doped titanium oxides, which is obtained by injection of a titanium oxide precursor in the liquid or gaseous form and of a gaseous nitrogenous compound into a laser pyrolysis reactor. The material is used as cosmetic agent for protecting against ultraviolet radiation, thereby improving protection against... Agent: Merchant & Gould PC

20100291168 - Antimicrobial formulations comprising a combination of a pyridine thiol and a bis-quinolinium salt: An antimicrobial formulation containing a pyridine thiol and a bis-quinolinium salt which contains a cation of formula (I) below: wherein n is an integer from 3 to 18. The formulation may in particular be used for the treatment of a bacterial condition, more particularly acne or body odour. It is... Agent: Weaver Austin Villeneuve & Sampson LLP

20100291169 - Polyelectrolyte complex for imparting antimicrobial properties to a substrate: Anionic polyelectrolytes are used as binding agents to reduce the solubility of cationic antimicrobial polyelectrolytes. Ionic attraction between the anionic stabilizing polyelectrolytes and the antimicrobial cationic polyelectrolytes results in formation of a polyelectrolyte complex (PEC). A treatment liquid comprising a stable colloid, suspension, dispersion, solution, coacervate, or emulsion of the... Agent: Elman Technology Law, P.C.

20100291171 - Hyaluronic acid derivatives obtained via \"click chemistry\" crosslinking: Crosslinked derivatives of polycarboxylated polysaccharides are described, wherein at least one of the polysaccharide chains consists of hyaluronic acid or a derivative thereof, crosslinked by means of reactions of the “click chemistry” type and their use in the field of viscosupplementation, plastic surgery, oncologic and reconstructive surgery and also as... Agent: Birch Stewart Kolasch & Birch

20100291170 - Novel therapies for chronic renal failure: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic... Agent: Ropes & Gray LLP

20100291172 - Sterile autologous, allogenic or xenogenic implant and the method of its production: The subject of the invention is a sterile, dehydrated acellular implant, which during its rehydration by water or bodily fluids displays anisotropic expansion and can act as a substrate for adhesion, migration and growth of live cells. Collagen structures of the transplant are at least partially denatured through the action... Agent: Notaro, Michalos & Zaccaria P.C.

20100291174 - Biologically active device and method for its production: The present invention is directed to a biologically active device with a main body made from a polymer, in which bioactive nanoparticles of one or several materials are embedded, wherein the nanoparticles of at least one material proliferatively act on a biological material contacted by the device, and wherein nanoparticles... Agent: Flynn Thiel Boutell & Tanis, P.C.

20100291179 - Composite biomaterial for controlled release of active ingredients: The present invention relates to a composite biomaterial and a process for producing a composite biomaterial with controlled release of active ingredients, comprising a three-dimensional polymer-based support structure, and a polymer-based matrix structure. The active ingredients are in this case incorporated into the composite biomaterial via the matrix structure, and... Agent: Klarquist Sparkman, LLP

20100291176 - Manufacturing three-dimensional scaffolds using cryogenic prototyping: The present invention refers to a method of fabricating a three dimensional scaffold suitable for tissue-engineering having a controlled micro- and macroporous structure using cryogenic prototyping. The present invention also refers to scaffolds obtained by the method of the present invention and to their use.... Agent: Pabst Patent Group LLP

20100291173 - Method of improving renal function: A method of improving renal function in a mammal suffering from, or at risk of developing, at least partial renal failure or renal dysfunction, includes administering to renal tissue of the mammal, a combination comprising a non-viral vector comprising a non-viral particulate carrier which carries a therapeutically effective amount of... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100291178 - Multi-phased, biodegradable and osteointegrative composite scaffold for biological fixation of musculoskeletal soft tissue of bone: Methods and apparatuses are provided for musculoskeletal tissue engineering. For example, a scaffold apparatus is provided which comprises microspheres of selected sizes and/or composition. The microspheres are layered to have a gradient of microsphere sizes and/or compositions. The scaffold provides a functional interface between multiple tissue types.... Agent: Cooper & Dunham, LLP

20100291175 - Polymers comprising amorphous terpolymers and semicrystalline blocks: The present invention provides an implantable article comprising an amorphous terpolymer and a semi-crystalline polymer. The amorphous terpolymer can be admixed with the semi-crystalline polymer or form a block copolymer with the semi-crystalline polymer.... Agent: Squire, Sanders & Dempsey LLP

20100291177 - Prevention of staphylococcus biofilm formation: The present application discloses antibodies directed to protein SE2232 (SesC) of Staphylococcus epidermis, and homologus proteins which are useful in preventing biofilm formation by said micro-organism. The antibodies can be used to coat medical devices which are inserted or implanted into the mammalian, preferably human body. Further these antibodies or... Agent: Jackson Walker LLP

20100291182 - Drug-loaded fibers: Implants and methods for the delivery of a therapeutic agent to a target location within a patient's body are disclosed. The implants include a fiber comprising a polymeric material and having a diameter of up to about twenty microns, and a first therapeutic agent within the fiber. The therapeutic agent... Agent: Bingham Mccutchen LLP

20100291180 - Nerve guidance tubes: Provided herein are cell guidance tubes and methods for their use.... Agent: Viksnins Harris & Padys Pllp

20100291181 - Therapeutic devices for patterned cell growth: The invention provides therapeutic devices comprising a polymeric anti-inflammatory agent that biodegrades to release anti-inflammatory agents. The therapeutic devices are useful for repair and regeneration of a variety of injured tissues.... Agent: Viksnins Harris & Padys Pllp

20100291183 - Enhanced moisture barrier immediate release film coating systems and substrates coated therewith: The present invention is directed to immediate release film coating systems for use on oral dosage forms such as compressed tablets and other orally-ingestible substrates which have improved moisture barrier properties. The film coating systems can be applied either directly to a substrate or after the substrate has been coated... Agent: Lucas & Mercanti, LLP

20100291184 - Wound dressing with apertured cover sheet: A wound dressing comprising an antimicrobial absorbent layer containing silver, and an apertured sheet covering the antimicrobial absorbent layer, wherein the apertured sheet is formed from a liquid-impermeable sheet material having an array of apertures therein, said apertures having a mean effective diameter of from about 0.5 mm to about... Agent: Morgan, Lewis & Bockius LLP

20100291185 - Theritol phosphates, salts thereof and methods of use: This application discloses compositions containing synthetic threitol phosphates, in particular threitol monophosphate, threitol-bis-phosphate, threitol diphosphate, and/or threitol triphosphate. The threitol phosphates are useful in treating wounds, for cosmetic applications, and for bone and periodontal regeneration.... Agent: David S. Resnick

20100291187 - Adhesive laminates for rapid wound occlusion: Provided herein are protective laminate devices comprising a biocompatible non-adherent substance and a fast-setting adhesive and methods of use. Also provided is a dispenser for an adhesive tape. The protective laminate devices and methods may be used for wound closure.... Agent: Benjamin Aaron Adler Adler & Associates

20100291186 - Transdermal administration of tamsulosin: In an aspect of the invention, a composition for making a patch for the transdermal delivery of tamsulosin is provided. The composition comprises (a) at least about 1 wt % tamsulosin or a pharmaceutically acceptable salt of tamsulosin, (b) at least about 40 wt % polyisobutylene adhesive or hydrophobic synthetic... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100291194 - Compositions and methods for inhibiting expression of a mutant gene: The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a complementary RNA strand having a complementary region that is substantially complementary to a portion of the mutant gene, and which is partially complementary to the corresponding wild-type gene. The invention... Agent: Alnylam/fenwick

20100291192 - Detoxification method for lipopolysaccharide (lps) or lipid a of gram-negative bacteria: The invention relates to a method of detoxifying a lipopolysaccharide (LPS) or a lipid A from a Gram-negative bacterium, which comprises mixing the LPS or the lipid A with a cationic lipid so as to form a complex in which the LPS or the lipid A is associated with the... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100291193 - Immunogenic compositions comprising progastrin and uses thereof: The present invention is drawn to immunotherapeutic methods to treat tumors/cancers that produce progastrin ectopically or are dependent on progastrin for their growth. Disclosed herein are immunogenic compositions comprising agents that target progastrin, agents that target the progastrin receptor, annexin II, or both. Such a composition may be administered in... Agent: Benjamin Aaron Adler Adler & Associates

20100291189 - Method for producing a membrane protein: A method is provided for producing a membrane protein folded to its native structure or active structure in a lipid disc or a liposome. The method comprises: (a) preparing a reaction solution for cell-free protein synthesis containing a polynucleotide encoding a membrane protein, a steroidal detergent, and a phospholipid, wherein... Agent: Birch Stewart Kolasch & Birch

20100291196 - Method of treatment of autism spectrum disorder with liposomal reduced glutathione: The invention proposes the use of reduced glutathione encapsulated in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to improve symptoms in disease states related to diminished function of the methylation pathway such as autism, other neurodegenerative diseases and abnormalities of neurotransmitter levels in... Agent: Brooke Schumm Iii Daneker, Mcintire, Schumm, Prince, Goldstein Et Al

20100291188 - Periostin inhibitory compositions for myocardial regeneration, methods of delivery, and methods of using same: We claim the compositions of matter and methods described herein.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100291190 - Topical composition for anti-aging skin treatment using dual dna repair mechanism and method of use: A topical composition for anti-aging treatment of the skin includes water soluble extract of Uncaria species, Arabidopsis thaliana extract, lipoic acid, dimethylethanolamine, tetrahexyldecyl ascorbate, dimethyl sulfoxide, Glycyrrhiza Glabra(Licorice) root extract, methylsulfonylmethane, phytosterols, D-ribose, tocotrienol, tocopherol, glucosamine hydrochloride, Pisum sativum extract; Bambusa vulgaris extract, and a dermatologically acceptable liposomal delivery medium.... Agent: Melvin K. Silverman And Assocs PC

20100291195 - Topical delivery of l-arginine to cause beneficial effects: A preparation is disclosed for producing enhanced blood flow in tissue thus causing beneficial effects such as promoting hair growth on scalp tissue lacking sufficient hair, restoring normal sexual function in males with erectile dysfunction. Specifically, this is a preparation which provides local delivery of the amino acid L-arginine, an... Agent: Wolf Greenfield & Sacks, P.C.

20100291191 - Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix: The incorporation of polymeric excipients into an injectable hydrogel matrix, for example, methyl cellulose in the case of a hydrogel matrix comprising hyaluronan and methylcellulose (HAMC) has been found to increase the solubility of sparingly soluble hydrophobic drugs and tune their rate of release. The hydrogel matrix may also include... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20100291197 - hot melt-filled soft capsules: The present invention relates to a soft capsule, comprising a capsule case and a filling material with at least one pharmacologically or physiologically active substance, characterized in that the capsule case is made by melt extrusion of thermoplastically processable polymer material, and the filling material is solid at under 10°... Agent: The Nath Law Group

20100291198 - Compositions of phytosterols with enhanced bioavailability: A method for preparing porous microparticles containing phytosterol, by preparing a homogeneous melt of phytosterol and a partially water soluble component, cooling the melt to obtain an amorphous solid material, processing the material into a fine powder, and bringing the powder into contact with an aqueous phase under stirring conditions.... Agent: Young & Thompson

20100291199 - Compositions and methods for the treatment and prevention of disease: The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use. In one aspect the present invention relates to compositions and methods for the treatment and prevention of disease in a mammal comprising administering the compounds of the... Agent: Mccarter & English, LLP Stamford

20100291200 - Formulations for poorly soluble drugs: The present invention provides a drug delivery system comprising nanoparticles or microparticles of a water poorly soluble drug dispersed in a polymeric bead containing essentially only of hydrophilic polymers (i.e. without hydrophobic polymers). The present invention further provides a method of producing the drug delivery system of the invention.... Agent: The Nath Law Group

20100291201 - Coated pharmaceutical capsule dosage form: Pharmaceutical compositions in unit dose form comprising a hard or soft capsule containing a fill consisting of one or more inert ingredients, and one or more coatings on the capsule, wherein at least one coating comprises at least one active pharmaceutical ingredient.... Agent: Arent Fox LLP

20100291202 - Coated pharmaceutical or nutraceutical preparation with enhanced pulsed active substance release: The present invention relates to a pharmaceutical or nutraceutical preparation comprising a) a core containing a pharmaceutically or nutraceutically active substance and a substance that acts in a modulatory manner with regard of the release of pharmaceutically or nutraceutically active substances; and b) a controlling layer surrounding the core comprising... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100291204 - Combination of a long-acting hypnotic agent and a short-acting hypnotic agent and therapeutic use thereof: The invention relates to the combination of: a short-acting hypnotic agent which is selected from among a modulators of receptors GABA-A, a benzodiazepine, a phenothiazine, a melatonin derivative and a melatonin receptor agonist; and a long-acting hypnotic agent which is selected from among a modulator of receptors GABA-A, a benzodiazepine,... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100291203 - Opioid agonist/antagonist combinations: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective... Agent: Davidson, Davidson & Kappel, LLC

20100291205 - Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse: Abuse resistant polyglycol-based pharmaceutical compositions are disclosed. The composition contains one or more polyglycols and one or more active substances and it is resistant to crushing, melting and/or extraction. Moreover, such compositions have the same or lower solubility in ethanolic-aqueous medium, i.e. they are not subject to ethanol-induced dose dumping... Agent: Stoel Rives LLP - Slc

20100291206 - Oral dosage form: A pharmaceutical or nutraceutical tablet for oral administration comprising at least two fatty acids or derivatives thereof and cyclodextrin. Surprisingly, we have now found that fatty acids or derivatives thereof, especially fatty acid esters, preferably in the form of complexes with cyclodextrins prepared as stable solid materials, can easily be... Agent: Nixon & Vanderhye, PC

20100291207 - Pharmaceutical formulation comprising ezetimibe: The present invention relates to novel formulations comprising ezetimibe as active ingredient. In particular the invention relates to a pharmaceutical composition comprising 5 to 20 wt-% ezetimibe, 50 to 85 wt-% diluent, 3 to 25 wt-% disintegrant, 1 to 10 wt-% binder, and 0.5 to 1 wt-% lubricant, characterized in... Agent: Smith Patent Consulting, LLC

20100291208 - Controlled porous osmotic pump tablets of high permeable drugs and the preparation process thereof: The present invention relates to controlled porous osmotic pump tablets of high permeable drugs and the preparation process thereof. The controlled porosity osmotic pump tablets do not need to be drilled by laser, but provides controlled porosity for drug release by adding a suitable quantity of pore-forming agents into the... Agent: Foley And Lardner LLP Suite 500

20100291209 - Organic compounds: A dosage form adapted for twice-a-day administration comprising a naproxen species in an immediate release phase and an opioid analgesic in a sustained release phase. The dosage form is useful in the treatment of pain.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100291213 - Composite non-woven fibrous webs having continuous particulate phase and methods of making and using the same: The disclosure relates to composite nonwoven fibrous web including an embedded phase having a population of particulates forming a substantially continuous three-dimensional network, and a matrix phase comprising a population of fibers forming a three-dimensional network around the particulates. The disclosure also relates to methods of making a composite nonwoven... Agent: 3m Innovative Properties Company

20100291211 - Material compositions which comprise adult stem cells obtained from exocrine glandular tissue, in particular for use in regenerative medicine, e.g. for restoring injured or damaged myocardial tissue: The invention relates to material compositions comprising adult stem cells obtained from exocrine gland tissue and a supporting matrix having the shape of a thread structure and/or of a net. The supporting matrix preferably consists of a plastic material which is physiologically acceptable and degradable in the body. The material... Agent: Pearl Cohen Zedek Latzer, LLP

20100291210 - Novel lipid peptide and hydrogel: n represents the number of 1 to 4; X represents an amino group, a guanidine group, a —CONH2 group or a 5-membered ring, a 6-membered ring or a fused heterocyclic ring composed of a 5-membered ring and a 6-membered ring which optionally have 1 to 3 nitrogen atom(s); and in... Agent: Oliff & Berridge, PLC

20100291212 - Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use: FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to... Agent: Woodcock Washburn LLP

20100291215 - Drug delivery matrices to enhance wound healing: Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either... Agent: Pabst Patent Group LLP

20100291214 - Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure: Disclosed is a three-dimensional microfiber extrudate structure and a process of forming a three-dimensional microfiber extrudate structure. The three-dimensional microfiber extrudate structure includes a matrix having a three-dimensional geometry wherein the three-dimensional geometry is a visco-elastic relaxation state of a preform introduced to a medium.... Agent: Mcnees Wallace & Nurick LLC

20100291216 - Pharmaceutical compositions: The present invention relates to pharmaceutical compositions for sustained release comprising a water soluble salt of the HMG-CoA reductase inhibitor fluvastatin as active ingredient, said composition being selected from the group comprising matrix formulations, diffusion-controlled membrane coated formulations; and combinations thereof.... Agent: Novartis Corporate Intellectual Property

20100291217 - Pharmaceutical compositions: The present invention relates to pharmaceutical compositions for sustained release comprising a water soluble salt of the HMG-CoA reductase inhibitor fluvastatin as active ingredient, said composition being selected from the group comprising matrix formulations, diffusion-controlled membrane coated formulations; and combinations thereof.... Agent: Novartis Corporate Intellectual Property

20100291220 - Antibiotic formulation and method of treatment: A formulation comprised of particles which may be in groups and are comprised of a biocompatible polymer and an antimicrobial drug for controlled release of the drug is disclosed. The particles may be in an aqueous solution comprising thrombin and be dispersed in a gel. The formulation is administered to... Agent: Bozicevic, Field & Francis LLP

20100291222 - Antioxidant nanosphere comprising [1,2]-dithiolane moieties: The present invention is directed to multiple a-lipoic acid-containing hydrophobic compounds (mALAs) capable of acting as scavengers of free radicals, metals and reactive oxygen species (ROS). Methods of synthesizing novel antioxidant mALAs, spontaneous emulsification or nanoprecipitaion thereof to produce antioxidant nanospheres and their use in preventing or treating diseases or... Agent: Davis Wright Tremaine LLP/los Angeles

20100291218 - Immunomodulatory compositions, formulations, and methods for use thereof: The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMO/MC) complexes comprising 3-6mer immunomodulatory oligonucleotides. The IMO/MC complexes may be covalently or non-covalently bound. Also provided are immunomodulatory compositions comprising a 3-6mer IMO encapsulated in an MC.... Agent: Morrison & Foerster LLP

20100291221 - Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation: Disclosed are methods, and related compositions, that include administering a dose-sparing amount of a formulation that includes inhalation particles to a subject by inhalation; wherein the inhalation particles comprise formoterol fumarate and budesonide, the formoterol fumarate and budesonide being in a distributed encapsulated morphology with respect to one another within... Agent: Owen J. Bates

20100291219 - Methods and compositions relating to progenitor cells: The invention provides compositions and methods for harvesting and enriching cells such as connective tissue progenitors cells using stirred bioreactors, and in some embodiments fibrin microcarriers.... Agent: Wolf Greenfield & Sacks, P.C.

20100291223 - Treatment for dermatological conditions: A composition and method of using a composition containing kunzea oil for treating dermatological conditions in humans and animals, particularly greasy heel occurring in horses, in which the kunzea oil is formulated into a composition for topical application at ambient temperatures to the skin of the animal or human to... Agent: Pearne & Gordon LLP

20100291224 - Nanostructures, methods of preparing and uses thereof: c

20100291225 - Stabilized sustained release composition of bupropion hydrochloride and process for preparing the same: Disclosed herein is a stabilized sustained release pharmaceutical composition of bupropion hydrochloride and process for preparing the same, wherein said pharmaceutical composition comprising therapeutically effective amount of uncoated fine bupropion hydrochloride and pharmaceutically acceptable adjuvants, and wherein the composition is free of an acidic stabilizer and contains less than about... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20100291226 - Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use: The present invention refers to pharmaceutical formulations based on lipids for ophthalmic use comprising a phospholipid component composed of zwitterionic phospholipids of natural origin and an oily component composed of oils of natural origin emulsified in water. In particular, the invention refers to ophthalmic formulations useful, for example, for transporting... Agent: Shoemaker And Mattare, Ltd

20100291227 - Lip lubricant and method of lubricating the lips: A lip lubricant for use as a lip coating during dental work, the lip lubricant comprising: one or more of a vegetable wax, a vegetable oil, a fruit wax, a fruit oil, a vegetable-based liquid wax ester, and a fruit-based liquid wax ester; and in which the lip lubricant has... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20100291228 - Scavenger of in vivo harmful reactive oxygen species and/or free radicals: An object of the present invention is to provide a scavenger of in vivo harmful reactive oxygen species and/or free radicals, which is capable of effectively reducing the concentrations of in vivo reactive oxygen species and/or free radicals and exhibiting given effects such as the suppression of aging process, the... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100291229 - Fungicidal compositions and methods of enhancing plants such as turfgrass: The present disclosure provides fungicidal compositions and methods of enhancing vegetation, e.g. turfgrass. The composition may be a combination of chlorothalonil, a phosphonate and a phythalocyanine dye. Phthalocyanine green dye is preferred. This composition is mixed with water and inert ingredients such as surfactants and other inert ingredients. A phosphonate... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20100291231 - Compositions as wound sealant: e

20100291232 - Fungicidal composition comprising a pyridylethylbenzamide derivative and a compound capable of inhibiting the transport of electrons of the respiratory chain in phytopathogenic fungal organisms: A composition comprising at least a pyridylethylbenzamide derivative of general formula (I) (a) and a compound capable of inhibiting the transport of electrons of the respiratory chain in phytopathogenic fungal organisms (b) in an (a)/(b) weight ratio of from 0.01 to 20. A composition further comprising an additional fungicidal compound.... Agent: Ostrolenk Faber Gerb & Soffen

20100291230 - Novel pesticide compositions: Novel pesticide compositions and formulations, containing a phosphorous-containing compound and a nitrogen-releasing compound, are disclosed. These novel compositions exhibit a synergistic pesticidal activity and are particularly useful in treating pests such as nematodes (including root-not nematodes), fungi and bacteria. Methods utilizing these compositions for controlling pests, articles-of-manufacture containing same and... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100291233 - Treatment of neurological disorders: This invention relates to the use of selenate or a pharmaceutically acceptable salt thereof in methods and compositions of treating or preventing non-tauopathy neurological disorders. In some embodiments, the invention relates to the use of selenate or a pharmaceutically acceptable salt thereof in combination with other therapies for use in... Agent: Knobbe Martens Olson & Bear LLP

20100291234 - Compositions and methods for treating inflammatory arthritis: Methods for treating or preventing one or more symptoms of rheumatoid arthritis or other types of inflammatory arthritis involves administering a formulation containing an effective amount of arsenic trioxide to an affected patient. The arsenic trioxide formulation can be administered orally, for example, as a solution, suspension, syrup, emulsion, tablet,... Agent: Pabst Patent Group LLP

20100291235 - Composition for treating sterile inflammation: Biological medical means for treating sterile inflammatory diseases are disclosed. The invention relates to the use of L-arginine-hydrochloride (Arg) or lysine (Lys) and L-leucine (Leu) for the manufacture of a pharmaceutical composition for treating or preventing sterile inflammation. The composition further comprises trace elements chromium (Cr), tin (Sn), selenium (Se),... Agent: Ladas & Parry LLP

20100291236 - Osmium compounds: The present invention relates to osmium compounds of formula (I), their preparation and use in methods of treatment, particularly for cancer treatment.... Agent: Hoxie & Associates LLC

20100291237 - Boron-containing compositions: The present invention relates to boron-containing compositions. The invention relates to comminuted, heteroge-neousboron-containing compositions which are obtainable by a process which comprises heating to a temperature sufficiently high that calcination occurs but insufficient for the formation of a homogeneous melt a mixture comprising components capable, under the conditions of heating,... Agent: Clark & Elbing LLP

20100291238 - Appetite suppressant product and method: An appetite suppressant composition that is effective for the control of mammalian weight and methods of administration of the composition of the invention are provided. The composition is a cellulose product prepared with ethanol preferably with added sweetener, spice(s), salt and protein for oral administration to a patient.... Agent: Lynn E Barber

20100291239 - Mixture of citric flavonoids to improve ruminal fermentation: The invention refers to the use of a mixture of naringin, bitter orange extract and sepiolite to improve ruminal fermentation in ruminants.... Agent: Birch Stewart Kolasch & Birch

20100291240 - Method to stabilize a dietary supplement to facilitate joint health in humans: The present invention provides for compositions comprising glucosamine wherein the glucosamine has improved and/or enhanced stability. Additionally, the present invention provides for methods of stabilizing compositions for use in preparing an oral dosage form comprising glucosamine.... Agent: Wyeth LLC Patent Law Group

20100291242 - Antagonist against tolerance to anticancer drugs: An ABC transporter protein expression inhibitor comprising, as the active ingredient(s), 0.001 to 100 nM of one or more members selected from among steroid hormones, compounds having a female hormone function, analogous compounds thereof and antagonistic inhibitors therefor; an anticancer composition containing this ABC transporter protein expression inhibitor and an... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100291243 - Extractor having pottery with a dark brown glaze and the method for extracting using thereof: Disclosed are an extractor having a “pottery with dark brown glaze” called “Onggi” in Korean, and a method of extracting using the same. The extractor includes a body, a body cover, a heating part, a pottery and a gas valve. The pottery is located within the body. The extractor extracts... Agent: Nixon & Vanderhye, PC

20100291241 - Method of production of extract derived from swinglea glutinosa leaves: The invention of the present Application provides a standardized method to obtain an extract and the extract from leaves of Swinglea glutinosa, wherein the method yields an amount of extract that is about 60% the weight of the Swinglea glutinosa leaves.... Agent: John J. Martinez Md. Jd.

20100291244 - Methods for preparing a fermented ginseng concentrate or powder: The present invention relates to a method for preparing a fermented ginseng concentrate. The method first involves subjecting ginseng to an extraction with a solvent to obtain a ginseng extract. Next, pectinase and beta-galactosidase are added to the ginseng extract under conditions effective to ferment the ginseng extract. The fermented... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100291246 - Anti-infection p-compound™: The present invention is related to a botanical extract, called P Compound, comprises anti-infection activities. The botanical sources, extracting process, formulation, and applications are disclosed within this invention.... Agent: Limin Wen

20100291245 - Soft, chewable and orally dissolvable and/or disintegrable products: A soft, chewable and orally dissolvable and/or disintegrable product includes a biopolymer-sugar based matrix and botanical powder dispersed throughout the biopolymer-sugar based matrix. The biopolymer-sugar based matrix includes at least one biopolymer, at least one sugar and optional additives. Soft, chewable and orally dissolvable and/or disintegrable product can also include... Agent: Buchanan, Ingersoll & Rooney PC

20100291247 - Oil formulations and methods of use: The invention generally relates to various essential oil formulations for protecting plants from nematodes and other pathogens. The invention provides specific formulations which do not require the use of chemical additives. These formulations have low phytotoxicity and low volatility. Also, methods of applying the formulations for agricultural use are disclosed.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100291248 - Compositions for preventing and treating obesity, hyperlipidemia, atherosclerosis, fatty liver, diabetes or metabolic syndrome containing extracts of glycine max leaves or fractions isolated from the same as an active ingredient: The present invention relates to compositions for preventing and treating obesity, hyperlipidemia, atherosclerosis, fatty liver, diabetes or metabolic syndrome containing extracts of Glycine max leaves or fractions isolated from the same.... Agent: Greenlee Sullivan P.C.

20100291249 - Pomegranate-derived products for the treatment of skin sores and lesions: A method of treating skin sores is described, using medical compositions derived from pomegranate fruit. Methods for preparing such medical compositions are also described, including pomegranate seed oil extract, pomegranate inflorescence and peel extracts, and pomegranate peel powder.... Agent: Mdip LLC

20100291250 - Use of an active ingredient that is obtained from cyperus esculentus for its anti-aging cutaneous action: A method of treating cutaneous aging using of at least one active ingredient obtained from Cyperus esculentus in a cosmetic and/or dermopharmaceutical composition that is designed to combat cutaneous aging, preferably by working on the specific markers of the dermis. Cosmetic and/or dermopharmaceutical compositions that include an active ingredient that... Agent: Young & Thompson

20100291251 - Method for production of carotenoid: The present invention provides a composition comprising a high content of highly pure, low-cost, and safe carotenoid and a method for industrially producing the same. The present invention also provides functional food, a pharmaceutical composition and a cosmetic product comprising such a composition. The present invention further provides a method... Agent: Mcdermott Will & Emery LLP

20100284905 - Methods and agents for inhibiting tumor growth by targeting the ssdna replication intermediate of tumor stem cells: The application is based on the observation that tumor stem cell (TSC) replication involves a replicative intermediate configuration wherein a substantial fraction of the TSC genome is present as single-stranded DNA (ssDNA) when bell-shaped nuclei commence separation into two nuclei. During this replicative intermediate configuration large amounts of ssDNA are... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100284906 - Internalizing anti-cd74 antibodies and methods of use: The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which... Agent: Immunomedics, Inc.

20100284909 - Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins: The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of... Agent: Nixon Peabody LLP - Patent Group

20100284910 - Novel method of diagnosing, monitoring, staging, imaging and treating various cancers: The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating selected cancers including gynecologic cancers such as breast, ovarian, uterine and endometrial cancer and lung cancer.... Agent: Jane Massey Licata Or Kathleen A. Tyrrell Licata & Tyrrell P.C.

20100284911 - Preparations and methods for treating malignancies: Disclosed are therapeutic formulations comprising antibodies for the monomeric isoform of A-protein and a physiologically acceptable carrier. Methods for the treatment of subjects using these therapeutic formulations are also disclosed.... Agent: Rissman Hendricks & Oliverio, LLP

20100284908 - Proteins: The present invention provides new polypeptides. Said polypeptides are of use in the screening, diagnosis and prognosis of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T-cell leukaemia), melanoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer and renal cell cancer, in... Agent: Klauber & Jackson

20100284907 - Treatment of tumors by ablating bone marrow-derived endothelial progenitor cells: This invention provides methods of treating tumors and other conditions characterized by abnormal neoangiogenesis by inhibiting bone marrow-derived endothelial progenitor cells.... Agent: Wolf Greenfield & Sacks, P.C.

20100284912 - Homogenization of a radiopharmaceutical using sonification and/or rotor-stator technology to produce a homogenous suspension, emulsion, mixture or solid suspension of immiscible ingredients: A homogenous dispersion of aqueous droplets of a radiopharmaceutical or radiodiagnostic agent within a non-aqueous medium and method of making the same is provided. The homogenous dispersion is largely free of impurities and constitutes a substantially uniform distribution of sodium thiosulfate and radiopharmaceutical which is stable for a time sufficient... Agent: Kramer Levin Naftalis & Frankel LLP

20100284913 - Methods and compositions for studying, imaging, and treating pain: h

20100284914 - Novel amine-borane compounds and uses thereof: Novel families of amine-borane compounds, including fluorinated aminoboranes, novel bis-aminoboranes and aminoboranes having saturated and unsaturated ling alkyl chains are provided. Processes of preparing, pharmaceutical compositions and methods utilizing these novel compounds are also provided. Radiolabeled aminoboranes and uses thereof in radioimaging (e.g., PET) and radiotherapy are further provided.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100284916 - Antibodies against human cytomegalovirus (hcmv): The present invention provides novel antibody sequences that bind human cytomegalovirus (hCMV) and neutralize hCMV infection. The novel sequences can be used for the medical management of hCMV infections, in particular for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of hCMV infections.... Agent: Marshall, Gerstein & Borun LLP

20100284917 - Compounds and markers for surface-enhanced raman scattering: The present invention relates to compounds and markers for surface-enhanced Raman scattering (SERS), and methods for the preparation of the SERS markers. The present invention further relates to compositions, methods and uses, wherein the present SERS markers are employed.... Agent: Foley And Lardner LLP Suite 500

20100284915 - Genes associated with chemotherapy response and uses thereof: The invention provides molecular markers that are associated with responsiveness of a cancer patient to a chemotherapy treatment, and methods and computer systems for determining such responsiveness based on measurements of these molecular markers. The present invention also provides methods and compositions for enhancing the efficacy of chemotherapies in patients... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20100284919 - Injectable radio-opaque compositions for tissue augmentation: Injectable radio-opaque compositions for tissue augmentation and in particular hard tissue augmentation, and kits and methods of using thereof are described herein. The injectable compositions form porous, biologically degradable, fibrin matrices. The compositions are formed from fibrinogen, thrombin or another agent that causes the fibrinogen to crosslink, and strontium salts.... Agent: Pabst Patent Group LLP

20100284922 - Marker: The invention relates to the use of a cell death marker labelled with a wavelength-optimised label for identifying cell death in the eye. Suitable cell death markers are the Annexins and fragments and derivatives thereof. The invention also relates to a pharmaceutical composition comprising a cell death marker labelled with... Agent: Stites & Harbison, PLLC

20100284923 - Methods of diagnosing latent and active malignancies: Disclosed are procedures and methods for diagnosing latent and active cancers in a subject. The described methods include the use of sandwich ELISA assays containing antibodies specific for certain epitopes on the A-protein. This enables the assay to discriminate between the monomelic and homopolymeric forms of A-protein.... Agent: Rissman Hendricks & Oliverio, LLP

20100284924 - Nano-devices having impellers for capture and release of molecules: A nanodevice has a containment vessel defining a storage chamber therein and defining at least one port to provide transfer of molecules to or from the storage chamber, and a plurality of impellers attached to the containment vessel. The plurality of impellers are of a structure and are arranged to... Agent: Venable LLP

20100284918 - Protein: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer and pancreatic cancer, for monitoring the effectiveness of breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer and pancreatic cancer treatment, and for drug development.... Agent: Klauber & Jackson

20100284921 - Targeted nanoparticles for intracellular cancer therapy: This invention provides constructs comprising a targeting member immobilized on a detectable particulate, in which binding of the targeting member to a target structure on a surface of a cancer cell triggers internalization of the construct. Such constructs can be used to identify or monitor cancer cells in cell cultures... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100284920 - Uses of monoclonal antibody 8h9: This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20100284925 - Small molecule intervention for obesity: Methods and compositions for activating PLTP gene expression include administering an effective amount of a limonoid.... Agent: Macmillan Sobanski & Todd, LLC

20100284926 - Use of g-csf for the treatment of stroke: The invention relates to the use of G-CSF for the treatment of cerebral stroke, particularly cerebral stroke with a large baseline infarct volume. Administration of G-CSF at a total dose of 30 to 180 μg per kg body weight over a treatment period of about 3 days is suitable for... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100284927 - Use of mri contrast agents for evaluating the treatment of tumors: Described herein are methods for using macromolecular MRI contrast agents to evaluate the effectiveness of anti-cancer treatments. The methods take advantage of MRI for evaluating more specifically and accurately one or more tumor properties of the tumor in response to a particular treatment. Ultimately, the 5 methods described herein help... Agent: Gardner Groff Greenwald & Villanueva. PC

20100284928 - Methods for in vivo atherosclerotic plaque characterization using magnetic susceptibility to identify symptom-producing plaques: Methods and uses of in vivo atherosclerotic plaque characterization in a subject in need thereof, that include detecting a level of one or more iron complexes in plaque in the subject, and comparing detected level to a known value determined from subjects without an atherosclerotic condition are disclosed.... Agent: Macmillan Sobanski & Todd, LLC

20100284933 - Biomarkers of multiple sclerosis: Biomarkers of multiple sclerosis (MS) and of anti-TWEAK/TWEAK-Receptor therapy for MS are described.... Agent: Biogen Idec / Finnegan Henderson, LLP

20100284934 - Diagnostic agent: The invention provides an agent comprising an amino acid sequence for use in a method of diagnosis of a synucleinopathic disease.... Agent: Townsend And Townsend And Crew, LLP

20100284935 - Markers and diagnostic methods for metastasis: The present invention provides methods for the prediction, prognosis and/or diagnosis of metastasis. The present invention also provides proteins (or the related nucleic acid sequences) or protein expression profiles which are predictive and/or prognostic for metastasis. The invention thus relates to the use of said proteins and the corresponding amino... Agent: Craig J Arnold Amster Rothstein & Ebenstein

20100284936 - Contrast agents: The present invention relates to liposomes comprising particles with cores of tungsten or tungsten in mixture with other metallic elements as the contrast enhancing material and to the use of such pharmaceuticals, specifically as contrast agents in diagnostic imaging and in particular in X-ray imaging of liver tumours.... Agent: Ge Healthcare, Inc.

20100284932 - Fluorescent emulsions for optical imaging: The invention relates to a fluorescent emulsion, to a diagnostic reagent containing the same, and to the use thereof in the preparation of a diagnostic reagent for in vivo fluorescence imaging.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100284930 - Fluorescent imaging of skin cancers using phospholipid ether compounds: The invention generally relates to novel fluorescent phospholipid compounds, compositions comprising these compounds, and their use in a variety of diagnostic applications, including fluorescence imaging of tumors. A preferred compound of the present invention has the following structural formula:... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100284929 - Fluorescent imaging of tumors using phospholipid ether compounds: The invention generally relates to the use of novel fluorescent phospholipid ether compounds and compositions comprising these compounds in fluorescence imaging of tumors. A preferred compound of the present invention has the following structural formula:... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100284931 - Fluorescent phospholipid ether compounds, compositions, and methods of use: The invention generally relates to novel fluorescent phospholipid compounds, compositions comprising these compounds, and their use in a variety of diagnostic applications, including fluorescence imaging of tumors. A preferred compound of the present invention has the following structural formula:... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100284939 - Hair care compositions and methods of treating hair using same: The present invention provides kits and methods for treating hair on the scalp comprising non-toxic compositions providing beneficial effects on hair without employing high temperatures, free radical initiators or rinsing hair after applying the compositions.... Agent: Fitzpatrick Cella Harper & Scinto

20100284938 - Penetrating pharmaceutical foam: The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic... Agent: Wilmerhale/boston

20100284937 - Vaginal lubricant comprising hyaluronic acid: A vaginal lubricant comprising high molecular weight hyaluronic acid combined with low molecular weight hyaluronic acid and/or chitosan which has improved stability and which has applications in, for example, maintaining and/or promoting sperm motility.... Agent: Winstead PC

20100284940 - Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile: Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (Cmax) and slightly delaying the peak such as... Agent: Morrison & Foerster LLP

20100284943 - Active formulations based on plant extracts; phytocosmetic and/or phytotherapeutic formulations comprising the same method for: The present invention provide formulations with antibacterial and biofilm removing actions comprising plant extracts, comprising at least one plant oil wherein the plant is selected from the group comprising the genus Protium, Guatteria, Cyperus in a suitable vehicle.... Agent: Smith, Gambrell & Russell

20100284942 - Compositions: There are provided personal care products and compositions that comprise at least one diol compound selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol, 2-methyl-1,3-propandiol, and 3-(2-ethyl-hexyloxy)-1,2-propandiol in a total concentration of 0.1% to 0.5% (w/w); and at least one preservative enhancer compound selected from the group consisting of benzaldehyde,... Agent: Parfomak, Andrew N. Norris Mclaughlin & Marcus Pa

20100284941 - Hair treatment composition comprising a pressure sensitive adhesive: A hair treatment composition comprising an acrylic pressure sensitive adhesive.... Agent: Unilever Patent Group

20100284946 - Compressed chewing gum comprising sterol: A compressed chewing gum tablet including at least one chewing gum module, the chewing gum module including a chewing gum composition including chewing gum particles containing gum base, wherein the chewing gum tablet includes at least one sterol compound, and wherein at least a part of the at least one... Agent: St. Onge Steward Johnston & Reens, LLC

20100284945 - Formulations for the treatment of mucositis induced by antitumor or immunosuppressive therapy: Formulations containing sanguinarine or chelerythrine or the salts thereof or extracts containing them in admixture with suitable carriers and/or excipients for the treatment and/or prevention of mucositis.... Agent: Lucas & Mercanti, LLP

20100284944 - Off-note blocking sensory organic compounds: Disclosed are Compounds that block off-notes in consumables and methods of blocking off-notes in consumables including off-notes provided by artificial sweeteners including aspartame, Saccharin, acesulfame K (Acesulfame potassium), sucralose and cyclamate; and including stevioside, swingle extract, glyccerhizin, perillartine, naringin dihydrochalcone, neohesperidine dihydrochalcone, mogroside V, rubusoside, rubus extract, and rebaudioside A.... Agent: Curatolo Sidoti Co., Lpa

20100284947 - Food product to prevent tooth decay: An anti cavity bioconsumable liquid which may be provided in the liquid form or frozen form is disclosed herein. The liquid may include up to about 5 wt. % xylitol for the purposes of mitigating tooth decay when the bioconsumable liquid is ingested or consumed by a person. Moreover, the... Agent: Stetina Brunda Garred & Brucker

20100284948 - O/w-emulsifiers, o/w-emulsions and methods of manufacture thereof: in each case with respect to the total mass of the emulsifier. Further described are corresponding O/W-emulsions, comprising an aqueous phase, an oil phase dispersed in the aqueous phase and between 0.25 and 15% by weight of the abovementioned O/W-emulsifier. Finally, also described are methods for manufacturing such an O/W-emulsion.... Agent: Connolly Bove Lodge & Hutz LLP

20100284949 - Water-containing composition which can be used as external composition:

20100284950 - Water based concentrated product forms of oil-soluble organic uv absorbers: The instant invention refers to the use of a concentrated aqueous polymer dispersion with an average particle size of less than 1000 nm comprising (a) a polymer carrier prepared by heterophase radical polymerization of at least one ethylenically unsaturated monomer in the presence of (b) an oil-soluble organic UV absorber... Agent: Basf Corporation Patent Department

20100284951 - Novel compositions for the treatment of wounds and skin care: The present invention provides novel compositions which comprise sodium hypochlorite, sodium, chloride, both organic and inorganic trace minerals in hypertonic condition presented in the forms of a clear aqueous solution (low or high concentrations for further reconstitution with purified water to obtain the final ready-to-use solution), gel or salve, lotion,... Agent: Thavisith Pongprapansiri

20100284953 - Hair care compositions and methods of treating hair using same: The present invention provides kits and methods for treating hair on the scalp comprising non-toxic compositions providing beneficial effects on hair without employing high temperatures, free radical initiators or rinsing hair after applying the compositions.... Agent: Fitzpatrick Cella Harper & Scinto

20100284952 - Hair treatment compositions: The invention provides a hair treatment composition comprising a combination of a sugar, an aliphatic amino acid and a basic amino acid. The composition is particularly suitable for the treatment of hair which is dry, damaged and/or prone to manageability problems.... Agent: Unilever Patent Group

20100284956 - Hair cosmetic composition: (In the formula, R5 represents an alkyl group having 8 to 30 carbon atoms, -A- represents an amide group or an ether group, m represents 0 or 1; when -A- is an amide group R6 represents an alkylene group or hydroxyalkylene group having 2 to 4 carbon atoms and when... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100284954 - Process for relaxing keratin fibres: The invention relates to a process for relaxing keratin fibres by applying to the keratin fibres a relaxing composition containing at least one denaturing agent with a molecular mass of greater than 18.1 g/mol, present in a molar concentration of between 1M and 8M, and raising the temperature of the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100284955 - Cationic polymers and fixative applications therefor: This invention relates to cationic Cassia polymers and to their use in hair fixative applications. The cationic Cassia polymers demonstrate superior stiffness profiles and a high level of curl retention when subjected to high humidity conditions for extended periods of time.... Agent: The Lubrizol Corporation

20100284957 - Powder treated with (meth)acrylic-grafted silicone polymer and product using the same: A powder treated with a (meth)acrylic-grafted silicone polymer, the treated powder being obtained from a mixture containing a volatile silicone oil, a (meth)acrylic-grafted silicone polymer in which a monomer component comprising a (meth)acrylic series monomer has been grafted onto the main chain of a polysiloxane, and a powder.... Agent: 3m Innovative Properties Company

20100284958 - Bont/a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy: The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.... Agent: Allergan, Inc.

20100284959 - Sequence specific double-stranded dna/rna binding compounds and uses thereof: The present invention provides specific double-stranded DNA/RNA binding compounds having a polymeric structure, which are in fact, triplex forming molecules capable of binding tightly and specifically to predetermined sequences in the major groove of double stranded nucleic acid molecules; as well as pharmaceutical compositions comprising thereof. The triplex forming molecules... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100284960 - Dosage forms and co-administration of opioid agonist and opioid antagonist: The present invention provides compositions comprising an opioid agonist and a water-soluble, non-peptidic polymer-opioid antagonist conjugate. Among other things, dosage forms and methods of administering the dosage forms are also provided.... Agent: Jones Day

20100284961 - Mcp-1 binding nucleic acids: The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group comprising type 1A nucleic acids, type 1B nucleic acids, type 2 nucleic acids, type 3 nucleic acids, type 4 nucleic acids and nucleic acids having a nucleic acid sequence according to any of... Agent: Mdip LLC

20100284962 - Modified tumor necrosis factor-beta: Compositions including modified TNF-beta polypeptides and methods of using the compositions are disclosed herein.... Agent: Fish & Richardson P.C.

20100284964 - Cancer therapy: The subject invention provides for cancer therapy.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100284965 - Compositions and methods for adoptive and active immunotherapy: Modular aAPCs and methods of their manufacture and use are provided. The modular aAPCs are constructed from polymeric microparticles. The aAPCs include encapsulated cytokines and coupling agents which modularly couple functional elements including T cell receptor activators, co-stimulatory molecules and adhesion molecules to the particle. The ability of these aAPCs... Agent: Pabst Patent Group LLP

20100284963 - Growth regulatable recombinant bcg immunogenic compositions: Immunogenic compositions comprising growth regulatable recombinant intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, but are not limited to, growth regulatable and growth limited recombinant intracellular pathogen immunogenic compositions.... Agent: K&l Gates LLP

20100284966 - Methods and compositions for managing resistance of hepatitis c virus to immunosuppressant: Method for determining susceptibility of a hepatitis C virus (HCV) in a patient, especially one who received a liver transplant, to cyclosporine A (CsA), comprising determining the nucleic acid sequence of HCV, and comparing the viral nucleic acid sequence to that of a wild-type, CsA susceptible strain, wherein the existence... Agent: Kening Li Pinsent Masons LLP

20100284967 - Modified phage for displaying post-translationally modified proteins and uses thereof: Disclosed herein are modified phage comprising a fusion protein located on the surface of the phage wherein the fusion protein comprises a surface protein and a post-translationally modified protein. Also disclosed are methods of making and using modified phage comprising post-translationally modified proteins located on the surface of the phage.... Agent: Mckeon Meunier Carlin & Curfman LLC

20100284968 - Use of ps20/wfdc1 and interferons to diagnose, monitor and treat viral diseases: Methods for detecting, diagnosing or monitoring viral diseases in a subject are described comprising measuring ps20 polypeptides or ps20 polynucleotides and interferons and interferon polynucleotides in a sample from the subject. The invention also contemplates therapeutic applications for viral diseases employing modulators of ps20 polypeptides and ps20 polynucleotides in combination... Agent: Dann, Dorfman, Herrell & Skillman

20100284969 - Methods and compositions for delivery of medicaments to the lungs: The disclosure provides a drug composition formulated for inhalation comprising a conjugate of a surface active agent and a pulmonary active drug. The surface active agent has an affinity for the human alveolar/gas interface and comprises at least a portion of a mammalian lung surfactant of a mimic thereof. The... Agent: Goodwin Procter LLP Patent Administrator

20100284970 - Benzimidazole modulators of h1 receptor and/or ns4b protein: The present invention relates to new benzimidazole modulators of H1 receptor activity and/or inhibitors of NS4B protein activity, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group, LLC

20100284971 - Modified factor viii and factor ix genes and vectors for gene therapy: The present invention relates to a modified and optimized Factor VIII or Factor IX nucleic acid for inclusion in a chimeric virus vector. Use of such vector can be used for treatment of hemophilia.... Agent: Moore & Van Allen PLLC

20100284978 - Cultures, products and methods using umbilical cord matrix cells: Stem cells from human sources can have a variety of useful applications in disease treatment and biotechnology. More particularly the umbilical cord matrix cell cultures of the invention have a variety of totipotent, pluripotent, or multipotent cells for a variety of end uses from a non-controversial, universally available, species-specific source.... Agent: Casimir Jones, S.c.

20100284972 - Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans: Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject... Agent: Ratner Prestia

20100284973 - Use of a l. casei strain for the preparation of a composition for inhibiting mast cell activation: The present invention pertains to the field of prevention and treatment of chronic or acute diseases involving mast cells, such as allergy and some autoimmune diseases. More precisely, the present invention concerns the use of probiotics containing a L. casei strain and/or a B. breve strain for inhibiting mast cell... Agent: Morgan Lewis & Bockius LLP

20100284979 - Modulation of tissue fatty acid composition of a host by human gut bacteria: The current invention provides use of a CLA-producing bacterium for the in vivo conversion in the gut of polyunsaturated fatty acids to CLA. The CLA-producing bacterium is selected from one or more of the group consisting of propionibacteria, lactobacilli, lactococci and streptococci, and bifidobacteria.... Agent: Foley & Lardner LLP

20100284980 - Nutritional composition to promote healthy development and growth: A nutritional formula which includes a lipid or fat; a protein source; about 5 to about 100 mg/100 kcal of a source of long chain polyunsaturated fatty acids which comprises docosahexanoic acid; about 0.1 to about 1 mg/100 kcal of a prebiotic composition, wherein the prebiotic composition comprises at least... Agent: Waddey & Patterson, P.C.

20100284981 - Microorganisms and methods for treating poultry: An isolated Bacillus strain LSSAO1 is provided. When fed to a bird, this and other Bacillus strains described herein provide benefits to the birds. For example, administration of the one or more Bacillus strain can increase low G+C, gram positive bacteria in the gastrointestinal flora of the bird. These type... Agent: Whyte Hirschboeck Dudek S.c. Intellectual Property Department

20100284975 - Polypeptides comprising fas activation and nkg2d-ligand domains: The present invention is drawn to fusion proteins comprising (a) a ligand for an NK receptor and (b) a Fas activation domain, and to nucleic acids encoding such fusion proteins. The invention also includes methods of making and using such proteins and nucleic acids, including their use in preventing or... Agent: Foley And Lardner LLP Suite 500

20100284974 - Viral capsid proteins and any peptides or compositions thereof for the treatment of pathologic disorders: The present invention relates to viral capsid proteins, as a medicament for the treatment of a pathologic disorder. More particularly, the invention relates to the viral capsid proteins VP1, VP2 and VP3, preferably, the SV40 VP1 or any peptide, fragment, mutant, derivative and mixtures thereof or of virus-like particles (VLP's)... Agent: Fleit Gibbons Gutman Bongini & Bianco Pl

20100284976 - Compositions for the preparation of mature dendritic cells: The invention relates to a method for in vitro maturation of at least one immature dendritic cell, comprising stimulating said immature dendritic cell with TNFα, IL-1β, IFNγ, a TLR7/8 agonist and prostaglandin E2 (PG). Furthermore, the invention relates to a composition comprising said factors as well as to mature dendritic... Agent: Fulbright & Jaworski L.L.P.

20100284977 - Expression of anti-nociceptive compounds from endogenously regulated promoters: Expression of anti-nociceptive compounds under the control of endogenously regulated promoters is disclosed. Methods and materials can be used to modify nociception, the process activated by detection of noxious stimuli. The activity of endogenous promoters employed is up-regulated following nociception in animal models of pain. Thus, expression of anti-nociceptive compounds,... Agent: Dority & Manning, P.A.

20100284982 - Erythrocyte-encapsulated l-asparaginase for enhanced acute lymphoblastic leukemia therapy: Compositions for transporting L-asparaginase across the cellular membrane of erythrocytes, comprising a low molecular weight protamine peptide. Process of preparation of compositions comprising conjugates of L-asparaginase and a low molecular weight protamine peptide. Method of treatment comprising administration of adapted L-asparaginase is also described.... Agent: Jones Day

20100284984 - Adenosine and its mimetics. modulators, transport inhibitors, and receptor agonists as a therapeutic tool to replace or improve the efficacy of deep brain stimulation: The present invention relates to a method of enhancing brain stimulation of a subject. This method involves selecting a subject in need of brain stimulation and electrically stimulating the brain of the subject. Adenosine, an adenosine mimetic, an adenosine modulator, an adenosine transport inhibitor, or an adenosine receptor agonist are... Agent: Nixon Peabody LLP - Patent Group

20100284983 - Coenzyme q10-containing water-soluble composition and process for production thereof: A coenzyme Q10-containing water soluble composition comprises coenzyme Q10, a hydrophilic polyglycerol fatty acid ester, a lipophilic sucrose fatty acid ester and an aqueous phase component and a process for producing the same are disclosed. A coenzyme Q10-containing water-soluble dry powder can be obtained by drying the above-mentioned coenzyme Q10-containing... Agent: Sughrue Mion, PLLC

20100284985 - Composition: The present invention provides a composition comprising (a) an antimicrobial compound of the formula (I) wherein R1 is a fatty acid chain; R2 is a linear or branched alkyl residue having from 1 to 12 carbon atoms; n is an integer from 0 to 10; X− is selected from Br−,... Agent: Steptoe & Johnson LLP

20100284986 - Compositions and methods for prevention and treatment of migraines: A therapeutic composition for preventing migraines is described. The therapeutic composition may include riboflavin, magnesium, feverfew and coenzyme Q10.... Agent: Patton Boggs LLP

20100284989 - 15-pgdh in colon cancer: The disclosure provides, among other things, a method of decreasing resistance to the chemopreventive properties of non-steroidal anti-inflammatory agents, e.g., celecoxib, particularly in the prevention of cancer, e.g., colon cancer, by increasing the levels or activity of 15-hydroxyprostaglandin dehydrogenase (15-PGDH). The disclosure also provides a method of identifying compounds that... Agent: Ropes & Gray LLP

20100284987 - Tablettable formulations of lipophilic health ingredients: The present invention is directed to a formulation of a lipophilic health ingredient comprising a lipophilic health ingredient, a protective colloid comprising a modified starch and an emulsifier. The present invention is further directed to a formulation of (a) lipophilic health ingredient(s) comprising (a) lipophilic health ingredient(s) and a protective... Agent: Nixon & Vanderhye, PC

20100284988 - Utilization of shield effect for dopamine detection and reagent development: The present invention relates to fusion proteins of monoamine oxidase B (MAO B)-green fluorescent protein (GFP) and utilizes “shield effect” to detect the dopamine under physiological condition, providing the reagent and method for dopamine detection.... Agent: Wpat, PC Intellectual Property Attorneys

20100284990 - Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity: The present invention is directed to compositions, methods and kits for regulation of gene therapies for Huntington's Disease, including, without limitation, reversible gene therapies and allele-specific therapies.... Agent: Kenneth J. Collier - C/o Kathy Illg Medtronic, Inc.

20100284991 - Methods for the treatment and diagnosis of bone mineral density related diseases: The present invention relates to methods of the treatment and diagnosis of bone mineral density related disorders. More particularly, the present invention relates to a method of diagnosing or predicting a bone mineral density related disease, or a risk of a bone mineral density related disease, in a subject, which... Agent: Mcandrews Held & Malloy, Ltd

20100284993 - Enhancing the efficacy of anti-infective therapeutics: In an embodiment of the invention, a method of enhancing the efficacy of an anti-infective therapeutic agent against an obligate or facultative intracellular parasite in a host is provided. The method comprises administering to the host an effective amount of a bifunctional compound of less than about 5000 Daltons comprising... Agent: Bozicevic, Field & Francis LLP

20100284992 - Phospholipase c and method of use: The present invention provides a method for reducing angiogenesis using a phospholipase C.... Agent: Don D. Cha

20100284994 - Use of edta and its derivatives for prevention and treatment of bacterial intestinal diseases of pigs and for increasing the effects of antibiotics exerted in such diseases: The invention relates to the use of ethylenediamine tetraacetic acid (EDTA) and its derivatives, i.e. its salts and complexes for prevention and treatment of bacterial intestinal diseases of pigs and for increasing the effects of antibiotics exerted in such diseases. The invention also relates to compositions for animal husbandry, i.e.... Agent: Speckman Law Group PLLC

20100284995 - Temperature sensitive mutants of matrix metalloproteases and uses thereof: Provided are modified matrix metalloprotease (MMP) enzymes that exhibit temperature-dependent activity and uses thereof. The MMPs can be used, for example, to treat ECM-mediated diseases or disorders characterized by increased deposition or accumulation of one or more ECM components.... Agent: K&l Gates LLP

20100284996 - Assays for detection of von willebrand factor (vwf) multimers and for degradation of vwf by agents such as adamts13 and related methods: Methods of analyzing the electrophoretic mobility distribution of von Willebrand factor (vWF) multimers include providing a sample medium comprising a plurality vWF multimers. The vWF multimers are electrophoretically separated by electrohoretic mobility in the sample medium by subjecting said sample medium to an electric field to provide separated vWF multimers.... Agent: Myers Bigel Sibley & Sajovec

20100284997 - Dosing regimen of activated protein c and variants having reduced anticoagulant activity: Recombinant activated protein C (APC) and APC variants with reduced anticoagulant activity were used to reduce mortality in murine models of sepsis. These models included endotoxemia and bacteremia models. We discovered that single or multiple bolus doses of APC, especially of APC variants such as RR230/231AA-APC, KKK192-194AAA-APC and 5A-APC (containing... Agent: Loeb & Loeb LLP

20100284998 - Fibrin sealant: A fibrin sealant, comprises (a) thrombin, (b) fibrinogen, (c) polyP, and (d) calcium. The thrombin and the fibrinogen are separated prior to application.... Agent: Evan Law Group LLC

20100284999 - Characterization of the cbir1 antigenic response for diagnosis and treatment of crohn's disease: This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and... Agent: Davis Wright Tremaine LLP/los Angeles

20100285001 - Method and compositions related to synergistic responses to oncogenic mutations: Disclosed are compositions and methods related to new targets for cancer treatment.... Agent: Ballard Spahr LLP

20100285003 - Therapeutic peptides and uses thereof: The present invention is directed to a family of therapeutic peptides capable of modulating cytokine expression and/or stimulating the immune system of subject without producing or sustaining serious side-effects. Methods using the peptides to modulate cytokine expression in a subject, treat a disease, enhance vaccination, and stimulate a subject's immune... Agent: Fennemore Craig

20100285002 - Treatment or prevention of inflammation by targeting cyclin d1: In one aspect, the invention relates to the treatment and/or prevention of inflammation by inhibition of cyclin D1. In one embodiment, Th1-mediated inflammation is selectively inhibited or reduced by a method comprising administering an agent that inhibits cyclin D1. In another embodiment, an autoimmune disease or a disorder characterized by... Agent: David S. Resnick

20100285000 - Use of vegfr-2 inhibitors for treating metastatic cancer: The present application provides compositions and methods for treating metastatic cancer. Patients having or at risk of developing metastases may be treated. Compositions useful for the invention include VEGFR-2 specific inhibitors.... Agent: Ropes & Gray LLP

20100285004 - Anti-cd38 human antibodies and uses thereof: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the... Agent: Foley And Lardner LLP Suite 500

20100285005 - Anti-cxcr4 antibodies: The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.... Agent: Eli Lilly & Company

20100285008 - Benzoquinone derivative e3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis: Disclosed are novel methods for the therapeutic treatment of cancer and angiogenesis. The enzyme Ape1/Ref-1, via its redox function, enhances the DNA binding activity of transcription factors that are associated with the progression of cancer. The present invention describes the use of agents to selectively inhibit the redox function of... Agent: Barnes & Thornburg LLP

20100285006 - Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases: The present invention relates to novel thiazole-substituted indolin-2-ones as inhibitors of CSCPK and related kinases; to methods of inhibiting cancer stem cells by using a kinase inhibitor; to pharmaceutical compositions containing such compounds; and to methods of using such compounds in the treatment of a protein kinase related disorder in... Agent: Milstein Zhang & Wu LLC

20100285007 - Differential diagnosis of b-cell chronic lymphocytic leukemia: Provided are methods of diagnosing in a subject a type of B-cell chronic lymphocytic leukemia (B-CLL). Also provided are antibodies, including monoclonal antibodies, that specifically bind FCRL2, FCRL3 or FCRL5 and methods of treating B-CLL using the antibodies.... Agent: Fish & Richardson P.C.

20100285011 - High concentration antibody-containing liquid formulation: The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100285009 - Humanized anti-egfl7 antibodies and methods using same: The present invention concerns antibodies to EGFL7 and the uses of same.... Agent: Genentech, Inc.

20100285012 - Methods and compositions for the treatment of cancers and pathogenic infections: The subject application provides small compounds that are able to suppress autophagy in various cells. These compounds are useful in augmenting the existing treatments of various cancers and microbial/parasitic infections. Thus, the subject application also provides methods of treating various types of cancers and microbial/parasitic infections. Also provided by the... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100285013 - Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof: The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-PD-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.... Agent: Jones Day

20100285010 - Tumor therapy with an anti-vegf antibody: The present invention provides a method of treating a patient suffering from relapsed HER2 positive cancer with an anti-VEGF antibody during or after treatment with an anti-HER2 antibody. The invention also provides a kit comprising an anti-VEGF antibody.... Agent: Genentech, Inc.

20100285014 - Immunoglobulin fusion proteins: The present invention relates to novel methods for making fusion proteins comprising a cytokine or growth factor fused to an immunoglobulin domain. The growth factor/cytokine can be fused directly to an immunoglobulin domain or through a peptide linker. The purified growth factor/cytokine-IgG fusion proteins produced by the novel methods are... Agent: Sheridan Ross PC

20100285015 - Targeting recombinant therapeutics to circulating red blood cells: Fusion proteins comprising a single chain antigen-binding domain (scFv) of a monoclonal antibody, linked to an anti-thrombotic agent, anti-inflammatory agent, or a pro-drug thereof are provided, where the polypeptide binds to a binding site (antigen) expressed on the surface of a red blood cell at a density greater than 5,000... Agent: Howson & Howson LLP

20100285017 - Matriptase protein and uses thereof: The present invention provides methods and compositions for treatment, screening, diagnosis, prognosis and therapy of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer, for monitoring the effectiveness of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer treatment, and for drug... Agent: Klauber & Jackson

20100285016 - Pro34128 nucleic acids: The present invention is directed to novel polypeptides having sequence similarity to GDNFR and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies... Agent: Arnold & Porter LLP (24126) Attn: Sv Docketing Dept.

20100285018 - Estrogen receptors and methods of use: The present invention provides isolated polypeptides having an amino acid sequence having at least 70% identity to SEQ ID NO:20, wherein the polypeptide has ER-α36 activity. The invention further provides methods for identifying agents that bind to such polypeptides, methods for detecting such polypeptides, and methods for altering the activity... Agent: Mueting, Raasch & Gebhardt, P.A.

20100285019 - Anti-il-17f antibodies and methods of use thereof: This invention provides fully human monoclonal antibodies that recognize IL-17F and/or the heterodimeric IL-17A/IL-17F complex, but do not recognize IL-17A. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.... Agent: Mintz Levin Cohn Ferris Glovsky And Popeo, P.C.

20100285020 - Leukemic cell cns infiltration controlled by notch-induced chemotaxis: The present invention is directed to methods of preventing central nervous system leukemia, treating T-cell acute lymphoblastic leukemia, and treating immune system disorders associated with CCR7-CCL19 mediated signaling. Suitable therapeutic agents for inhibiting CCR7-CCL19 signaling and methods of identifying additional therapeutic agents useful in the methods of the present invention... Agent: Nixon Peabody LLP - Patent Group

20100285021 - Ligands for use in therapeutic compositions for the treatment of hemostasis disorders: The invention, in general, features a method of treatment and/or prevention of a thrombotic pathological condition, in a mammal, which includes administering to the mammal in need of such treatment a therapeutically effective amount of a composition including an antibody directed against the C1 domain of Factor VIII, which is... Agent: Nixon & Vanderhye, PC

20100285022 - Anti-rsv g protein antibodies: Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections.... Agent: Morrison & Foerster LLP

20100285027 - Antibodies specific for human hepcidin: The present invention relates to antigen-binding proteins having specificity for hepcidin, and their use for treating and diagnosing diseases associated with hepcidin.... Agent: Mcandrews Held & Malloy, Ltd

20100285025 - Antibodies specific for the c-terminal regulatory domain of egfr and their use: Disclosed herein are antigen-binding molecules, such as antibodies, that specifically recognize a portion of the EGFR C-terminal (intracellular) regulatory domain that interacts with one or more regulatory molecules (such as Suppressor of Cytokine Signaling (“SOCS”) proteins). In certain normal or neoplastic cells and/or tissues, this region is inaccessible to the... Agent: Klarquist Sparkman, LLP

20100285023 - Detecting cyp24 expression level as a marker for predisposition to cancer: This invention pertains to the discovery that an amplification of the CYP24 gene or an increase in CYP24 activity is a marker for the presence of, progression of, or predisposition to, a cancer (e.g., breast cancer). Using this information, this invention provides methods of detecting a predisposition to cancer in... Agent: Weaver Austin Villeneuve & Sampson LLP

20100285028 - Methods of treating coagulopathy: The invention provides compositions and methods for enhancing clearance of coagulation factors {e.g., VWF) and platelets from the blood stream of a patient in need thereof. The methods comprise administering to the patient a therapeutically effective amount of an agent that increases clearance of coagulation factors or platelets. Such an... Agent: Townsend And Townsend And Crew, LLP

20100285026 - Phosphorylation of histone h3 at threonine 11 - a novel epigenetic mark for transcriptional regulation: The present invention relates to a process for controlling at least one androgen receptor- (AR-) regulated mechanism in mammalian cells under histone-phosphorylating conditions, said process comprising allowing at least one inhibitor with specificity for at least one protein kinase C-related kinase (PRK) to act on said at least one PRK1... Agent: Greenblum & Bernstein, P.L.C

20100285024 - Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases: The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include vaccine compositions having an FTR polypeptide or an antigenic fragment of the polypeptide; a vector including a nucleotide sequence that is substantially complimentary... Agent: Mcdermott, Will & Emery

20100285036 - Anti-cd100 neutralizing antibodies and methods of using the same: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100285030 - Antibodies to ox-2/cd200 and uses thereof: This application provides methods and compositions for modulating and/or depleting CD200 positive cells.... Agent: Ropes & Gray LLP

20100285033 - Compositions and methods for camkii inhibitors and uses thereof: Embodiments herein generally relate to methods, compositions and uses of CaMKII inhibitors. Other embodiments relate to methods, compositions and uses of agents that target CaMKII. Yet further embodiments relate to compositions, methods and uses of CaMKIIN-derived molecules and other CaMKII inhibitor molecules that inhibit autonomous CaMKII activity. In accordance with... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20100285032 - Estrogen receptor-related receptor gamma (err gamma) in bone and cartilage formation and methods and compositions relating to same: ERRγ is expressed in bone and cartilage in vivo and osteoblastic and chondrocytic cells in vitro. ERRγ is a transcriptional activator of an osteoblast-associated osteopontin (OPN) and chondrocyte-associated (Sox9) gene in osteoblasts and chondrocytes respectively. Knockdown of ERRγ expression by antisense oligonucleotide strategies in osteoblastic cell cultures reduces alkaline phosphatase... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100285035 - High affinity antibody antagonists of interleukin-13 receptor alpha 1: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody... Agent: Licata & Tyrrell P.C.

20100285031 - Hox compositions and methods: The present invention relates to compositions to treat HOXB7 related disorders. The invention also relates to methods treating HOXB7 related disorders. The invention further relates to kits for treating HOXB7 related disorders in a subject. The invention further relates to methods of identifying novel treatments for treating HOXB7 related disorders... Agent: Edwards Angell Palmer & Dodge LLP

20100285034 - Method: Described are methods of separating viable cells, apoptotic cells and dead cells and antibodies or use in such methods. The antibodies may also be used in treatment of inflammatory disease, cancer and in wound healing.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100285029 - Treatment of fungal infections with polyene or beta glucan synthase inhibitor anti-fungals combined with anti-hsp90 antibodies: The present invention relates to novel compositions and preparations that are effective antifungal agents, and a novel antibody which can be incorporated into the compositions and preparations.... Agent: Jones Day

20100285037 - Antibodies to cll-1: Anti-CLL-1 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind CLL-1 and treat diseases, such as hematologic malignancies, which are characterized by expression of CLL-1.... Agent: Fulbright & Jaworski L.L.P.

20100285039 - B7-h1 (cd274) antagonists induce apoptosis of tumor cells: Compositions and methods for restoring killing of cancer cells are provided. Preferably, the compositions are administered to a subject in an effective amount to antagonize, inhibit, reduce, or block B7-H1 mediated signal transduction in cancer cells expressing B7-H1. It has been discovered that B7-H1 transmits an anti-apoptotic signal in cancer... Agent: Johns Hopkins Technology Transfer

20100285038 - Factor involved in metastasis and uses thereof: The present invention is related to a nucleic acid coding for a factor involved in a biological process, whereby the process is a PI 3-kinase pathway regulated process, preferably a process selected from the group comprising glucose metabolism, amino acid and glucose deprivation processes, diabetes, wound healing, stress response, apoptosis,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100285041 - Class a oligonucleotides with immunostimulatory potency: The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.... Agent: Wolf Greenfield & Sacks, P.C.

20100285044 - Method and compositions for treatment of cancers: A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore... Agent: Clark & Elbing LLP

20100285042 - Methods of enhancing adjuvaticity of vaccine compositions: The immunogenicity of vaccines is enhanced by co-administering a synthetic glycolipid, designated PBS-57, with the vaccine. PBS-57 has the ability to stimulate both a cell-mediated and humoral immune response. Co-administration of PBS-57 with a vaccine may be used in methods to stimulate one or more of a humoral immune response,... Agent: Merchant & Gould PC

20100285040 - Methods of enhancing immune response using electroporation-assisted vaccination and boosting: Disclosed are methods of enhancing immune responses. Such methods involve the administration of vaccine compositions to different tissues to elicit an enhanced immune response. The enhanced response arises from the vaccination and boosting route of administration in two separate patient tissues, for example, by first administering a priming vaccination into... Agent: Vgx Pharmaceuticals, LLC

20100285043 - Mite antigenic rice: To achieve the above objective, the present inventors have tried to generate seeds (rice) of rice plants that have accumulated mite antigen peptide variants. As a result, the present inventors developed genetically modified rice plants which express and accumulate these mite antigen peptide variants, and demonstrated their effect on asthma,... Agent: Fenwick & West LLP

20100285046 - Nontoxic ricin mutant compositions and methods: Disclosed are nontoxic ricin mutants and uses in connection with vaccines and cancer therapy.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100285045 - Novel neurotrophic factor protein and uses thereof: The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is... Agent: Birch Stewart Kolasch & Birch

20100285047 - Therapeutics and diagnostics for group a streptococci: Immunogenic compositions and vaccines are described comprising GAS Markers. Methods for detecting GAS diseases in a subject are also described comprising measuring GAS markers in a sample from the subject. The invention further provides kits for carrying out the methods of the invention and therapeutic applications for GAS diseases employing... Agent: Howson & Howson LLP

20100285048 - Use of flagellin in the immunotherapy of yersinia pestis: The invention provides a fusion protein comprising a flagellin adjuvant and a Yersinia pestis antigen. Also provided are compositions comprising a flagellin adjuvant and a Yersinia pestis antigen. The invention also discloses methods of making a fusion protein comprising a flagellin adjuvant and a Yersinia pestis antigen. The invention further... Agent: Myers Bigel Sibley & Sajovec

20100285049 - Ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in the method: The invention relates to an ex vivo animal or challenge model as a method to identify protective (recombinant) proteins and rapidly measure protective immunity in intestinal segments directed against parasites and vaccines directed against parasitic infections. The invention further relates to vaccines directed against infection with parasites, such as Fasciola... Agent: Traskbritt, P.C.

20100285050 - Compositions and methods: The invention relates to a composition suitable for inducing a T cell mediated immune response against an influenza virus in a vertebrate, said composition comprising nucleic acid encoding one or more epitopes of one or more internal proteins of influenza virus, wherein said composition comprises nucleic acid encoding at least... Agent: Mcandrews Held & Malloy, Ltd

20100285051 - Vaccine: e

20100285052 - Chemically programmable immunity: Methods and compositions for immediately immunizing an individual against any molecule or compound are provided. The present invention is directed to an immunity linker with at least two sites; (1) at least one first binding site that binds to an immune response component in an individual, and (2) at least... Agent: Johnson & Associates

20100285054 - Antimicrobial composition comprising fungal extract, process for producing fungal extract and method for protecting organisms: The present invention is directed to a fungal extract comprising antimicrobial activity. More specifically, the fungus used belongs to the family Polyporaceae, especially genus Trametes, namely Trametes sp. 11 E4. Specifically, the extract demonstrated activity against bacteria such as R. sonalacearum, E. coli, S. aureus, B. cereus and S. anatum.... Agent: Smith, Gambrell & Russell

20100285053 - Immunosuppressive extract of cordyceps sinensis and uses thereof: The present invention described herein relates to aqueous extracts of Cordyceps sinensis for use as an immunosuppressant agent.... Agent: Fenwick & West LLP

20100285055 - Activation of natural killer (nk) cells and methods of use: The present invention relates to filovirus VLPs and their use in activating innate immunity, specifically natural killer cells, and in enhancing an immune response to an antigen in an animal.... Agent: U.s. Army Medical Research And Materiel Commnad Attn: Mcmr-ja (ms. Elizabeth Arwine)

20100285056 - Baculovirus-based vaccines: The present invention relates to a recombinant baculovirus comprising: (a) a nucleotide sequence encoding a foreign virus envelope protein; (b) a first promoter operatively linked to the envelope-encoding nucleotide sequence; (c) a nucleotide sequence encoding an antigen protein; and (d) a second promoter operatively linked to the antigen-encoding nucleotide sequence;... Agent: Clark & Elbing LLP

20100285057 - Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins: Heat treated bacterins, a method of producing heat treated bacterins, and porcine emulsion vaccines prepared from such heat treated bacterins are disclosed.... Agent: Pharmacia & Upjohn

20100285060 - Alpha thymosin peptides as vaccine enhancers: The present invention provides methods of vaccination as well as pharmaceutical combinations and kits for enhancing vaccine effectiveness, including for immunodeficient or immunecompromised patients, including non-responders and low-responders to vaccination. As disclosed herein, the invention relates to administering a vaccine and a regimen of thymosin alpha peptide so as to... Agent: Cooley LLP Attn: Patent Group

20100285059 - Cytomegalovirus vaccines and methods of production: Methods of increasing diversity in cytomegalovirus vaccines through the selection of cell type in which the virus is propagated, and the use of cytomegalovirus produced by those methods in the development of vaccine compositions, are disclosed. Vaccine compositions comprising CMV isolated from epithelial cells are also disclosed.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100285058 - Dna vaccine for treating or preventing cervical cancer comprising a gene encoding hpv protein: Disclosed herein is a DNA vaccine for treating cervical cancer including an E5 gene of human papillomavirus (HPV). Also, disclosed is a combination DNA vaccine for preventing and treating cervical cancer including a gene encoding HPV L1 and/or L2 along with the HPV E5 gene.... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20100285061 - Dna vaccination protocols: This invention provides DNA vaccines for the treatment of patients undergoing anti-retroviral therapy. The vaccines are surprisingly effective at controlling viremia.... Agent: Townsend And Townsend And Crew, LLP

20100285062 - Combined mucosal and parenteral immunization against hiv: HIV antigens are mucosally administered in one or more priming immunization(s), and then HIV antigens are parenterally administered in one or more boosting immunization(s). Thus the invention provides a method for raising an immune response in a patient, comprising: (i) administering a HIV antigen to the patient via a mucosal... Agent: Novartis Vaccines And Diagnostics Inc.

20100285063 - Novel canine influenza virus and vaccine therefore: Novel influenza viruses A/Canine/Korea/01/07 (H3N2), A/Canine/Korea/02/07 (H3N2) and A/Canine/Korea/03/07 (H3N2) are disclosed. A vaccine composition comprising at least one of the viruses, a method for preventing or treating diseases resulting from influenza virus infection by administering the vaccine composition, and an assay kit for detecting the viruses are also disclosed.... Agent: Knobbe Martens Olson & Bear LLP

20100285064 - Adjuvant composition for vaccine: The present invention provides a Withania somnifera fraction rich in withanolides and a vaccine comprising a “Withania somnifera fraction” as an adjuvant.... Agent: Lucas & Mercanti, LLP

20100285066 - Canine leishmania vaccine: The present invention provides vectors that contain and express in vivo Leishmania KMP11 or an epitope thereof that elicits an immune response in a dog against Leishmania, compositions comprising said vectors, methods of vaccination against Leishmania, and kits for use with such methods and compositions.... Agent: Judy Jarecki-black Ph.d., J.d.

20100285065 - Modified cea nucleic acid and expression vectors: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. One... Agent: Patrick J. Halloran, Ph.d., J.d

20100285067 - Interferon-beta production modulating listeria strains and methods for using same: Mutant Listeria bacteria that modulate interferon-β production are provided. The subject bacteria are characterized by having a mutation in a gene chosen from a TetR gene, a LadR gene, a VirR gene, a MarR gene a MdrL gene, a MdrT gene and a MdrM gene. The subject bacteria find use... Agent: Bozicevic, Field & Francis LLP

20100285068 - Method for the internalization of non-invasive bacteria in eukaryote cells: The present invention relates to the use of adenylate cyclase toxin (ACT), or a functionally equivalent variant thereof, as an inducing agent for the internalization of non-invasive bacteria in eukaryotic cells. Due to ACT, said non-invasive bacterium can move through the plasma membrane of a eukaryotic cell and transfer plasmid... Agent: Moore & Van Allen PLLC

20100285069 - Meningococcal vaccine formulations: A dual formulation for vaccines against Neisseria meningitidis serogroup B (‘Men-B’) comprises (i) an oil-in-water emulsion adjuvant and (ii) a Men-B immunogenic component in lyophilised form. The lyophilised Men-B antigens can be reconstituted into liquid adjuvanted form at the time of use ready for administration to a patient. This formulation... Agent: Novartis Vaccines And Diagnostics Inc.

20100285070 - Polynucleotides of haemophilus parasuis and its use: The present invention relates to Haemophilus parasuis polynucleotides produced by recombinant technology. It also relates to polypeptides that are expressed by said polynucleotides and also to a vaccine against H. parasuis that comprises said polypeptides. In another aspect, the invention also relates to the use of polynucleotides to determine if... Agent: Sughrue Mion, PLLC

20100285071 - Purification of her-2 variants: The present invention provides for a novel method for purification of EGFR family proteins obtained from cultures of insect cells. The process comprises subsequent steps of a) diafiltration and exchange of culture medium with buffer, b) immobilized metal affinity chromatography (IMAC), C) size exclusion chromatography (SEC), and d) anion exchange... Agent: Law Office Of Salvatore Arrigo

20100285072 - Method for producing dendritic cells: The present invention relates to a method for producing dendritic cells and their use in medicaments by genetic engineering aimed at functionally improving their therapeutic efficacy in the treatment of cancer, microbial infections, allergies, auto-immune diseases or organ and stem cell transplant rejection.... Agent: Fulbright & Jaworski L.L.P.

20100285073 - a micro-rna family that modulates fibrosis and uses thereof: The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice... Agent: Cooley LLP Attn: Patent Group

20100285075 - Novel hemioxalate salt of eletriptan: The present invention relates to novel hemioxalate salt of eletriptan, process for preparation, pharmaceutical compositions, and method of treating thereof. The present invention relates to solid forms of eletriptan hemioxalate, processes for preparation, pharmaceutical compositions, and method of treating thereof. The solid form of eletriptan hemioxalate is useful for preparing... Agent: Cantor Colburn, LLP

20100285074 - Phenoxyalkylcarboxylic acid derivatives in the treatment of irritable bowel syndrome: A method of treating irritable bowel syndrome in a patient suffering therefrom comprising: administering an effective amount of a compound selected from compound 1, its metabolite 2 and pharmaceutically acceptable salts or prodrugs thereof:... Agent: Foley And Lardner LLP Suite 500

20100285078 - Alloplastic injectable dermal filler and methods of use thereof: A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent is provided. A method of making a composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material... Agent: Hunton & Williams LLP Intellectual Property Department

20100285077 - Cosmetic composition comprising hydroxymethionine and 3-aminopropanesulfonic acid: The present invention relates to cosmetic compositions comprising an association of hydroxymethionine and 3-aminopropanesulfonic acid, and a cosmetic method for the skin. These compositions are intended to prevent and/or treat the signs of the cutaneous ageing such as the sagging of the cutaneous and subcutaneous tissue, the loss of cutaneous... Agent: Jones Day

20100285080 - Cosmetic treatment system and methods: A cosmetic treatment system is provided having ingredients that may prevent signs of aging, improve the aesthetic appearance of skin, and promote recovery from environmental stresses. The composition includes natural ingredients, including at least one ingredient or extract from rosemary; at least one ingredient or extract from Centella, Echinacea, Alpinia... Agent: In Re: 28533 Brinks, Hofer, Gilson & Lione

20100285076 - Fluid cosmetic composition comprising a monoalcohol: The present invention relates to the field of making up and/or caring for the skin and is targeted in particular at providing a fluid care and/or make-up cosmetic composition in the form of a water-in-oil emulsion dedicated to the skin comprising a fatty phase, an aqueous phase and at least... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100285079 - Method for producing a cosmetic preparation: Provided is a method of producing a cosmetic by molding a powder composition under pressure, the method including: applying a vibration having a frequency of 10 to 40 kHz and an amplitude of 10 to 100 μm to a powder composition while the powder composition is molded under pressure, the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100285081 - Bactericidal nanofibers, and methods of use thereof: One aspect of the invention relates to an antimicrobial fiber formed from an electroprocessed blend of at least one polymer, at least one antimicrobial agent, and at least one crosslinker. Another aspect of the invention relates to an antimicrobial fiber formed from an electroprocessed blend of at least one polymer... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100285083 - Drug delivery system: It is a main object of the present invention to provide a drug delivery system in which drugs can be changed or which can be recharged with drugs, which continuously delivers drugs at effective concentrations to local lesional sites in a body and allows the use of drugs for which... Agent: Sughrue Mion, PLLC

20100285082 - Integrated biosensor and simulation system for diagnosis and therapy: BioMEMS/NEMS appliance biologically monitors an individual, using biosensors to detect cellular components. Data is simulated or analyzed using systems-biology software, which provides diagnostic or therapeutic guidance.... Agent: Fernandez & Associates, LLP

20100285084 - Antimicrobial coatings for medical devices and methods for making and using them: Embodiments of the invention provide methods for using compositions to inhibit microbial growth on a surface of a medical device having the composition applied thereto, to medical devices having the composition applied to a surface thereof and to methods for using the compositions to coat medical devices.... Agent: Gates & Cooper LLP Howard Hughes Center

20100285085 - Balloon coating with drug transfer control via coating thickness: A coated medical device, such a balloon or stent. The coating includes a therapeutic agent having a thickness of the coating is between about 1.5 to 10 μm and less than 30% of the coating remains on the balloon post delivery to a vessel.... Agent: Baker Botts L.L.P.

20100285086 - Biomimetic extracellular matrices: The present invention is directed to hydrogel compositions for biotechnology applications. Specifically, the invention provides hydrogels mimicking the ECM and uses thereof.... Agent: Pearl Cohen Zedek Latzer, LLP

20100285089 - Medical devices, drug coatings and methods for maintaining the drug coatings thereon: Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of... Agent: Woodcock Washburn LLP

20100285087 - Single phenothiazine enantiomers as agents for the prevention of bone loss: Enantomerically purified phenothiazines are provided as active ingredients of medicaments to limit activity of bone resorbing cells so as to reduce bone loss. Novel phenothiazine derivatives are provided. A method of synthesizing enantiomerically pure phenothiazine derivatives is provided that avoids post-synthetic enantiomeric resolution.... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20100285088 - Tissue adhesives and sealants and method for their use: Compositions provided by mixing a biotin-containing component and an avidin-containing component are useful as an adhesive or sealant for medical/surgical uses.... Agent: Tyco Healthcare Group Lp D/b/a Covidien

20100285090 - Methods and compositions for repair of cartilage using an in vivo bioreactor: Methods and compositions for the biological repair of cartilage using a hybrid construct combining both an inert structure and living core are described. The inert structure is intended to act not only as a delivery system to feed and grow a living core component, but also as an inducer of... Agent: Fulbright & Jaworski, LLP

20100285091 - Methods and compositions for repair of cartilage using an in vivo bioreactor: Methods and compositions for the biological repair of cartilage using a hybrid construct combining both an inert structure and living core are described. The inert structure is intended to act not only as a delivery system to feed and grow a living core component, but also as an inducer of... Agent: Fulbright & Jaworski, LLP

20100285092 - Methods and compositions for repair of cartilage using an in vivo bioreactor: Methods and compositions for the biological repair of cartilage using a hybrid construct combining both an inert structure and living core are described. The inert structure is intended to act not only as a delivery system to feed and grow a living core component, but also as an inducer of... Agent: Fulbright & Jaworski, LLP

20100285093 - Methods and compositions for repair of cartilage using an in vivo bioreactor: Methods and compositions for the biological repair of cartilage using a hybrid construct combining both an inert structure and living core are described. The inert structure is intended to act not only as a delivery system to feed and grow a living core component, but also as an inducer of... Agent: Fulbright & Jaworski, LLP

20100285094 - Polymeric compositions and methods of making and using thereof: Described herein are polymeric compositions that comprise at least one polymer residue and at least one crosslinking moiety, wherein the polymer residue is crosslinked by the crosslinking moiety and wherein the crosslinking moiety is formed from a reaction between a boronic acid moiety and a hydroxamic acid moiety. Also, described... Agent: Ballard Spahr LLP

20100285095 - Hygiene article having calcium sugar acid salt: A hygiene article having calcium sugar acid salt is provided. The calcium sugar acid salt reduces the production of Toxic Shock Syndrome Toxin-1 (TSST-1) by S. aureus.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100285096 - Hygiene article having calcium sugar phosphate: A hygiene article having calcium sugar phosphate is provided. The calcium sugar phosphate reduces the production of Toxic Shock Syndrome Toxin-1 (TSST-1) by Staphylococcus aureus.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100285097 - Vaginal delivery system: The present invention is related to an intravaginal delivery system for the controlled release of drospirenone and an estrogen, optionally also comprising one or more therapeutically active or a health-promoting substance capable of giving and/or enhancing protection against bacterial and fungal infections, and/or enhancing protection against sexually transmitted diseases. The... Agent: Birch Stewart Kolasch & Birch

20100285098 - Adhering troches with santacid for treatment of throat esophagus and stomach: A method for combating unwanted conditions downstream of the mouth with adhering troches. A method to treat or reduce replication of a virus in throat tissues by releasing an anti-viral from an adhering disc. A method to treat sore throat with time release of Glycyrrhiza extract or collagen from an... Agent: Jeffrey T Haley

20100285099 - Vaccination by transcutaneous targeting: The present invention relates to a method of vaccination via hair follicles that makes it possible to target vaccine components to the antigen-presenting cells in order to induce a protective and effective immune response against pathogens.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100285102 - Colloidal collagen burn wound dressing produced from jellyfish: The present invention relates to methods of forming wound dressings from jellyfish collagen. A jellyfish tissue is provided, after which an acid is added to produce a collagen-salt solution. The solution is mixed to form a viscous colloidal gel, and a film or a film/fabric composite is created from the... Agent: Daniel J Swirsky

20100285101 - Composite nonwoven fibrous webs and methods of making and using the same: The disclosure relates to composite nonwoven fibrous webs including a population of sub-micrometer fibers having a median diameter less than one micrometer (μm), and a population of microfibers having a median diameter of at least 1 μm. At least, one of the fiber populations is oriented, and each composite nonwoven... Agent: 3m Innovative Properties Company

20100285100 - Compositions and medical devices for controlled release of nitric oxide and methods of production thereof: The present disclosure describes compositions providing for controlled release of nitric oxide (NO) and methods for production of these compositions. In some embodiments, the compositions may include a biodegradable polymer and a nitric oxide-releasing material at least partially encapsulated by the biodegradable polymer. Nitric oxide-releasing materials may include, for example,... Agent: Winstead PC

20100285110 - Composition comprising mucilaginous polysaccharides derived from aloe barbadensis combined with liposomes, method for obtaining same and use thereof as a sun protector, an anti-acne agent, an epidermal regenerator and a moisturiser: Provided is a composition including mucilaginous polysaccharides of aloe barbadensis, including for example aloeride and acemannan, and phospholipids, including for example, sphingosomes, ceramides and liposomes in combination with collagen, for the treatment of premature aging, overexposure to ultraviolet rays, and acne. Also provided is a process for preparing the composition.... Agent: The Nath Law Group

20100285104 - Compositions and methods for the delivery of oxygen: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H-NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The... Agent: Morrison & Foerster LLP

20100285113 - Enhanced stability of inverse thermal gelling composite hydrogels: The present invention relates to a composite hydrogel comprising a blend of an aqueous solution of an anionic polysaccharide or a derivative thereof, such as hyaluronan (also commonly referred to as hyaluronic acid) or a derivative thereof and an aqueous solution of methylcellulose or another water soluble cellulose derivative thereof,... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20100285103 - Medicament for treatment of tumors and the use thereof: The present invention discloses an anti-tumor conjugate and pharmaceutical composition or kits comprising the conjugate, as well as a method of producing the anti-tumor conjugate. The anti-tumor conjugate of the present invention is metabolically stable in vivo, and is ultimately available for the treatment of tumors and production of anti-tumor... Agent: Millen, White, Zelano & Branigan, P.C.

20100285108 - Method for therapeutic use: The present invention is related to methods for the therapeutic use in the treatment of diseases and disorders where T-helper independent antibody responses are beneficial. In particular, the present invention relates to a method wherein these diseases and disorders above are treated in immunocompromised or autoimmune diseased animals or humans.... Agent: Johnson & Associates

20100285112 - Methods of delivering oligonucleotides to immune cells: The invention relates to the field of delivery of nucleic acid-based agents to immune cells.... Agent: Lando & Anastasi, LLP A2038

20100285106 - Multicomponent vaccine: The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to a multicomponent vaccine and method of using same to protect against HTV-I infection.... Agent: Nixon & Vanderhye, PC

20100285105 - Oil producing microbes adn method of modification thereof: Disclosed are compositions and methods related to a eukaryote of the order Thraustochytriales and family Thraustochytriaceae which when cultured produce quantities of unsaturated fatty acids, such as omega 3 (n-3) and/or omega 6 (n-6) oils, such as DHA, EPA and DPA, capable of being purified and used as all such... Agent: Ballard Spahr LLP

20100285111 - Self-assembling micelle-like nanoparticles for systemic gene delivery: Nanoparticles containing nucleic acid and suitable for use as in vivo delivery agents for nucleic acids are provided. The nanoparticles use a covalent conjugate of a polycation such as polyethylenimine and phospholipids. The final DNA-containing nanoparticle has a vesicular structure with a polyplex core surrounded by a mixed lipid/PEG-lipid monolayer... Agent: Wilmerhale/boston

20100285107 - Short nucleic acid molecule-mediated modulation of aurora b kinase expression and combinations for use in anticancer therapy: This invention relates to the use of short nucleic acid molecules that modulate Aurora-B kinase (AurkB) expression. The invention includes compounds, compositions and methods useful for the modulation of expression and activity of genes involved in the AurkB pathway. In one embodiment, the present invention provides short nucleic acid molecules,... Agent: Foley And Lardner LLP Suite 500

20100285109 - Truncated secretory aspartyl proteinase 2: The present invention relates to a truncated form of the secretory aspartyl proteinase 2 (Sap2), as well as to nucleic acid molecules encoding same. This truncated Sap2 polypeptide (tSap2) is surprisingly stable and devoid of enzymatic activity but retains full immunogenicity upon intravaginal administration and confers full protection against intravaginal... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100285114 - Pharmaceutical compositions of rhein or diacerein: The invention relates to pharmaceutical compositions of rhein or diacerein, or salts or esters or prodrugs thereof which are bioequivalent to a 50 mg diacerein formulation marketed under the trade name Art 50®. The compositions exhibit no variability in fed and fasted state conditions. The compositions also result in significant... Agent: Bio Intellectual Property Services (bio Ips) LLC

20100285115 - Novel antiretroviral combination: The invention relates to pharmaceutical compositions containing a combination of atazanavir and ritonavir, to methods of making them, and their use in medicine.... Agent: Conley Rose, P.C.

20100285116 - Physically/molecularly distributed and/or chemically bound medicaments in empty, hard capsule shells: The present invention incorporates medicaments in the empty hard capsule shells (body and cap). The medicament is either physically/molecularly distributed and/or chemically bound to the polymer matrix of the capsule shell composition. Other medicaments in the form of drug-loaded matrices (powders, granules, beads, pellets, mini-tablets, and mini-capsules) can be filled... Agent: Hemant N. Joshi/tara Enterprises

20100285117 - Combination of triazine derivatives and insulin sensitisers: The present invention relates to combinations of triazine derivatives and of insulin sensitisers.... Agent: Millen, White, Zelano & Branigan, P.C.

20100285118 - Encapsulated omega-3 fatty acids and/or omega-6 fatty acids and/or esters thereof with a coating: Encapsulated omega-3 fatty acids and/or omega-6 fatty acids and/or esters thereof with a coating comprising isoflavones, as well as a process to make such by coating encapsulated omega-3 fatty acids and/or omega-6 fatty acids and/or esters thereof with a coating comprising isoflavones.... Agent: Unilever Patent Group

20100285119 - Multiparticulate extended release pharmaceutical composition of carbamazepine and process for manufacturing the same: Disclosed herein is an extended release pharmaceutical composition comprising at least two populations of extended release minitablets having a core comprising carbamazepine or its pharmaceutical salts, solvates, hydrates, an extended release polymer(s), wherein the extended release polymer of each population of minitablets is unalike. The process for manufacturing said composition... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20100285120 - Controlled release preparation: A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100285121 - Capsule formulation: The present invention provides the following capsule preparation, which is superior in dissolution property and the like of a pharmaceutically active ingredient and contains liquid and solid pharmaceutically active ingredients: a seamless capsule containing liquid and solid pharmaceutically active ingredients, wherein the liquid pharmaceutically active ingredient is encapsulated in the... Agent: Foley And Lardner LLP Suite 500

20100285122 - Tablets for combination therapy: The invention provides solid dose forms (e.g. tablets) comprising a compound of Formula I, a compound of Formula II, a compound of Formula III and a salt of Formula IV.... Agent: Viksnins Harris & Padys Pllp

20100285123 - Controlled release dosage formulation of duloxetine: The preset invention provides a controlled release dosage form of duloxetine comprising a homogenous core comprised of duloxetine or its pharmaceutically acceptable salts, pharmaceutically acceptable polymeric carrier, solubility enhancer, a hydrophobic component, a hydrodynamic diffusion enhancer, a viscolyzing agent and pharmaceutically acceptable excipients; a entering coat on said core and... Agent: Ladas & Parry LLP

20100285124 - Tetrahydrocyclopenta[c]acridine derivatives as kinase inhibitors and biological: The invention relates to kinase inhibitors of the formula (I) in which —R1 to R4=H; ether or polyether, amino; NO2; NH— carbamate; NH—CO—R, with R such as defined above; N3 and derivatives thereof of the 1,2,3-triazole type; —R5=—OH; halogen; —OR with R such as defined above; OH-carbamate; OH-carbonate; NH2, NH-carbamate;... Agent: Nixon & Vanderhye, PC

20100285125 - Delivery system for poorly soluble drugs: The present invention relates to an oral drug delivery system for poorly soluble drugs, which can provide sustained near zero order release of poorly water soluble drugs from erodible matrix systems. Erodible matrix core is prepared using at least one active and erosion modulators in a matrix of low molecular... Agent: Seyfarth Shaw LLP

20100285126 - Pharmaceutical compositions of fenofibrate: The invention relates to pharmaceutical compositions comprising non-micronized fenofibrate with one or more pharmaceutically acceptable vehicles. The invention also relates to pharmaceutical compositions comprising non-micronized fenofibrate with one or more cyclodextrin derivatives. The invention also relates to processes for the preparation of such compositions.... Agent: Bio Intellectual Property Services (bio Ips) LLC

20100285127 - Taste masked pharmaceutical compositions of s-alkylisothiouronium derivatives: The present invention relates to taste masked compositions of S-alkylisothiouronium derivatives, including, but not limited to, S-ethylisothiouronium diethylphosphate, in the form of a coated oral tablet having a desirable dissolution profile.... Agent: Fennemore Craig

20100285130 - Coating of complexed actives in film formulations: The present invention relates to products and methods of making products having a dual taste masked active component. In particular, the present invention relates to film dosage forms including at least one dual taste masked active, where the dual taste masked active includes a coated complexed active composition.... Agent: Hoffmann & Baron, LLP

20100285131 - Fgf21 mutants and uses thereof: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.... Agent: Amgen Inc.

20100285129 - Novel agent for salting out active principles in dressings containing at least one of fatty substance: The present invention relates to the use, as an agent for salting out an active substance in a composition for a dressing, of a copolymer of a salt of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulphonic acid and the 2-hydroxyethyl ester of propenoic acid. It also relates to dressings of the type comprising at least one... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100285128 - Space filled drug release structure and method of manufacturing the same: A space filled drug release structure and a method of manufacturing the same are disclosed. The structure is composed of a highly water-absorbing polymeric matrix and drug particles dispersed in the matrix. The matrix has pores and passages interconnecting the pores together. Because some water is present in the matrix,... Agent: Muncy, Geissler, Olds & Lowe, PLLC

20100285132 - Immunotherapy compositions, method of making and method of use thereof: The present invention directs to compositions and methods for modulating immune system. One aspect of the present invention relates to a composition comprising FADD-dependent signaling pathway modulators. Another aspect of the 5 present invention relates to biodegradable microparticles, such as a chitosan microparticic, or PLGA/PEI microparticle, designed to deliver nucleic... Agent: Novak Druce + Quigg LLP (wpb)

20100285133 - Transdermal drug delivery system containing granisetron: Disclosed herein is a transdermal system in a matrix form capable of enhancing granisetron carrying efficiency and improving transdermal absorption while inhibiting recrystallization, which comprises: at least one transdermal enhancer selected from a group consisting of polyglyceryl-3 oleate, polyethyleneglycol-20 almond glyceride, polyethyleneglycol-12 palm kernel glyceride, isopropyl myristate and oleyl alcohol;... Agent: Lucas & Mercanti, LLP

20100285134 - Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases: An intra-articular pharmaceutical composition is used for the treatment and/or the prevention of acute or chronic osteoarticular diseases and acute or chronic osteoarticular symptoms especially osteoarthritis. The composition includes a possibly adequate pharmaceutical carrier or diluent, a glycosaminoglycan, a compound activating the alpha 2 adrenergic receptor, an anti-inflammatory agent and... Agent: Merchant & Gould PC

20100285137 - Antibiotic/bone morphogenic protein formulation and method of treatment: A formulation comprised of particles which may be in groups and are comprised of a biocompatible polymer and an antimicrobial drug for controlled release of the drug is disclosed. The particles may be in an aqueous solution comprising thrombin and be dispersed in a gel. The formulation is administered to... Agent: Bozicevic, Field & Francis LLP

20100285140 - Antimicrobial agent for gram-positive bacteria: A novel antibacterial agent for Gram-positive bacteria which disregards the drug-resistant mechanisms of bacteria is disclosed. The antibacterial agent contains as an effective ingredient particles having a particle diameter of not more than 5 μm, which particles are adhesive to cell wall of Gram-positive bacteria and not adhesive to mammalian... Agent: Birch Stewart Kolasch & Birch

20100285138 - Compositions comprising nanoparticles and apoptotic agents and methods of use: Compositions comprising nanoparticles, such as silver or gold nanoparticles or carbon nanotubes (CNTs), and apoptotic agents are described. The nanoparticles can significantly enhance the cancer chemotherapeutic effects of the apoptotic agents. In particular, a highly increased anti-tumor activity has been demonstrated for the combination of etoposide and CNTs against HeLa... Agent: Morris Manning Martin LLP

20100285135 - Nanoparticles for use in immunogenic compositions: Disclosed herein are sterile-filtered lyophilized nanoparticle compositions which contain at least one biodegradable polymer, at least one surfactant, at least one cryoprotective agent and at least one antigen. Also disclosed are methods of making and using such compositions and kits supplying such compositions.... Agent: Novartis Vaccines And Diagnostics Inc.

20100285139 - Pharmaceutical composition for the prophylaxis and/or symptomatic treatment of cystic fibrosis: A pharmaceutical composition for prophylaxis and/or treatment of infections and/or infectious diseases occurring in cystic fibrosis includes at least one antidepressant; at least one dispersant; and at least one pharmaceutically tolerable carrier material.... Agent: Ip Group Of Dla Piper LLP (us)

20100285136 - System comprising bacteriophages and particles that contain active substances: The present invention concerns a system, comprising bacteriophages and particles comprising active agents, in which a first additional peptide is fused to proteins of the bacteriophage, the first additional peptide adheres to the surface of the particle and furthermore a second additional peptide is fused to proteins of the bacteriophage.... Agent: Briscoe, Kurt G. Norris Mclaughlin & Marcus, Pa

20100285141 - Compositions and methods for enhancing the activity of podophyllotoxin: A method of increasing an activity of a podophyllotoxin or a derivative thereof is disclosed. The method comprises contacting the podophyllotoxin or the derivative with a liquid composition having a liquid and nanostructures, each of the nanostructures comprising a core material of the nanometric size surrounded by an envelope of... Agent: Foley And Lardner LLP Suite 500

20100285142 - Method of making particles for use in a pharmaceutical composition: A method for making composite excipient particles for use in a pharmaceutical composition comprises a milling step in which particles of an excipient material are milled in the presence of an additive material. The product particles are of small size and the milling requires relatively low input of time and... Agent: Davidson, Davidson & Kappel, LLC

20100285143 - Orally administerable solid pharmaceutical composition and a process thereof: The invention relates to improvised pharmaceutical compositions permitting ingestion via oral delivery of proteins/peptides or their conjugates, and/or cation-insulin conjugate complexes demonstrating desirable pharmacokinetic profiles and potency in efficacy models of diabetes in dogs and humans. A preferred formulation comprises 0.01%-20% w/w of insulin, insulin compound conjugates and/or cation insulin... Agent: Harness, Dickey & Pierce, P.L.C

20100285144 - Polymer-epothilone conjugates, particles, compositions, and related methods of use: Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer or neurological deficits. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles,... Agent: Lando & Anastasi, LLP

20100285145 - Gpr 119 modulators: Compounds of Formula (I) that modulate the activity of the G-protein-coupled receptor GPR119 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.... Agent: Pfizer Inc. Patent Department

20100285146 - Peptides and methods for the treatment of systemic lupus erythematosus: A method is disclosed for treating systemic lupus erythematosus in a mammalian subject, comprising administering to said subject an effective dose of at least one laminin peptide, or an analog or a derivative thereof. In one exemplary embodiment, the laminin peptide is selected from the group consisting of R38 (SEQ.... Agent: Edward Langer C/o Shiboleth Yisraeli Roberts Zisman & Co.

20100285147 - Crude drug extract-blended liquid medicine: A liquid preparation containing an animal-origin extract having pH of 3.0 to 5.5 and containing the animal-origin extract at concentration of 5 to 50 w/v % (dry weight) to the total amount of the liquid preparation, containing a caramel at concentration of 0.5 to 20 w/v % to the total... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100285148 - Oral care method and kit: A method of moisturizing while decolonizing mammalian tissue, the method comprising applying a multi-valent cationic antiseptic composition to the tissue, and applying a moisturizer composition to at least a portion of the same tissue; wherein the mammalian tissue is oral tissue of a subject; wherein the multi-valent cationic antiseptic is... Agent: 3m Innovative Properties Company

20100285149 - Novel tetrahydropyridothiophenes: Compounds of a certain formula I, in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.... Agent: Millen, White, Zelano & Branigan, P.C.

20100285150 - Dental sterilizing water, method for producing the water, and device for producing the water: This aims to produce dental sterilizing water having not only a sterilizing action but also an action to break a bio-film. Provided is a sterilizing water producing device (51) comprising a stock solution tank (3) for storing a stock solution (52), a stroke pump (4) connected in communication to the... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100285151 - Methods and compositions for treating conditions associated with infection and/or inflammation: The present invention provides methods and compositions for treating and preventing conditions characterized by infection and/or inflammation, especially of the eyes, ears, nose, and/or throat. The methods of the invention involve administering hypohalous acid to the patient, such as in the form of a composition described herein.... Agent: Cooley LLP Attn: Patent Group

20100285152 - Composition for improving liver metabolism and diagnostic method: There is a need to develop a treatment for metabolic syndrome, which is directed to maintaining healthy liver metabolism and not indirectly through weight loss. The present invention provides a composition comprising whey protein for supporting and improving liver metabolism, especially in connection with fatty liver. The composition can further... Agent: Sughrue Mion, PLLC

20100285155 - Cleanser composition and methods for using the same: The present invention is directed to anti-microbial cleanser compositions comprising linalool, hinokitiol and dipropylene glycol. The present invention further provides methods for using these compositions to maintain eyelid hygiene, to treat an ocular disorder or to clean a skin surface. The cleanser compositions of the present invention can be in... Agent: Edwards Angell Palmer & Dodge LLP

20100285156 - Composition for preventing and treating metabolic diseases comprising the extract of lysimachiae foenum-graeci herba: Disclosed are raw material, functional foods, and herb medicines for preventing and treating metabolic diseases, which comprise a Lysimachiae Foenum-Graeci Herba extract as an effective ingredient. The Lysimachiae Foenum-Graeci Herba extract have an activity of reducing blood glucose levels, triglycerides and cholesterol levels, AST and ALT levels, and fat in... Agent: Edwards Angell Palmer & Dodge LLP

20100285153 - Lipolysis stimulator: To provide a lipolysis agent, a slimming agent, and a cellulite-ameliorating agent, which stimulate decomposition of fat accumulated in the adipose tissue, to thereby exhibit body-slimming effect and which is effective for inhibition or prevention of obesity and amelioration of prone to obesity. The lipolysis stimulator of the invention contains,... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100285154 - Use of lignan compounds for treating or preventing inflammatory disease: The present invention relates to the use of lignan compounds for treating or preventing an inflammatory disease. More particularly, it relates to a method for preventing or treating an inflammatory disease, comprising administering to a subject in need thereof an effective amount of macelignan represented by Chemical Formula I or... Agent: Jhk Law

20100285157 - Granules, tablets and method of producing the same: When a light and porous inorganic substance is employed in a large amount as a excipient, it is impossible in the subsequent tabletting step using a tabletting machine to supply a desired amount of the resultant powder into a mortar having a definite diameter. As a result, extremely light tablets... Agent: Pryor Cashman, LLP

20100285158 - Effervescent composition including cranberry extract: Disclosed is an effervescent composition that includes an effervescent agent and cranberry extract, preferably in an amount sufficient to decrease the measurable amount of bacteria present in the urine of an individual having a urinary tract infection.... Agent: Allison Johnson, P.A.

20100285159 - Combination of unsaponifiable lipids combined with polyphenols and/or catechins for the protection, treatment and repair of cartilage in joints of humans and animals: The present invention relates to a composition and a kit for the protection, treatment and repair of cartilage in humans and animal joints. The composition or kit contains a combination of unsaponifiable lipids together with one or more of polyphenols and/or catechins. Preferably, the composition or kit contains avocado:soybean unsaponifiables... Agent: Arent Fox LLP

20100285160 - Anti-influenza viral composition containing bark or stem extract of alnus japonica: The present invention relates to an antiviral composition comprising an Alnus japonica extract, more specifically, relates to a method for preparing high activated anti-influenza viral composition, which comprises an extract of the bark or stem of Alnus japonica, and an anti-influenza viral composition comprising the extract. An extract of the... Agent: Moore & Van Allen PLLC

20100285161 - Herbal composition for maintaining/caring the skin around the eye, methods of preparing the same and uses thereof: Disclosed is a novel herbal composition for maintaining/caring the skin around the eye, the composition comprising extracts of Saxifraga ligulata syn. Bergenia ligulata, Cipadessa baccifera and Emblica officinalis and cosmeceutical excipients thereof. Also disclosed is a method of extraction, delivery system comprising the same and use thereof.... Agent: Knobbe Martens Olson & Bear LLP

20100285162 - Herbal composition for maintaining/caring the skin around the eye, methods of preparing the same and uses thereof: Disclosed is a novel herbal composition for maintaining/caring the skin around the eye, the composition comprising extracts of Saxifraga ligulata syn. Bergenia ligulata, Cipadessa baccifera and Emblica officinalis and cosmeceutical excipients thereof. Also disclosed is a method of extraction, delivery system comprising the same and use thereof.... Agent: Knobbe Martens Olson & Bear LLP

20100285163 - Composition for treating or preventing hot flashes and use thereof: The present invention provides compositions and methods of their use for treating or preventing climacteric symptoms such as hot flashes. A composition of the invention preferably comprises Chaihu, Yujin, Mudanpi, Zicao, Baiwei, Baishao and Wuweizi or extracts thereof, and is preferably administered as a single composition.... Agent: Marshall, Gerstein & Borun LLP

20100285164 - Orally disintegrating excipient: The present invention is directed to coprocessed excipient particles comprising a cellulosic material such as microcrystalline cellulose in intimate association with silicon dioxide, a disintegrant and a polyol, sugar or a polyol/sugar blend. The excipient particles display good processing and are useful in prepared compressed solid dosage forms that exhibit... Agent: Davidson, Davidson & Kappel, LLC

20100278724 - Inhibition of migration and induction of cell death by the type ii collagen amino propeptides: The present invention provides combinations and methods for inducing cell death, inhibiting angiogenesis, and inhibiting cell migration. In particular, the present invention provides methods for inducing cell death in a cell expressing an αvβ3 and/or an αvβ5 integrin.... Agent: Polsinelli Shughart PC

20100278725 - Methods and devices for lymphatic targeting: The present invention is directed to an implantable device comprising a biocompatible and biodegradable matrix impregnated with a bioactive complex suitable for selectively targeting the lymphatic system, wherein the bioactive complex comprises one or more particle forming materials and one or more bioactive agents. The invention is further directed to... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20100278727 - Alpha-emitting constructs and uses thereof: The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic... Agent: Benjamin Aaron Adler Adler & Associates

20100278728 - Anti-mullerian inhibiting substance type ii receptor (misiir) immunoconjugates to detect and treat cancer: Compositions and methods for detecting and treating cancers expressing Mullerian inhibiting substance Type II receptor (MISIIR) are provided.... Agent: Dann, Dorfman, Herrell & Skillman

20100278726 - Modified antibodies to prostate-specific membrane antigen and uses thereof: Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies,... Agent: Proskauer Rose LLP

20100278729 - Breast cancer eradication program: A method of treating breast cancer that is at least partially ER+ is disclosed. The method comprises administering at a tumor site in a mammalian subject a pharmaceutically acceptable form of Fe(II) or Fe(III) in a suitable carrier. A four-part program aimed at eradicating breast cancer includes (a) local treatment... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20100278731 - Mechanism-based targeted pancreatic beta cell imaging and therapy: Compositions for imaging pancreatic beta cells comprise chelator-antidiabetic agent conjugates and optionally chelated metals.... Agent: Vinson & Elkins, L.L.P.

20100278730 - Non-invasive molecular imaging of cellular histone deacetylase substrate using magnetic resonance spectroscopy (mrs) or positron emission tomography (pet): We disclose methods of detecting histone deacetylase activity in a mammal by administering to the mammal a compound comprising at least one atom having a nucleus detectable by magnetic resonance spectroscopy, wherein the compound is a substrate of histone deacetylase; and observing the compound or a cleavage product thereof in... Agent: Williams, Morgan & Amerson

20100278732 - 1h-[1, 2, 3] triazole substituted amino acids and uses thereof: Tracers for cationic amino acid transport systems and methods of synthesis are disclosed, including compounds comprising a 1H-[1,2,3]triazole moiety. Further disclosed are uses of the analogues, including in vivo imaging of tumors by Positron emission tomography (PET) or Single Photon Emission Computed Tomography (SPECT).... Agent: Zackson Law LLC

20100278733 - Composition for diagnosis of amyloid-related disease: There is provided a composition comprising a compound represented by general formula (I), wherein Rl represents a 5-iodothiophen-2-yl group or the like, and R2 represents a 4-dimethylaminophenyl group or the like. This composition is useful for diagnosis of an amyloid-related disease such as Alzheimer's disease because the compound has high... Agent: Millen, White, Zelano & Branigan, P.C.

20100278736 - Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy: The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.... Agent: Marshall, Gerstein & Borun LLP

20100278738 - Method to detect and monitor ischemia in transplanted organs and tissues: Disclosed is a method of detecting and/or monitoring ischemia in a tissue or organ, such as a free flap transfer. The method includes the steps of measuring in real time or near-real time interstitial glucose concentration, or rate of change of interstitial glucose concentration over time, or both, in the... Agent: Intellectual Property Dept./dewitt Ross & Stevens Wisconsin Alumni Research Foundation

20100278735 - Methods for detection of vulnerable plaque with quantitative colorimetry during angeoscopy: Methods are provided for detecting lipid cores underneath thin fibrous caps (LCTC) and thin-cap fibroatheromas (TCFA) in a subject in need of diagnosis for having a vulnerable plaque, a plaque at risk of disruption or thrombosis, or risk of an acute coronary syndrome, and for screening compounds for modulators of... Agent: Lawson & Weitzen, LLP

20100278734 - Nanoparticle contrast agents for diagnostic imaging: Compositions of nanoparticles functionalized with at least one net positively charged group and at least one net negatively charged group, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in... Agent: General Electric Company Global Research

20100278737 - Organic-inorganic hybrid particles containing contrast agent: This invention provides organic-inorganic hybrid particles containing as the essential components a block copolymer comprising an uncharged hydrophilic polymer chain segment and a polymer chain segment containing a repeated structural unit having a carboxylate ion group at its side chain; calcium ion (Ca2+), phosphate ion (PO43−) or carbonate ion (CO32−),... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100278739 - Targeted, nir imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging: Compounds and methods related to NIR molecular imaging, in-vitro and in-vivo functional imaging, therapy/efficacy monitoring, and cancer and metastatic activity imaging. Compounds and methods demonstrated pertain to the field of peripheral benzodiazepine receptor imaging, metabolic imaging, cellular respiration imaging, cellular proliferation imaging as targeted agents that incorporate signaling agents.... Agent: Stites & Harbison PLLC

20100278742 - Methods and compositions for detection and diagnosis of infectious diseases: Methods and compositions for the detection and diagnosis of infectious diseases are provided. In particular, efficient and sensitive methods and compositions for the detection of active mycobacterial disease are provided for distinguishing between individuals having active disease, and individuals who have been immunologically exposed, such as those infected with a... Agent: Johnson & Associates

20100278743 - Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling: Methods for treating or preventing tauopathies and/or Aβ amyloidosis by modulating CRF receptor signaling. Accumulation of hyperphosphorlyated tau protein in the CNS may be reduced by administration of CRF-R1 selective antagonists and/or CRF-R2 selective agonists. For example, in some aspects, methods for preventing the onset of Alzheimer's disease by administration... Agent: Fulbright & Jaworski, L.L.P.

20100278741 - Novel compositions including sphingosine kinase type 1 inhibitors, and processes for using same: Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).... Agent: Enzo Biochem, Inc.

20100278740 - Streptococcus pneumoniae proteins and nucleic acid molecules: Protein antigens from Streptococcus pneumoniae are disclosed, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.... Agent: Hunton & Williams LLP Intellectual Property Department

20100278744 - Preparation for restenosis prevention: The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one... Agent: Millen, White, Zelano & Branigan, P.C.

20100278748 - Nanoparticle contrast agents for diagnostic imaging: Compositions of nanoparticles functionalized with at least one net positively charged group and at least one net negatively charged group, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in... Agent: General Electric Company Global Research

20100278749 - Nanoparticle contrast agents for diagnostic imaging: Compositions of nanoparticles functionalized with at least one net positively charged group and at least one net negatively charged group, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in... Agent: General Electric Company Global Research

20100278750 - Polylysine dendrimer contrast agent: The present invention relates generally to branched macromolecules and their use as imaging or contrast agents. In particular, the invention relates to dendrimers, derived from lysine or lysine analogues, bearing a plurality of functional moieties and their application to imaging techniques in which a disease state may be imaged with... Agent: Knobbe Martens Olson & Bear LLP

20100278751 - Radiolabeled 2-amino-4-alkyl-6-(haloalkyl)pyridine compounds and their use in diagnostic imaging: Radiolabeled 2-amino-4-alkyl-6-(haloalkyl)pyridine compounds are disclosed. In some aspects, the compounds bind to inducible nitric oxide synthase (iNOS) with high specificity. In some configurations, a compound comprising a radioisotope can be used for diagnostic imaging of iNOS distribution in a mammalian subject such as a human, using a scanning method such... Agent: Zackson Law LLC

20100278747 - Carrier: The invention relates to a carrier for delivering agents to the posterior region of the eye, the carrier comprising a Vitamin E derivative, especially tocopherol. The carrier may also comprise a cell death marker, such as an annexin.... Agent: Stites & Harbison, PLLC

20100278745 - Compounds for fluorescence imaging: Methods and compositions involving enzyme-activatable fluorophore polymer imaging agents for photodetection of specific tissues and/or human diseases and disorders are provided. In certain embodiments, the imaging agent comprises a hydrophilic polymer backbone (e.g., poly(L)lysine), a hydrophobic fluorophore, and a hydrophilic solubilizing agent. The solubilizing agent may comprise a quarternary ammonium... Agent: Fulbright & Jaworski L.L.P.

20100278746 - Method for measuring neurotransmitters in vivo: A method is provided for in vivo detection of a biochemical substance in an animal by culturing neurofluocytes that stably express a receptor of the biochemical substances by transfecting cells with cDNA of the receptor and a tag that will emit a detectable energy in the presence of the biochemical... Agent: Procopio, Cory, Hargreaves & Savitch LLP

20100278753 - Device and method for the diagnosis of gastrointestinal allergy: A method and device for the diagnosis of gastrointestinal allergy. The method and the device expose a surface to at least one antigen at a fixed depth. The device includes an application point each having an antigen allowing for the application of the antigen to the surface at a fixed... Agent: Factor & Lake, Ltd

20100278752 - Methods for detection and prevention of tick infestation and pathogen transmission: The invention generally features methods for the prevention and detection of a tick infestation. The present invention also features methods for decreasing the ability of a tick to feed on a subject.... Agent: University Of Rhode Island Division Of Reasearch And Economic Development

20100278754 - Orally disintegrating tablets with speckled appearance: Orally disintegrating tablets containing colored granules of a water-soluble sugar which give them a speckled appearance are described. The orally disintegrating tablets with speckled appearance are readily and easy identifiable by physicians, nurses and patients.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100278755 - Composition containing p-menthane-3, 8-diol and its use as insect repellant: An economical and simple method of producing para-menthane-3,8-diol in relatively high yield is disclosed. The product is useful as a repellent against noxious insects and other arthropods.... Agent: Goodwin Procter LLP Patent Administrator

20100278756 - Peptides having activities of insulin like growth factor-1 and their uses: The present invention relates to a peptide having the activity of insulin like growth factor-1 (IGF-1) and derived from IGF-1, a composition for improving skin conditions or treating a periodontal disease comprising the peptide. The IGF-1 mimicking peptides of this invention have identical functions or actions to natural-occurring IGF-1 and... Agent: The Nath Law Group

20100278757 - Water-absorbent adhesive compositions and associated methods of manufacture and use: An adhesive composition is provided that is water-insoluble yet water-absorbent, i.e., capable of absorbing up to 15 wt. % water or more. The composition is composed of a film-forming hydrophilic polymer with at least one linear segment having a plurality of recurring polar groups along the polymer backbone, a complementary... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100278758 - Gel for teeth tissues remineralization: Technical result of the invention is achieved by practical use of effective remineralizing formulation containing accessible components, which can be used by a patient without any help for caries prophylaxis, non-carious affections treatment, teeth hypersensitivity treatment and teeth visual appearance (color and gloss) improvement. The problem specified is solvable by... Agent: Brooks Kushman P.C.

20100278764 - Cosmetic and/or pharmaceutical composition comprising at least one copolymer comprising at least one ionizable group, and cosmetic treatment process: Disclosed herein is a cosmetic and/or pharmaceutical composition comprising, in a physiologically acceptable medium, at least one (co)polymer comprising a polymer backbone and at least one junction group linked to the polymer backbone and capable of establishing H bonds with at least one partner junction group, each pairing of a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100278760 - Cosmetics: The cosmetic of the present invention is a cosmetic that alleviates skin irritation by blending in polypropylene glycol, a specific polar oil, or polybutylene glycol, as well as an ultraviolet absorbent. The present invention also relates to an agent and a method for alleviating irritation by lipophilic drugs. Since the... Agent: Townsend & Banta C/o Portfolio Ip

20100278762 - Long-acting, waterproof or water-resistant, topical sun protection agent with activity up to weeks: Disclosed herein are compositions for use as a sunscreen or sunblock which, in some embodiments, may provide long-acting, waterproof or water-resistant, broad spectrum topical sun protection with activity up to weeks without reapplication. In some embodiments, the compositions may include a base and one or more active ingredients. In some... Agent: Louis C. Paul Louis C. Paul & Associates, PLLC

20100278761 - Method of making up with a light-sensitive makeup, and a light-sensitive makeup composition: s

20100278759 - Topical therapeutic delivery system: The present invention relates to an oil-in-water emulsion topical delivery system comprising an oil phase; an aqueous phase; phenoxyethanol; an effective exfoliatingamount of a hydrophobic hydroxycarboxylic acid; a non-ionic emulsifier having an HLB of from about 7 to about 10; and at least one skin-supporting ordermatopharmaceutically active agent.... Agent: Townsend And Townsend And Crew, LLP

20100278763 - Water-soluble or water-swellable polymers on the basis of salts of acryloyldimethyltaurine acid or the derivatives thereof, the production thereof and the use thereof as thickener, stabilizer and consistency agents: where R1 and A are R1 and A from formula (1) and X+ is [HNR5R6R7]+, where R5, R6 and R7 can independently from each other be hydrogen, a linear or branched alkyl group with 1 to 22 carbon atoms, a linear or branched, simple or polyunsaturated alkenylene group with 2... Agent: Clariant Corporation Intellectual Property Department

20100278765 - Regulation of mammalian keratinous tissue using hexamidine compositions: In additional embodiments, the above composition is suitable for preventing, retarding, and/or treating dark under-eye circles, puffy eyes, sagging, sallowness as well as spider vessels and/or red blotchiness of skin, promoting skin desquamation, exfoliation, and/or turnover, regulating and/or reducing pore size appearance, preventing/retarding tanning, regulating oily/shiny appearance, preventing, retarding, and/or... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100278766 - Nitrocellulose-free nail polish compositions: The present invention relates to a nail polish composition, comprising at least one high gloss film forming agent chosen from an esterified styrene maleic anhydride copolymer, a non-esterified styrene maleic anhydride copolymer and mixtures thereof, at least one co-film forming agent chosen from an epoxy resin, optionally, at least one... Agent: L'oreal Usa Patent Department

20100278767 - Lightening agents and/or dyes that contain aldehyde(s): wherein each of R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 independently represents —H or —CN or —F or —Cl or —Br or —I or —CHO or —NH2 or —NO2 or —CF3 or —CCl3 or —CF2CF3 or —CCl2CCl3 or an optionally substituted (C1-C6) alkyl group or a... Agent: Connolly Bove Lodge & Hutz LLP

20100278768 - Compounds and methods for inhibiting axillary malodour: Enzymes mediating in the release of compounds characteristic of human malodour and in particular axillary malodour, and compounds that inhibit said enzymes having the general formula (I)... Agent: Parfomak, Andrew N. Norris Mclaughlin & Marcus Pa

20100278769 - Hair care compositions and methods of treating hair: The present invention provides compositions, kits and methods for treating scalp hair. The compositions include fluorinated (but not perfluorinated), non-polymeric compounds in a suitable excipient to provide beneficial effects on hair.... Agent: Fitzpatrick Cella Harper & Scinto

20100278770 - Wax-in-water emulsion comprising a combination of a glutamic acid derivative and an alkylpolyglycoside: The present invention relates to a composition for coating keratin fibres, more particularly the eyelashes, characterized in that it is present in the form of a wax-in-water emulsion comprising a combination of at least one glutamic acid derivative and/or salt thereof and at least one alkylpolyglycoside.... Agent: Oliff & Berridge, PLC

20100278771 - Optically clear biofouling resistant compositions and methods for marine instruments: An optically clear biofouling resistant coating compositions specially formulated for very high light transmission and more particularly coating compositions which can be applied to marine instruments and sensors. The compositions provide a biofouling resistant coating on the surface of the marine instruments and sensors which prevents underwater organisms from adhering... Agent: Dobe Law Group, LLC

20100278773 - Chimeric flavivirus vaccines: A chimeric live, infectious, attenuated virus containing a yellow fever virus, in which the nucleotide sequence for a prM-E protein is either deleted, truncated, or mutated, so that functional prM-E protein is not expressed, and integrated into the genome of the yellow fever virus, a nucleotide sequence encoding a prM-E... Agent: Clark & Elbing LLP

20100278772 - Dna methylation markers and methods of use: The present invention provides methods for identifying metastases by detecting nucleic acid hypermethylation of one or more genes in one or more samples, and in particular in the lymph nodes. The invention further relates to DNA methylation as a predictor of disease recurrence and patient prognosis, specifically in the field... Agent: Edwards Angell Palmer & Dodge LLP

20100278774 - Fusion molecules and il-15 variants: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.... Agent: Edwards Angell Palmer & Dodge LLP

20100278778 - Method for bone marrow preservation or recovery: Methods for enhancing or stimulating hematopoiesis including the step of administering Interleukin-12 (IL-12) to yield hematopoietic recovery in a mammal in need. Preferred methods include the step of administering IL-12 as an adjuvant therapy to alleviate the hematopoietic toxicities associated with one or more treatment regimens used to combat a... Agent: Foley & Lardner LLP

20100278777 - Method for treating deficiency in hematopoiesis: Methods for enhancing or stimulating hematopoiesis including the step of administering Interleukin-12 (IL-12) to yield hematopoietic recovery in a mammal in need. Preferred methods include the step of administering IL-12 as an adjuvant therapy to alleviate the hematopoietic toxicities associated with one or more treatment regimens used to combat a... Agent: Foley & Lardner LLP

20100278779 - Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine: Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine.... Agent: Jones Day

20100278776 - Pharmaceutical compositions for modulating a kinase cascade and methods of use thereof: The invention relates to a pharmaceutical composition comprising 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100278775 - Plant bioreactor for the production of interleukin-24 cytokine: The production of interleukin-24 (IL-24) cytokine in plants is described. A plant optimized nucleic acid molecule encoding a IL-24 polypeptide is disclosed. Also described are genetic constructs comprising a regulatory region operably linked to a plant optimized nucleic acid molecule encoding a IL-24 polypeptide. The regulatory region may be an... Agent: Schwegman, Lundberg & Woessner, P.A.

20100278780 - Grass endophyte enhanced attributes: Described is the method and use of AR584 endophyte (AGAL deposit no. NM98/04676 dated 12 May 1998) or variations in endophyte as exemplified by AR584, to produce a grass cultivar and AR584 combination wherein the plant or a part thereof produced by the combination retains viable AR584 endophyte after treatment... Agent: Knobbe Martens Olson & Bear LLP

20100278791 - Adeno-associated virus serotype i nucleic acid sequences, vectors and host cells containing same: The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors.... Agent: Howson & Howson LLP

20100278790 - Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage: The present invention provides compositions comprising mesenchymal stem cells (MSCs), and methods for their novel use in the repair of cardiac damage and treatment of inflammatory diseases. The invention also provides methods for using TSG-6 protein that is secreted by MSCs under certain conditions, for repair of cardiac damage and... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100278792 - Method of enhancing proliferation and/or hematopoietic differentiation of stem cells: The present invention provides a method for enhancing the proliferation and/or hematopoietic differentiation and/or maintenance of mammalian stem cells. The method is useful for generating expanded populations of hematopoietic stem cells (HSCs) and thus mature blood cell lineages. This is desirable where a mammal has suffered a decrease in hematopoietic... Agent: David S. Resnick

20100278781 - Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide: An infant and/or toddler nutrition comprising non-viable Bifidobacterium breve and a non-digestible oligosaccharide and its use are disclosed.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100278793 - Treatment of greasy skin with a bacterial lystate: The present invention relates to the cosmetic treatment of greasy skin and/or skin that tends to be greasy with a lysate of at least one microorganism of the genus Bifidobacterium species and/or a fraction thereof, as an active.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100278794 - Agent for promoting the secretion of and/or suppressing decrease of adiponectin: An agent for promoting the secretion of adiponectin and/or suppressing decrease of adiponectin, a food or beverage for promoting the secretion of adiponectin and/or suppressing decrease of adiponectin, and a feed, each of which comprises a culture supernatant of Lactobacillus gasseri SBT2055 (FERM BP-10953) as an active ingredient.... Agent: Greenblum & Bernstein, P.L.C

20100278795 - Lactic acid bacterium-containing preparation: An object of the present invention is to provide a useful composition that contains a highly safe lactic acid bacterium or a component derived from this lactic acid bacterium. The present invention relates to a composition comprising at least one lactic acid bacterium selected from the group consisting of Lactobacillus... Agent: Connolly Bove Lodge & Hutz LLP

20100278796 - Method for improving the digestibility and the assimilability of cereals and/or fibres in a monogastric herbivorous animal: The invention relates to a method for improving the digestibility and assimilability of fibres and/or cereals in a monogastric herbivorous animal comprising the step of administering to said monogastric herbivorous animal an effective amount of at least one strain of bacterium selected fromselected from the group consisting of strains of... Agent: Mcandrews Held & Malloy, Ltd

20100278787 - Cardiomyocyte-like cell clusters derived from hbs cells: A cluster is provided comprising cardiomyocyte-like cells, wherein the cluster has i) contracting cells, ii) cells that are electrically connected, and expresses iii) cardiac markers including Nkx.2.5, troponin and myosin, iv) markers for functional adrenergic receptors, v) markers for functional muscarinic receptors, vi) markers for functional ion-channels including hERG, Na+,... Agent: Buchanan, Ingersoll & Rooney PC

20100278782 - Differentiation of rat liver epithelial cells into hepatocyte-like cells: Methods for differentiation of cells of a rat liver epithelial (RLEC) cell line to hepatocyte-like cells are disclosed. In particular, methods involve sequential exposure of the RLEC to two or more differentiation agents. Cells obtained by the method are described as well as their uses in various pharmacological, toxicological, therapeutic,... Agent: Knobbe Martens Olson & Bear LLP

20100278785 - Injection device for injection into biological tissue and injection depot: An injection device (100), provided for injection with an injection syringe (50) into an organism (1), comprises a guide device (10) designed to receive the injection syringe (50), wherein an injection needle (51) and a syringe body (52) of the injection syringe (50) can be moved relative to the guide... Agent: Duane Morris LLP - PhiladelphiaIPDepartment

20100278783 - Method of preparing autologous cells and method of use for therapy: A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium which can be used in a clinical setting, and a business method for performing such expansions in the future as a service for patients. A method for expanding mesenchymal cells derived from autologous bone marrow... Agent: Crockett & Crockett, P.C.

20100278784 - Methods and compositions for treating skin conditions: The invention features methods, kits, and compositions for treating aging-related skin conditions (e.g., wrinkles), pigmentation disorders, acne, and scar formation, as well as methods, kits, and compositions for preventing scar formation.... Agent: Clark & Elbing LLP

20100278789 - Methods of generating expanded and re-differentiated adult islet beta cells capable of producing insulin: A method of increasing insulin content in adult islet beta cells is disclosed. The method comprises contacting the adult islet beta cells with an agent capable of down-regulating activity and/or expression of at least one component participating in a NOTCH pathway, the component being up-regulated in beta cell dedifferentiation above... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100278788 - Osteogenic differentiation of bone marrow stem cells and mesenchymal stem cells using a combination of growth factors: The invention relates to methods for osteogenic differentiation of human bone marrow stem cells (BMSC) or mesenchymal stem cells (MSC), in particular using human plasma or serum and FGF and TGFB growth factors. The invention also provides the so-obtained cells and cell populations, as well as further products comprising such... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100278786 - Use of the opposite cell differentiation program (ocdp) for the treatment of degenerated organs in the pathological state: The present invention relates to a method for the treatment of organs which are degenerative and/or in the pathological state by means of the use of cells, which are phenotypically stably differentiating or differentiated but not necessarily ultimately predetermined with respect to development, from a donor organ selected according to... Agent: Schwegman, Lundberg & Woessner, P.A.

20100278799 - Composition for improving nutritional status, reducing frequency of fever and/or increasing immunocompetence of the elderly: Provided is a composition for improving the nutritional status, reducing the frequency of fever, and/or increasing the immunocompetence of the elderly. The composition is one for improving the nutritional status, reducing the frequency of fever, and/or increasing the immunocompetence of the elderly and comprises the following components (a) to (e):... Agent: Hogan Lovells US LLP

20100278798 - Methods and systems for forming biocompatible materials: Methods and systems forming biocompatible materials are disclosed herein. Forming a biocompatible material may include contacting a liquid, having a linking material, with an adjoining material having embedded therein a nucleating material that causes the linking material to nucleate and grow into the liquid. After a time sufficient to cause... Agent: Miles & Stockbridge PC

20100278797 - Pharmaceutical composition and method for regulating abnormal cellular proliferation: A method of treating a disease associated with a cell population which proliferates abnormally in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of at least one modulator capable of modulating in the cell population a level and/or activity of a polypeptide having... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100278801 - Compositions comprising optimized her1 and her3 multimers and methods of use thereof: The invention provides for compositions comprising engineered Her3 multimers with improved binding affinity. Such multimers include, but are not limited to, Her1/Her 3 heterodimers in which the Her3 ligand binding domain has been optimized to increase binding to Her3. The composition also can include mixtures of Her 1 homodimers, Her... Agent: Morrison & Foerster LLP

20100278802 - Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof: The present invention is directed to phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention provides compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as... Agent: Jones Day

20100278800 - Stem cell factor-like proteins and uses thereof: The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor SCFA2, SCFA4 or SCFA4v polynucleotides and polypeptides. The invention further relates to the therapeutic use of SCFA2, SCFA4 or SCFA4v to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa.... Agent: Fulbright & Jaworski L.L.P.

20100278803 - Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation: A method of diagnosing Alzheimer's disease in a patient comprises determining whether the phosphorylation level of an indicator protein in cells of the patient after stimulus with an activator compound is abnormally elevated as compared to a basal phosphorylation level, the indicator protein being e.g. Erk1/2 and the activator compound... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20100278804 - Methods and formulations for modulating lyn kinase activity and treating related disorders: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder... Agent: Pepper Hamilton LLP

20100278805 - Compositions for inhibiting atherosclerosis: The present invention relates to compositions and methods for the reduction of atherosclerotic plaques and the decrease in the level of total serum cholesterol, triglycerides, serum LDL cholesterol, and serum HDL cholesterol.... Agent: Baker Botts L.L.P.

20100278806 - Composition containing arazyme for the prevention and treatment of arthritis: Disclosed herein is a composition containing arazyme as an active ingredient for prevention and treatment of arthritis. More specifically, arazyme produced from Aranicola proteolyticus of the present invention may be useful as a composition for prevention and treatment of arthritis by inhibiting the expression of TNF-α which is an inflammation-inducing... Agent: Greenlee Sullivan P.C.

20100278809 - Inhibitors of mrp4 for the treatment of vascular disorders: The invention relates to inhibitors of MRP4 for the treatment and/or the prevention of vascular disorders such as atherosclerosis, post-angioplasty restenosis, pulmonary arterial hypertension or vein-graft disease.... Agent: Mcandrews Held & Malloy, Ltd

20100278810 - Methods of modulating angiogenesis: The present invention provides methods of modulating angiogenesis in an individual, the methods generally involving administering to an individual an agent that modulates the expression or activity of GPR124. In one embodiment, the methods of the invention relate to inhibiting pathological angiogenesis by decreasing activity of GPR124, which method may... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20100278812 - Nasal immunization: Compositions and methods for intranasal delivery of antigens for immunization of a mammal are disclosed. Antigens include, peptides, proteins, peptidomimetics, DNA, RNA, carbohydrates and phospholipids. The compositions contain at least one antigen and a permeation enhancer.... Agent: Axinn, Veltrop & Harkrider LLP Attn. Michael A. Davitz

20100278807 - Novel antimicrobial agents: A novel class of antimicrobial polymeric agents which are designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance thereto and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and a method of treating medical conditions associated with pathological microorganisms,... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100278808 - Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods: The invention provides a polypeptide containing at least one IgG Fc region region, said polypeptide having a higher anti-inflammatory activity and a lower cytotoxic activity as compared to an unpurified antibody and methods of production of such polypeptide.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20100278811 - Vasculostatic agents and methods of use thereof: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other... Agent: Goodwin Procter LLP Patent Administrator

20100278818 - Antibody specific for the tn antigen for the treatment of cancer: The instant application provides a pharmaceutical composition comprising an antibody, directed against Tn antigen which comprises CDRs derived from 83D4 monoclonal antibody or an immunoconjugate of said antibody, said pharmaceutical composition being intended for the treatment of cancer.... Agent: Thompson Coburn LLP

20100278816 - B7-dc binding antibody: An antibody capable of potentiating immune responses and modifying existing states of immune responsiveness is described, as is the sequence of the antibody. Also described are compositions containing the antibody, as well as methods for using the antibody and the compositions to enhance immune responses, to enhance DC function, to... Agent: Fish & Richardson P.C.

20100278824 - Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer:

20100278817 - Compounds and methods for the treatment of renal disease: The present invention provides compounds and methods for the treatment and prophylaxis of renal disease and inflammation. In particular the invention provides methods for the treatment of kidney disease and failure through the administration of compounds which function as inhibitors of TLR2 function and expression.... Agent: Wolf Greenfield & Sacks, P.C.

20100278815 - Humanized monoclonal antibodies to hepatocyte growth factor: The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.... Agent: Townsend And Townsend And Crew, LLP

20100278825 - Mammalian receptor proteins; related reagents and methods: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.... Agent: Merck C/o Dnax

20100278813 - Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies: The present invention relates to methods for broad spectrum prevention and treatment of viral respiratory infection. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with respiratory syncytial virus (RSV), parainfluenza virus (PIV), and/or human metapneumovirus (hMPV) infection, the methods comprising administering to a... Agent: Jones Day

20100278821 - N-cadherin: target for cancer diagnosis and therapy: The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers according to their expression of N-cadherin, including prostrate and bladder cancers.... Agent: Townsend And Townsend And Crew, LLP

20100278814 - Prevention and treatment of synucleinopathic and amyloidogenic disease: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic... Agent: Townsend And Townsend And Crew, LLP

20100278820 - Reagents that bind ccx-ckr2: Antibodies that bind to CCX-CKR2 and methods of their use are provided.... Agent: Townsend And Townsend And Crew, LLP

20100278822 - Stable high protein concentration formulations of human anti-tnf-alpha-antibodies: The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics... Agent: Cristin Howley Cowles, Ph.d., J.d. Mccarter & English, LLP

20100278819 - Streptococcus pneumoniae vaccines: Streptococcus pneumoniae is a major cause of pneumoniae, meningitis, and major cause of morbidity and mortality throughout the world by bacterial otitis media, pneumoniae, meningitis, and bacteraemia. It is an important agent of disease in man especially among infants, the elderly and immunocompromised persons. The present invention provides a solution... Agent: Dinsmore & Shohl LLP

20100278823 - Treatment of type 1 diabetes before and after expression of predisposition markers: The present invention relates generally to the use of compounds, compositions, combinations, kits, and methods for the effective endocytic presentation of immunosuppressive factors for the down regulation of diabetogenic T cells for the treatment of type 1 diabetes.... Agent: K&l Gates LLP

20100278827 - Concatameric immunoadhesion molecule: Disclosed are concatameric proteins comprising two soluble domains, in which the C-terminus of a soluble domain of a biologically active protein is linked to the N-terminus of an identical soluble domain or a distinct soluble domain of a biologically active protein. Also, the present invention discloses dimeric proteins formed by... Agent: Greenblum & Bernstein, P.L.C

20100278826 - Designer ubiquitin ligases for regulation of intracellular pathogenic proteins: The present invention relates to a designer or recombinant ubiquitin ligase molecule that includes an antibody fragment that is specific for a toxin active fragment, wherein the toxin active fragment is an enzymatically active fragment of one or more toxins or toxin serotypes; and an E3-ligase domain that comprises an... Agent: Antoinette G. Giugliano, P.C. Dba Agg Intellectual Property Law

20100278828 - Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases: Compositions and methods are disclosed which are useful for the treatment and prevention of proliferative disorders, and which comprise an anti-CTLA4 antagonist with a tubulin modulating agent.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100278829 - Dual inhibition of immunophilin/cyclophilin family members and emmprin immunoglobulin receptor superfamily members: The present disclosure provides methods and compositions for modulating an adaptive immune response without significantly affecting an innate immunity response in a subject by modulating a combination of an Immunophilin/Cyclophilin Family Member and an EMMPRIN Immunoglobulin Receptor Superfamily Member. The present invention also provides methods and compositions for treating a... Agent: Perkins Coie LLP

20100278830 - Methods and systems for multi-antibody therapies: The present invention relates to methods and systems for administering antibody therapeutic agents. The methods include administering one or more (e.g., two or three) binding agents, wherein each of the binding agents has a binding region that is specific to a portion of a disease agent and one or more... Agent: Antoinette G. Giugliano, P.C. Dba Agg Intellectual Property Law

20100278831 - Nogo receptor-mediated blockade of axonal growth: Disclosed are NgR proteins and biologically active Nogo (ligand) protein fragments. Also disclosed are compositions and methods for modulating the expression or activity of the Nogo and NgR protein. Also disclosed are peptides which block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100278832 - Anti-bst2 antibody: BST2 antibodies were selected by using as an indicator the binding between BST2 antibodies and various splicing variants of human BST2 antigen. As a result, the present inventors successfully obtained BST2 antibodies that specifically recognize BST2D, which has been reported to be expressed at high levels in cancer cells. The... Agent: Foley & Lardner LLP

20100278833 - Thiophene-imidazopyridines: The invention relates to thiophene-imidazopyridine compounds according to formula (I), wherein the substituents and symbols are as defined in the description. The compounds are inhibitors of PIk1.... Agent: Millen, White, Zelano & Branigan, P.C.

20100278834 - Antibodies against h5n1 strains of influenza a virus: Provided are human antibodies that can neutralize a H5N1 strain of influenza A virus. Also provided are antibodies that can neutralize a strain of influenza A virus in clade 2 of the H5 subtype, that can neutralize a H5N1 strain of influenza A virus and have a lambda light chain,... Agent: Global Patent Group - Hmb

20100278835 - Novel compounds 660: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined in the specification, and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are... Agent: Astrazeneca R&d Boston

20100278836 - Diagnostic and therapeutic methods and compositions for cardiovascular disease: Low levels of antibodies reactive with a PAF-conjugate are related to an increased risk of developing cardiovascular diseases. Thus, compositions and methods of diagnosis and therapy for cardiovascular diseases are provided.... Agent: Fulbright & Jaworski L.L.P.

20100278839 - Antibodies against nerve growth factor (ngf) with enhanced in vivo stability: The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for... Agent: Paul D. Yasger Abbott Laboratories

20100278837 - Compositions and methods for reducing cancer and inflammation: This invention relates to the discovery of the convergence of diverse receptors and signaling pathways on the PI3gamma dependent activation of VLA4 (integrin a4b1). In particular, the invention relates to the role of myeloid cells in tumor inflammation and metastasis. The invention provides methods for inhibiting cancer in a subject... Agent: Peter G. Carroll Medlen & Carroll, LLP

20100278838 - Epha2 monoclonal antibodies and methods of use thereof: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and agonizes EphA2, thereby increasing EphA2 phosphorylation and... Agent: Medimmune, LLC Patrick Scott Alban

20100278840 - Methods for treating rheumatoid arthritis using il-17 antagonists: A method of treating a mammal afflicted with rheumatoid arthritis comprising administering a soluble form of IL-17 receptor is disclosed.... Agent: Immunex Corporation Law Department

20100278842 - Anti-ephb2 antibodies and methods using same: The invention provides anti-EphB2 antibodies, immunoconjugates, and compositions comprising and methods of using these antibodies and immunoconjugates.... Agent: Genentech, Inc.

20100278841 - Down-regulation of mortalin by sirna: Use of a siRNA molecule selected from the group consisting of SEQ ID NO: 173 to 344 for treating a disease associated with a pathological cell population in a subject in need thereof is disclosed. Pharmaceutical compositions and articles of manufacture comprising the siRNAs are also disclosed.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100278843 - Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity: The invention relates to a method and novel types of agents for modulating appetite and/or body weight in a subject. Moreover, the invention relates to a method of screening for agents which interact and modulate the activity of the receptor complex for macrophage inhibitory cytokine-1 (MIC-1).... Agent: Nixon & Vanderhye, PC

20100278844 - Cancer marker and therapeutic target: Chemokine receptor CCR4 and its ligands CCL1 7 and CCL22 are used as markers for the identification and/or staging of cancer. The level of CCR4, CCL17 and CCL22 are found to increase during malignant tumour progression. CCR4, CCL17 and CCL22 are used as markers for the stratification of cancer patients... Agent: Townsend And Townsend And Crew, LLP

20100278845 - Melanocortin receptor binding conjugates: The present invention relates to melanocortin receptor binding conjugates and methods of making and using the foregoing.... Agent: Philip S. Johnson Johnson & Johnson

20100278847 - Mutually suppressive gene/inhibitor combinations for non-antibiotic selection of recombinant strains: This invention relates to vector sequences that express growth inhibitory levels of essential genes used in combination with inhibitors that target the same gene. An example given is the use of the gene encoding the fatty acid biosynthesis enzyme enoyl-ACP reductase used in combination with the antimicrobial triclosan. The expression... Agent: Morse, Barnes-brown & Pendleton, P.C. Attn:IPManager

20100278846 - Nasal-administered vaccines using multi-screened nalt-targeting and phagocytic polypeptide transport sequences: Multiple sequential screening tests have been performed on phage display libraries, and polypeptide sequences have been identified that potently drive both: (i) intake into mucosal immune cells, including NALT cells in the nose and throat; and, (ii) phagocytic intake and processing by antigen-presenting cells, such as macrophages. Such polypeptide sequences... Agent: Patrick D. Kelly

20100278851 - Ctl inducer composition: The present invention provides a CTL inducer composition which comprises one or more peptides selected from the group consisting of the peptides of SEQ ID NOS: 1 to 27 in the Sequence Listing, and can be used for the treatment or prevention of cancer or a hepatitis C virus-related disease... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100278850 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.... Agent: Fulbright & Jaworski, LLP

20100278849 - Prostatic acid phosphatase antigens: The invention relates to peptides from Prostatic Acid Phosphatase (PAP), especially those identified as PAP.135 and PAP.161. The nucleic acid molecules encoding the peptides, antibodies against the peptides, and the use of such peptides, nucleic acids and antibodies in immunotherapy, vaccines and assays are also included in the scope of... Agent: Barnes & Thornburg LLP

20100278848 - Tumor antigen bfy3 for prevention and/or treatment of cancer: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of... Agent: Patrick J. Halloran, Ph.d., J.d

20100278852 - Antibodies against and methods for producing vaccines for respiratory syncytial virus: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The... Agent: Medimmune, LLC Patrick Scott Alban

20100278853 - Constrained hiv v3 loop peptides as novel immunogens and receptor antagonists: The present invention provides constrained peptides and other organic molecules, that mimic the three dimensional characteristics of the HIV-1 V3 loop peptide when bound by a highly potent human neutralizing monoclonal antibody specific for a V3 conformational epitope, which structure is determined by NMR. Methods for screening for, and designing... Agent: Shmuel Livnat Mckenna Long & Aldridge LLP

20100278854 - Chlamydia antigens: Chlamydia antigens (e.g., polypeptides, polypeptide fragments, and fusion proteins) are provided. Also provided are vaccines and pharmaceutical compositions for treating or preventing a bacterial infection, such as Chlamydia, in a subject.... Agent: Clark & Elbing LLP

20100278855 - Neuroprotective ganoderma compositions and methods of use: The subject invention provides methods for treatment of degenerative neurological disorders such as Parkinson's disease and Alzheimer's disease comprising administration of a Ganoderma lucidum extract. The subject invention also provides a method for inhibiting the activation of microglial cells by applying the Ganoderma lucidum extract to the cells.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100278856 - Bont/a peptides and methodsof predicting and reducing immunoresistance to botulinum toxin therapy: The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.... Agent: Allergan, Inc.

20100278857 - Dendritic cell binding proteins and uses thereof: The present invention provides novel peptides which specifically targets and binds to dendritic cells. Also provided are fusion compositions comprising these peptides and a non-dendritic protein of fragments thereof. Further provided are DNA sequences encoding these peptides and fusion compositions. Methods of using the peptides or fusion compositions to promote... Agent: Benjamin Aaron Adler Adler & Associates

20100278859 - Diagnostic test kits: This invention provides kits, devices, and methods for the detection of antibodies that recognize one or more proteins and/or antigens from porcine reproductive and respiratory syndrome virus (PRRSV). The antibodies may be in a biological fluid of a PRRSV infected or at risk subject. The invention may be advantageously applied... Agent: Patentique PLLC

20100278858 - Process for preparing attenuated viral strains: i

20100278860 - System and method for identifying complex patterns of amino acids: A method and system are disclosed for identifying and/or locating complex patterns in an amino acid sequence stored in a computer file or database. According to an aspect of the present invention, techniques are provided to facilitate queries of protein databases. For protein descriptions received in response to the queries,... Agent: Kenyon & Kenyon LLP

20100278861 - Methods and compositions for predicting emergence and expansion of drug resistant strains of influenza virus: The instant invention provides methods for determining, predicting and characterizing the genetic variability, emergence and expansion of viruses, in particular, influenza. Accordingly, the invention provides methods for identifying virulent pathogens, genetic mutations within pathogens that are relevant to animal health, and methods and compositions for prophylactic or therapeutic intervention against... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100278862 - Nipah virus vaccines: The present invention relates to recombinant anti-Nipah virus vaccines and the administration of such vaccines to animals, advantageously pigs. Advantageously, the anti-Nipah virus vaccine may comprise a recombinant avipox virus containing a Nipah virus glycoprotein gene. The invention encompasses methods of vaccinating animals, advantageously pigs, by administration of anti-Nipah virus... Agent: Judy Jarecki-black, Ph.d,j.d

20100278863 - Reoviruses: The present invention provides a reverse genetics system for viruses belonging to the Reoviridae (i.e. Reoviruses), various uses thereof, genetically modified Reoviruses, Reovirus selection/production and propagation systems, medicaments and vaccines.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100278864 - Rabies vaccine: An attenuated rabies virus for use as a live vaccine. The attenuated rabies virus expresses an immune factor that enhances immune response upon administration of the live vaccine.... Agent: Mueting, Raasch & Gebhardt, P.A.

20100278865 - Production and use of epitope-tagged hepatitis c virus particle: This invention relates to a nucleic acid comprising a nucleic acid sequence encoding an epitope tag peptide in the hypervariable region 1 of the E2 protein of naturally occurring or chimeric hepatitis C virus (HCV) genome, an epitope-tagged HCV particle encoded by such nucleic acid, and a method for purifying... Agent: Birch Stewart Kolasch & Birch

20100278866 - Borrelia diagnostics and screening methods: Compositions and methods of detecting Borrelia proteins, nucleic acid sequences encoding these proteins, and subject antibodies to these proteins in a sample are disclosed.... Agent: Casimir Jones, S.c.

20100278868 - Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b, and methods of use thereof: In one aspect, the invention provides a DNA molecule. The DNA molecule includes a nucleotide sequence that encodes the receptor-binding domain of Clostridium difficile toxin A or toxin B in which at least about 10% of the in-frame codons for each amino acid residue has a higher percentage use in... Agent: Irving N Feit Hoffman & Baron

20100278867 - Use of botulinum toxin for the treatment of chronic facial pain: The present invention includes a method of treating pain caused by neuralgia comprising administering botulinum toxin to an afflicted area of a patient. The pain may be caused by trigeminal neuralgia or be associated with dental extraction or reconstruction, and may be facial pain. The neuralgia may be associated with... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20100278869 - Plant produced vaccine for amebiasis: Disclosed herein are methods of making a vaccine against Entamoeba histolytica and methods of immunizing a subject using such vaccine. Specifically exemplified are plants expressing a LecA polypeptide and plant material obtained from such plant being used as a basis for vaccination... Agent: Timothy H. Van Dyke

20100278870 - Adenoviral vector-based malaria vaccines: The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum circumsporozoite... Agent: Leydig Voit & Mayer, Ltd

20100278871 - Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein: Novel nucleic acid vectors comprising sequences encoding (a) an antigen, (b) a signal peptide, and (c) a heat shock protein, are disclosed, as are methods for using such vectors to induce antigen-specific immune responses and to treat tumors.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100278872 - Medicaments and methods for treating mesothelioma: The present invention relates to the use of at least one attenuated measles virus for the manufacture of a medicament intended for treating malignant mesothelioma in an individual.... Agent: Michael Best & Friedrich LLP

20100278874 - Reagents and methods for cancer treatment and prevention: The invention generally relates to the prevention and/or treatment of cancer, and, more specifically, to the treatment of tumors, including solid tumors and their metastases, without radiation or standard chemotherapeutic agents. In one embodiment, the invention involves a method comprising: a) providing a subject with tumor cells, b) removing at... Agent: Morrison & Foerster LLP

20100278873 - Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28: The invention is concerned with fusions of dendritic cells and with tumor or cancer cells. Also provided are methods of making and using these cell fusions, including methods of adoptive immunotherapy as well as methods of stimulating anti-tumor immunity using fused cells and anti-CD3/CD28 antibodies.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100278875 - Prostaglandin e2 (pge2) as an adjuvant in monoclonal antibody generation: The present invention provides PGE2 as a novel adjuvant for enhancing the immune response in a host, as well as methods of using PGE2 to enhance B cell response and thereby increasing antibody titer against a given immunogen are also disclosed and antibodies produced by at least one method of... Agent: Philip S. Johnson Johnson & Johnson

20100278877 - Body tissue filling material and method for production thereof: There are provided a body tissue filling material having excellent engraftability and repairability, and a method for producing such a body tissue filling material in a simple manner. Specifically disclosed are: a body tissue filling material comprising a gelatin porous carrier, to the surface of which a coating having sulfated... Agent: Scully Scott Murphy & Presser, PC

20100278876 - High-solid antifouling paint composition, antifouling coating film, base material with coating film, antifouling base material, method for forming coating film on surface of base material, antifouling method for base material, and high-solid multi-package: The high-solid antifouling paint composition of the present invention provides an antifouling coating film that imposes less environmental burden, affects human bodies less, and has excellent antifouling performance, excellent persistence thereof and excellent mechanical strength.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100278880 - Pharmaceutical formulation for allergen preparation: Method for the production of a purified extract of natural allergens comprising the steps of extracting a natural source of allergens comprising allergenic proteins, purifying of said extract to remove non-protein components denaturating said purified extract, said purified denaturated extract comprising proteins, wherein the most abundant (w/w) proteins, forming together... Agent: Dardi & Herbert, PLLC

20100278878 - Quetiapine salts and their polymorphs: The present invention relates to novel and stable salt forms of quetiapine, processes for preparation, pharmaceutical compositions, and method of treating thereof. More particularly, the present invention provides novel acid addition salts of quetiapine wherein the acid counter ion is provided by an acid selected from the group consisting of... Agent: Cantor Colburn, LLP

20100278879 - Stable pharmaceutical composition and methods of using same: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.... Agent: K&l Gates LLP

20100278881 - Use of calcitonin in osteoarthritis: The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans.... Agent: Novartis Corporate Intellectual Property

20100278885 - C70-containing liposome, method for producing the same, and use of the same: A solution containing a C70 cyclodextrin complex and a solution containing a lipid that is capable of forming a liposome are mixed together at a temperature in a range of 10° C. to 45° C. This produces a C70-incorporated liposome which keeps a physical property that the C70 fullerene originally... Agent: Frost Brown Todd, LLC

20100278888 - Composition for cosmetic raw material containing cellulose dyed with natural coloring matter having improved photostability, and visual carrier system comprising the same: The present invention relates to a composition for cosmetic raw material containing cellulose dyed with a natural coloring matter having improved photostability, and a visual carrier system comprising the same. In the composition for cosmetic raw material and the visual carrier system comprising the same according to the present invention,... Agent: Ipla P.A.

20100278886 - Personal care dissolvable films: Personal care dissolvable films comprising a water soluble film forming agent, cosmetically acceptable plasticizer, and detackifying agent are described, along with methods of using the same.... Agent: Union Carbide Chemicals And Plastics Technology Corporation

20100278884 - Skin cosmetics comprising cocoon-shaped polymer fine particles: r

20100278887 - Use of a haemoglobin for the preparation of dressings and resulting dressings: The invention relates to the use of a haemoglobin for the preparation of dressings and to the resulting dressings.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100278883 - Use of amphiphilic self-assembling proteins for formulating poorly water-soluble effect substances: The invention relates to the use of amphiphilic self-assembling proteins for formulating poorly water-soluble effect substances.... Agent: Connolly Bove Lodge & Hutz, LLP

20100278882 - Use of protein microbeads in cosmetics: Use of protein microbeads in cosmetics... Agent: Connolly Bove Lodge & Hutz, LLP

20100278889 - Compositions having sustained-release insect repellency: The present invention pertains to the field of clay compositions, and to tick- or insect-repellent compositions containing clay, particularly to tick- or insect-repellant formulations comprising dihydronepetalactone, a nepetalactam, a dihydronepetalactam and/or their respective derivatives and clay that provide sustained release to improve utilization of the active ingredient and require less-frequent... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100278890 - Use of lignosulfonates in suspo-emulsions for producing pesticide compositions: Disclosed are compositions and methods related to powder and granular concentrate pesticide formulations. As disclosed, suspo-emulsions comprising pesticide actives may be prepared using a high purity, high molecular weight lignosulfonate as a stabilizer. The resulting suspo-emulsions may then be dried to obtain a powder or granular concentrate where the high... Agent: Andrus, Sceales, Starke & Sawall, LLP

20100278891 - Bi-phasic compressed porous reinforcement materials suitable for implant: A high strength porous biphasic polymeric reinforcement material manufactured by a compression and/or sintering process is disclosed. The material results in a network of interconnected collapsed pores, which forces thin overlapping walls and passages to be created. The network provides permeable access for fluid migration throughout the material. The strength... Agent: Kensey Nash Corporation

20100278892 - High affinity metal-oxide binding peptides with reversible binding: A dodecamer peptide, and its modified variant, having a repeating glycine-lysine sequence was created and found to bind with high affinity to oxide surfaces and certain activated polymeric surfaces. Reversible binding characteristics of the peptides were demonstrated. The peptides were integrated with proteins, cells and fusion proteins to provide attachment... Agent: Steptoe & Johnson LLP

20100278894 - Antioxidants and antimicrobial accessories including antioxidants: An antimicrobial accessory may include a polymer an antimicrobial mixed in the polymer, and an antioxidant. The antioxidant may include, for example, at least one of citric acid, maltol, kojic acid, malic acid, or vitamin A. In some examples, the antioxidant may include an ascorbate peroxidase in combination with ascorbic... Agent: Shumaker & Sieffert , P.a

20100278895 - Antioxidants and antimicrobial accessories including antioxidants: An antimicrobial accessory may include a polymer an antimicrobial mixed in the polymer, and an antioxidant. The antioxidant may include, for example, at least one of citric acid, maltol, kojic acid, malic acid, or vitamin A. In some examples, the antioxidant may include an ascorbate peroxidase in combination with ascorbic... Agent: Shumaker & Sieffert , P.a

20100278893 - Implantable material comprising cellulose and the glycopeptide xyloglucan-grgds: Implantable materials for medical or surgical applications comprising specific chemical groups on their surface to alter the physico-chemical properties of said material rendering it suitable implantation or biocompatible properties.... Agent: Morrison & Foerster LLP

20100278896 - Solid compositions: A solid, implantable dosage form comprising a therapeutically active agent in solid form, optionally with one or more pharmaceutically acceptable excipients, wherein the one or more excipients, when present, do not lead to a significant delay or prolongation of the release of active agent, as compared to an equivalent dosage... Agent: Stites & Harbison, PLLC

20100278897 - Intraocular bioactive agent delivery system with molecular partitioning system: The present disclosure generally provides intraocular implants including at least one therapeutic bioactive agent and a molecular partitioning system. The molecular partitioning system comprises at least two phases wherein the first phase has an inherent viscosity equal or greater than the inherent viscosity of a second phase. The molecular partitioning... Agent: Allergan, Inc.

20100278898 - Intraocular pressure reduction with intracameral bimatoprost implants: The present invention provides a method of treating an ocular condition in an eye of a patient, comprising the step of placing a biodegradable intraocular implant in an eye of the patient, the implant comprising a prostamide and a biodegradable polymer matrix that releases drug at a rate effective to... Agent: Allergan, Inc.

20100278899 - Edible film: An edible film to be ingested from an oral cavity of a living body to a body thereof is provided. The edible film is comprised of a laminated body consisting of a plurality of layers. The laminated body has surfaces and the plurality of layers include two surface layers forming... Agent: Brinks Hofer Gilson & Lione

20100278900 - Chlorine dioxide based gum and candy: Provided are oral compositions and devices comprising an active agent that is one of chlorine dioxide-generating components, a chlorine dioxide-containing solution, and combinations thereof.... Agent: Basf Corporation

20100278901 - Compositions and methods of making rapidly dissolving ionically masked formulations: The present invention includes compositions and methods for reduce the taste of the drug in the drug resin complex. The composition may include one or more drug-resin complexes and a highly compressible, free-flowing pharmaceutical excipient. The resin is present in an amount effective to reduce the taste of the drug... Agent: Hunton & Williams LLP Intellectual Property Department

20100278902 - Strontium doped bioactive glasses: The invention relates to bioactive glasses containing or doped with strontium, to a method for preparing the same and to the use thereof in methods for bone repair or reconstruction.... Agent: Morgan Lewis & Bockius LLP

20100278907 - Immunogenic compositions containing ceramide and methods of use thereof: Immunogenic compositions containing ceramide or ceramide analogs for treating or reducing the risk of developing one or more symptoms of a disease or disorder associated with ceramide-induced cell death are provided. The immunogenic compositions contain immunogenic ceramide, and, optionally, pharmaceutically acceptable excipients and one or more additional adjuvants. Methods of... Agent: Pabst Patent Group LLP

20100278906 - Moisturizing antimicrobial composition: An antimicrobial moisturizing composition includes benzethonium chloride or benzalkonium chloride, a non-benzyl cationic surfactant, and an aqueous carrier. The composition of the present invention provides a significant and unexpected reduction of irritation, inflammation, dryness and/or redness, all issues associated with known alcohol-based skin disinfectants. In particular, the present invention provides... Agent: Husch Blackwell LLP

20100278904 - Nucleotide vaccine: The present invention relates to a vaccine comprising a nucleic acid construct such as a DNA construct especially a nucleic acid construct comprising sequences encoding invariant chain operatively linked to antigenic protein or peptide encoding sequences. The vaccine stimulates an immune response, especially an immune response in an MHC-I dependent,... Agent: Davis Wright Tremaine LLP - San Francisco

20100278903 - Prophylactic and immunomodulatory compositions and uses: Provided is use of a sphingosine compound, or a derivative of a sphingosine compound, in the manufacture of a vaccine effective in the treatment and prevention of an infectious disease and treatment and/or prevention of an autoimmune disease. Also provided is use of a sphingosine compound, or a derivative of... Agent: Cermak Nakajima LLP

20100278905 - Stabilized lipid formulation of apoptosis promoter: An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment... Agent: Harness Dickey & Pierce, PLC

20100278908 - Compositions incorporating agents for reducing cellulite and unaesthetic appearance associated therewith and formulations containing them: The present invention relates to synergic compositions incorporating agents for reducing cellulite and unaesthetic appearance associated therewith which comprise a base matrix constituted by conjugated linoleic acid (CLA), grape seed extract, beta-glucan, organic calcium and dry extract of pine bark together with complementary synergic agents of the matrix. The invention... Agent: Pearl Cohen Zedek Latzer, LLP

20100278909 - Process for forming solid oral dosage forms of angiotensin ii receptor antagonists: A method for producing granules of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, which comprises: a) mixing the angiotensin II receptor antagonist or pharmaceutically acceptable salt thereof with a melt granulating agent to form a mixture; b) elevating the temperature of the mixture to the melting... Agent: Dr. D. Graeser Ltd.

20100278910 - Rare earth metal compounds, methods of making, and methods of using the same: Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100278911 - Controlled release preparation: A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100278913 - Chewable tablet: An excipient base for a chewable tablet comprising xylitol, sucralose and microcrystalline cellulose. The excipient base provides for an improved taste, stabilization, and mouthfeel qualities for the chewable tablet, as well as a greater likelihood for dosage compliance and use. The excipient base also enables the tablet to be directly... Agent: Stroock & Stroock & Lavan LLP

20100278912 - Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition: The present invention provides a pharmaceutical composition for use in a dosage form for oral administration to a patient. The composition expands upon contact with gastric fluid and promotes retention of the dosage form in the patient's stomach for a prolonged period of time. The present invention further provides pharmaceutical... Agent: Kenyon & Kenyon LLP

20100278914 - Fraction of melissa leaf extract having angiogenesis and mmp inhibitory activities, and composition comprising the same: The present application describes an ethyl acetate fraction of Melissa leaf having excellent angiogenesis and MMP inhibitory activities, and a composition comprising the same.... Agent: Jhk Law

20100278915 - Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations: The invention provides oral formulations for the treatment of cold and allergy symptoms. Each formulation combines an antihistamine, an antitussive, and/or a decongestant into one extended release composition. The invention further provides for methods of making and using such formulations, as well as for methods for preventing abuse or extraction... Agent: Foley And Lardner LLP Suite 500

20100278916 - Topical application and formulation of erythropoietin for skin wound healing: e

20100278917 - Formulations and methods of treating inflammatory bowel disease: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100278918 - Extended release formulation of nevirapine: The invention relates to an extended release pharmaceutical composition comprising nevirapine.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100278919 - Dendritic cell targeting compositions and uses thereof: The present invention provides compositions and methods for targeting dendritic cells of the immune system. In particular, the compositions comprise carbon nanoparticles, optionally magnetic carbon nanoparticles comprising iron, which are preferentially endocytosed by dendritic cells compared to macrophages when contacted with a biological sample. The nanoparticles of the present invention... Agent: Wisconsin Alumni Research Foundation (warf)

20100278922 - Methods and compositions for oral administration of insulin: The present invention provides a pharmaceutical composition formulated for oral delivery of insulin, comprising a particulate non-covalently associated mixture of pharmacologically inert silica nanoparticles having a hydrophobic surface, a polysaccharide, and insulin suspended in an oil. The present invention further provides methods of manufacturing same and therapeutic methods utilizing same... Agent: Fennemore Craig

20100278920 - Polyacrylate nanoparticle drug delivery: Drug delivery of resistance reversal agents by polyacrylate nanoparticles for treatment of drug (e.g. chloroquine) resistant malaria. Also provided are drug delivery by polyacrylate nanoparticles of ciprofloxacin for treatment of anthrax.... Agent: Smith Hopen, Pa

20100278921 - Solid oral formulation of abt-263: An orally deliverable pharmaceutical composition comprises (a) a pharmaceutically acceptable acid addition salt of ABT-263 in solid particulate form, and (b) a plurality of pharmaceutically acceptable excipients including at least a solid diluent and a solid disintegrant; wherein the salt is formed from more than one equivalent of acid per... Agent: Harness Dickey & Pierce, PLC

20100278923 - Functional nanoparticle-based antibiotics and preparation method thereof: The present invention is related to a novel functional nanoparticle-based antibiotics and preparation method thereof, especially related to an antibiotics-modified nanoparticle. The functional nanoparticle-based antibiotics according to the present invention can be used as the affinity probes and the photothermal agents to effectively inhibit the cell growth of pathogenic bacteria... Agent: Bacon & Thomas, PLLC

20100278924 - Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents: Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Type of surface properties that are altered by the disclosed methods include by electrostatic properties, hydrophobic properties and... Agent: K&l Gates LLP

20100278925 - Formulations of organo-platinic compounds in the presence of associative polymers, products thus obtained and uses thereof: The invention consists of formulations based on compounds of platinum encapsulated by associative and water-soluble polymers. These formulations are in aqueous form or in the form of granulates. The invention further pertains to pharmaceutical preparations which contain these formulations, and their implementation in the fabrication of an orally administered medication,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100278926 - Controlled release oral dosage form: A once a day bupropion salt formulation is disclosed.... Agent: Alan B. Clement Hedman & Costigan, P.C.

20100278928 - Polymer micelles containing anthracylines for the treatment of cancer: The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof.... Agent: Choate, Hall & Stewart LLP

20100278927 - Polymeric micelles for polynucleotide encapsulation: The present invention provides micelles having a polynucleotide encapsulated therein, the micelle comprising copolymers comprising hydrophobic moieties in a cationic complexing block. The invention further provides methods of preparing and using said micelles, and compositions thereof.... Agent: Choate, Hall & Stewart LLP

20100278929 - Antibody formulations having optimized aggregation and fragmentation profiles: The present invention provides methods of optimizing the production and purification of antibody formulations that immunospecifically bind to antigens of interest and are suitable for parenteral administration to a subject, which formulations exhibit increased stability due to reduced degradation and aggregation of the antibody component on long term storage. Such... Agent: Medimmune, LLC Patrick Scott Alban

20100278930 - Oral cavity disintegrating tablet and method of producing the same: The invention provides an orally disintegrating tablet containing (a) one or more saccharides or sugar alcohols selected from the group consisting of mannitol, lactose, xylitol, sucrose, erythritol and glucose and (b) low substituted hydroxypropylcellulose and substantially free of a starch disintegrant, which tablet is produced by steps of granulating a... Agent: Leydig Voit & Mayer, Ltd

20100278932 - Polymer micelles containing sn-38 for the treatment of cancer: The present invention provides micelles having SN-38 encapsulated therein.... Agent: Choate, Hall & Stewart LLP

20100278931 - Porous silicon drug-eluting particles: The invention provides a biodegradable drug-eluting particle useful for the delivery of diagnostic or therapeutic agents. In certain embodiments, the drug-eluting particle of the invention comprises a biodegradable porous silicon body, a reservoir formed within the porous silicon body having at least one opening to an exterior of the body,... Agent: Ropes & Gray LLP

20100278933 - Kinase inhibitor compounds: The invention relates to kinase inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating disorders, especially cancer.... Agent: Edwards Angell Palmer & Dodge LLP

20100278934 - Methods and compositions for conserving and/or preparing an organ or tissue for transplant: A method of conserving and/or preparing an organ or tissue for transplant for a subject, includes administering to a subject, organ or tissue in need of such treatment an effective amount of a composition including a polypeptide agent including thymosin beta 4 (TB4), an isoform, analogue or derivative of TB4... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100278935 - Immune system modulator formulation: Compositions and methods for treating and/or preventing a medical condition are provided. For example, in one aspect the present invention provides a composition for treating or preventing a medical condition in a subject. Such a composition may include a sodium phosphate compound, an ammonium compound, and a silicate compound. Such... Agent: Thorpe North & Western, LLP.

20100278936 - Composition for treating skin lesions: The present invention provides a composition for topical treatment of skin and mucosal membrane lesions comprising a synergistic combination of copper compound and hypericum perforatum extract.... Agent: Bozicevic, Field & Francis LLP

20100278937 - Compositions and methods to prevent and/or treat cancer with pa-card: The present invention relates to methods and materials for killing cancer cells with proteins derived from bacteria. The invention specifically relates to Azurin, Laz, Pa-CARD, and fusion proteins Azu-H.8 and H.8-Azu, and their use in killing leukemia cells and/or ovarian cancer cells.... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20100278938 - Genetic test and pet diet: The present invention provides a method of determining the susceptibility of a dog to liver copper accumulation comprising detecting the presence or absence of (a) a polymorphism in the GOLGA5, ATP7a or UBL5 gene of the dog that is indicative of susceptibility to copper accumulation and/or (b) a polymorphism in... Agent: Fulbright & Jaworski, LLP

20100278939 - Treating male infertility secondary to sperm oxidative stress: A profertility composition for administration to infertile men with sperm oxidative stress is disclosed. The composition comprises a unique combination of a pharmaceutically acceptable vitamin E, vitamin C, selenium, zinc, folic acid, lycopene and at least one carnitine source.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20100278940 - Calcium supplements: A composition comprising at least 15%, by weight, of calcium derived from a rhodolith coralline algae; magnesium; strontium; vanadium; vitamin K; and vitamin D3.... Agent: Nixon & Vanderhye, PC

20100278941 - Enhanced erythropoiesis and iron metabolism: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.... Agent: Fibrogen, Inc.

20100278942 - Pharmaceutical composition comprising at least one thrombolytic agent (a) and at least one gas (b) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon: The present invention relates to a pharmaceutical composition comprising at least one thrombolytic agent (A), such as the human recombinant form of tissue-type plasminogen activator (rt-PA), and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon, and mixtures thereof, as a combined... Agent: Foley And Lardner LLP Suite 500

20100278943 - Anti viral composition: The present invention relates to a composition enriched in but not confined to phenolic antioxidants obtained from oil palm, and more particularly this invention relates to a composition for promoting immunity in general and most essentially against Human Immunodeficiency Virus (HIV) and HCV related infections. Accordingly, the composition having the... Agent: Foley & Lardner LLP

20100278944 - Application of american ginseng to enhance neurocognitive function: Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total genosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness.... Agent: Orrick, Herrington & Sutcliffe, LLPIPProsecution Department

20100278945 - Processes of making north american ginseng fractions, products containing them, and use as immunomodulators: The invention is directed to chemical processes of preparing fractions from North American Ginseng (Panax quinquefolium) and pharmaceutical compositions containing these fractions. The products of the present invention may be used to stimulate the production of cytokines and/or antibodies, or as therapeutics targeted at conditions characterized by low immunity, such... Agent: Prout And Associates, LLC

20100278946 - Herbal compositions comprising plant material of artemisia herba-alba (asso) asteraceae and/or extracts thereof: A herbal composition including plant material of Artemisia herba-alba (Asso) and/or an extract thereof for alleviating, preventing and/or curing symptoms of any of the following conditions: Irritable Bowel Syndrome (IBS), Crohn's Disease, side effects of chemotherapy, colic, abdominal pain, intestinal worms, diarrhea, constipation, gastric ulcer, heartburn, nausea and vomiting, wherein... Agent: Sughrue Mion, PLLC

20100278947 - Methods for modulating eicosanoid metabolism: The inventive subject matter relates to methods for modulating an eicosanoid metabolic process in cells of an animal in need thereof, which comprises administering to the animal an amount of the inventive compositions effective for regulating the activity of an eicosanoid oxygenase. In particular, the inventive subject matter relates to... Agent: The Nath Law Group

20100278948 - Use of a cosmetic composition for the care of fatty skin: The present invention relates to the use of chrysin in a cosmetic composition for the care of fatty skin. The present invention also relates to a cosmetic treatment method for the prophylaxis or therapy of fatty skin that comprises the application onto the skin of a chrysin-containing cosmetic composition.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100278949 - Pre-procedure meal regimen: A colon prep method and kit for facilitating a method for evacuating a colon prior to a medical procedure, wherein the method minimizes potential patient discomfort. Three selected meals and a plurality of selected snacks are ingested on a day prior to the medical procedure. The meals include solid food... Agent: Fellers Snider Blankenship Bailey & Tippens